{"ae9c132b0cc534041ad7fd412de5bdedece2f5ba": [["IntroductionThere is continuing debate about the impact of horizontal gene transfer (HGT) in our ability to infer phylogenetic relationships among bacteria and archaea.", [["horizontal gene transfer (HGT)", "TREATMENT", 59, 89]]], ["Some recent work on this topic concluded that the death of a bacterial tree of life is a fait accompli [1] [2] [3] [4] [5] [6] [7] [8] [9] or, less drastically, that a bacterial tree of life is really a \"forest of life\" [10] .", [["death", "DISEASE", 50, 55], ["[1] [2] [3] [4] [5] [6] [7] [8] [9", "CHEMICAL", 103, 137], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "CHEMICAL", 103, 138], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 103, 138]]], ["Others argue that tree thinking in bacterial evolutionary biology is like accepting \"the tree of 1%\" [11] [12] [13] , implying that HGT is so prevalent that it impacts phylogenetic signal in 99% of the genetic elements used to infer phylogeny.IntroductionSpecifically, the argument is that some organisms experience processes oppositional to bifurcation and hence the representation of the evolutionary process in a tree-like structure is illogical.", [["phylogenetic signal", "TEST", 168, 187], ["some organisms experience processes oppositional to bifurcation", "PROBLEM", 290, 353], ["the evolutionary process", "PROBLEM", 386, 410], ["tree", "OBSERVATION_MODIFIER", 18, 22], ["bifurcation", "OBSERVATION_MODIFIER", 342, 353], ["evolutionary", "OBSERVATION_MODIFIER", 390, 402], ["process", "OBSERVATION", 403, 410], ["tree", "OBSERVATION_MODIFIER", 416, 420]]], ["The authors who hold this view suggested that network methods should supplant tree building as the basis of genealogical analysis.", [["genealogical analysis", "TEST", 108, 129]]], ["Hence, we examine the premise and logic behind this perspective in this review.HGT is the Hobgoblin of Bifurcation or Vertical DivergenceHGT has been referred to as the hobgoblin of bifurcation [14] , although we note that hobgoblins are not evil and malicious like goblins, they simply cause mischief and disarray.", [["hobgoblins", "CANCER", 223, 233], ["goblins", "CANCER", 266, 273], ["the Hobgoblin of Bifurcation", "TREATMENT", 86, 114], ["Bifurcation", "OBSERVATION_MODIFIER", 103, 114], ["Vertical", "OBSERVATION_MODIFIER", 118, 126]]], ["This vertical lineage disruption is the primary reason some argue that a strictly bifurcating tree of life should be shunned [1, 15] .", [["This vertical lineage disruption", "PROBLEM", 0, 32], ["vertical", "OBSERVATION_MODIFIER", 5, 13], ["lineage disruption", "OBSERVATION", 14, 32], ["bifurcating", "OBSERVATION_MODIFIER", 82, 93], ["tree", "OBSERVATION_MODIFIER", 94, 98]]], ["It is correct that HGT disrupts \"true\" phylogenetic signal and when it occurs one might be able to infer a network of gene relationships, but clearly not a bifurcating tree.", [["bifurcating tree", "OBSERVATION", 156, 172]]], ["This argument has been proposed as a real deal breaker for bacterial and archaeal lineages because these groups are thought to have experienced large amounts of the lineage confusing process of HGT [15] [16] [17] [18] [19] [20] [21] .HGT is the Hobgoblin of Bifurcation or Vertical DivergenceA slightly different argument has been raised by others who suggested that tree building methods give a tree even when the true evolutionary history is not bifurcating [17] .", [["HGT [15] [16] [17] [18] [19] [20]", "CHEMICAL", 194, 227], ["HGT [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 194, 232], ["bacterial and archaeal lineages", "PROBLEM", 59, 90], ["the Hobgoblin of Bifurcation", "TREATMENT", 241, 269], ["Vertical DivergenceA", "PROBLEM", 273, 293], ["Bifurcation", "OBSERVATION_MODIFIER", 258, 269], ["Vertical", "OBSERVATION_MODIFIER", 273, 281]]], ["Clearly, evolutionaryBifurcation as an Evolutionary PatternThe formalization of a preference for bifurcation as a major process in organic evolution comes from Darwin.", [["bifurcation", "TREATMENT", 97, 108], ["a major process", "PROBLEM", 112, 127], ["Bifurcation", "OBSERVATION_MODIFIER", 21, 32], ["major", "OBSERVATION_MODIFIER", 114, 119], ["process", "OBSERVATION", 120, 127], ["organic evolution", "OBSERVATION", 131, 148]]], ["The concept of genetic isolation as a means to delineate species arises from this definition and can also easily be applied to clonally reproducing organisms.", [["genetic isolation", "PROBLEM", 15, 32], ["genetic isolation", "OBSERVATION", 15, 32]]], ["Simply put, the principle of divergence leads to bifurcation, and Darwin's preferences for this mode of divergence is embodied in the only figure in On the Origin, which is a bifurcating diagram.", [["Darwin's preferences", "TREATMENT", 66, 86], ["bifurcation", "OBSERVATION_MODIFIER", 49, 60], ["Origin", "ANATOMY_MODIFIER", 156, 162], ["bifurcating diagram", "OBSERVATION", 175, 194]]], ["The simple fact that Darwin preferred this mode of divergence does not mean that we have to accept it though.Bifurcation as an Evolutionary PatternThe argument made by opponents of a bifurcating bacterial tree of life suggests that the seminal approaches to understanding how life on our planet diverged simply do not hold for bacteria, archaea and even for some deep relationships in the eukaryotic tree of life [5, 9, [15] [16] [17] .", [["a bifurcating bacterial tree of life", "TREATMENT", 181, 217], ["bacteria", "PROBLEM", 327, 335], ["archaea", "PROBLEM", 337, 344], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["bifurcating", "OBSERVATION_MODIFIER", 183, 194], ["bacterial tree", "OBSERVATION", 195, 209], ["tree", "ANATOMY_MODIFIER", 400, 404]]], ["These opposing views cite the fact that randomly generated data with no background pattern of bifurcation will give a bifurcating tree when methods that force a tree as a solution are used.", [["a bifurcating tree", "TREATMENT", 116, 134], ["a solution", "TREATMENT", 169, 179], ["bifurcation", "OBSERVATION", 94, 105], ["bifurcating", "OBSERVATION_MODIFIER", 118, 129], ["tree", "OBSERVATION_MODIFIER", 130, 134]]], ["Hence, the suggestion that tree building is verificationist has arisen.Bifurcation as an Evolutionary PatternWe point out that there are two approaches that we can take to look at this problem.", [["tree", "OBSERVATION_MODIFIER", 27, 31]]], ["First, some have suggested that the processes of divergence and speciation in bacteria and archaea are so radically different that using methods to recover bifurcation are illogical.", [["bacteria", "PROBLEM", 78, 86], ["archaea", "PROBLEM", 91, 98], ["bifurcation", "OBSERVATION_MODIFIER", 156, 167]]], ["We suggest that a detailed examination of the divergence process in bacteria and archaea can tell us whether or not this conclusion is warranted.", [["a detailed examination", "TEST", 16, 38], ["bacteria", "PROBLEM", 68, 76]]], ["By asking, do bacteria and archaea diverge in patterns that negate bifurcation as a valid explanatory process, we can test whether there is sufficient evidence to warrant the exclusion of bifurcation as an explanation.", [["bacteria", "PROBLEM", 14, 22], ["archaea diverge", "PROBLEM", 27, 42]]], ["Second, we contend that tree building in the context of phylogenetic analysis does not necessarily result in a tree.", [["phylogenetic analysis", "TEST", 56, 77]]], ["In fact, some approaches use a star phylogeny as a null hypothesis and there are some studies where the existence of monophyly (the central idea of tree building) of groups of organisms can be tested [24, 25] .", [["a null hypothesis", "PROBLEM", 49, 66], ["some studies", "TEST", 81, 93], ["monophyly", "PROBLEM", 117, 126]]], ["In addition, simple tests that allow one to determine if a dataset results in an interpretable bifurcating tree for the tree of life exist [26] .Bacterial and Archaeal Divergence: Nothing Special?Data from bacterial genomic studies have led to questions about the appropriate unit of evolution in bacterial biology [27] .", [["bifurcating tree", "MULTI-TISSUE_STRUCTURE", 95, 111], ["simple tests", "TEST", 13, 25], ["Bacterial and Archaeal Divergence", "PROBLEM", 145, 178], ["Data from bacterial genomic studies", "TEST", 196, 231], ["Archaeal Divergence", "OBSERVATION", 159, 178]]], ["However, the applicability at the bacterial level of the 'universal species concept', with its emphasis on reproductive isolation, has not been universally supported [28] [29] [30] .", [["reproductive isolation", "TREATMENT", 107, 129]]], ["Instead, we might be best served by asking three interrelated questions:Bacterial and Archaeal Divergence: Nothing Special?(1) what is the extent and pattern of non-genealogical sharing of genetic information? (2) Are particular classes of genetic information more or less likely to be involved in such exchanges, and (3) is the extent of such non-genealogical sharing sufficient to overwhelm the signature of vertical inheritance?Bacterial and Archaeal Divergence: Nothing Special?The ability of bacteria to acquire genetic information in unconventional ways is well-established [11, 31] .", [["vertical inheritance", "PROBLEM", 410, 430], ["Bacterial and Archaeal Divergence", "PROBLEM", 431, 464], ["bacteria", "PROBLEM", 497, 505], ["vertical inheritance", "OBSERVATION", 410, 430], ["Archaeal Divergence", "OBSERVATION", 445, 464]]], ["Further, whole genome sequencing reveals genetic exchange among even distantly related organisms [32, 33] .", [["whole genome sequencing", "TEST", 9, 32], ["genetic exchange", "PROBLEM", 41, 57]]], ["The surprise that the genomic revolution has revealed is thus not the existence of such genetic traffic, but its unexpected range and frequency, which is widespread across bacterial strains.", [["bacterial strains", "PROBLEM", 172, 189], ["widespread", "OBSERVATION_MODIFIER", 154, 164], ["bacterial strains", "OBSERVATION", 172, 189]]], ["But are these events sufficiently ubiquitous that they require us to abandon the fundamental unit of biological organization, the species?Bacterial and Archaeal Divergence: Nothing Special?This question is not merely a semantic one, but rather an empirical challenge.", [["Bacterial and Archaeal Divergence", "PROBLEM", 138, 171], ["an empirical challenge", "TREATMENT", 244, 266], ["Archaeal Divergence", "OBSERVATION", 152, 171]]], ["Vertical inheritance is still taking place, leaving behind a genomic signal that we can, in principle, retrieve.", [["Vertical inheritance", "PROBLEM", 0, 20]]], ["The question remains, however, are the phylogenetic reconstructions made possible by rich genomic datasets descending into chaos, suggesting that the noise created by HGT is swamping out the phylogenetic signal?", [["the phylogenetic reconstructions", "TEST", 35, 67], ["the noise", "PROBLEM", 146, 155], ["descending", "OBSERVATION_MODIFIER", 107, 117]]], ["In our view, the signal of vertical inheritance remains loud and clear.", [["loud", "PROBLEM", 56, 60], ["vertical inheritance", "OBSERVATION", 27, 47], ["loud", "OBSERVATION", 56, 60], ["clear", "OBSERVATION", 65, 70]]], ["In the majority of cases where multiple genes and/or genomes have been used for phylogenetic reconstruction, the resulting trees are resolved and largely congruent [34] [35] [36] .", [["multiple genes", "DNA", 31, 45], ["multiple genes and/or genomes", "PROBLEM", 31, 60], ["phylogenetic reconstruction", "TREATMENT", 80, 107]]], ["Furthermore-with some interesting exceptions-these reconstructions match established patterns of classification.Bacterial and Archaeal Divergence: Nothing Special?The availability of whole genome sequences provided our first glimpse into the dynamic nature of a species genome.", [["whole genome sequences", "DNA", 183, 205], ["species genome", "DNA", 262, 276], ["these reconstructions", "TREATMENT", 45, 66], ["Bacterial and Archaeal Divergence", "PROBLEM", 112, 145], ["whole genome sequences", "TEST", 183, 205], ["a species genome", "PROBLEM", 260, 276], ["Archaeal Divergence", "OBSERVATION", 126, 145], ["species genome", "OBSERVATION", 262, 276]]], ["Glasner and Perna [37] and Mau et al. [38] compared six complete genomes of Escherichia coli and revealed a highly conserved genome backbone with greater than 98% sequence similarity among the isolates.", [["Glasner", "CHEMICAL", 0, 7], ["Escherichia coli", "ORGANISM", 76, 92], ["Escherichia coli", "SPECIES", 76, 92], ["Escherichia coli", "SPECIES", 76, 92], ["Escherichia coli", "PROBLEM", 76, 92], ["a highly conserved genome backbone", "PROBLEM", 106, 140], ["Escherichia coli", "OBSERVATION", 76, 92]]], ["However, this conserved backbone was interrupted by hundreds of strain-specific 'sequence islands'.", [["strain-specific 'sequence islands", "DNA", 64, 97]]], ["These patterns of shared and unique sequences appear to be common among bacterial species [39] [40] [41] [42] .", [["[39] [40] [41] [42]", "SIMPLE_CHEMICAL", 90, 109]]], ["However, the relative fraction of the genome shared varies greatly from one bacterial species to the next [43] [44] [45] [46] [47] .", [["genome", "CELLULAR_COMPONENT", 38, 44], ["[43] [44] [45] [46] [47]", "SIMPLE_CHEMICAL", 106, 130], ["one bacterial species", "PROBLEM", 72, 93], ["fraction", "OBSERVATION_MODIFIER", 22, 30]]], ["A highly robust phylogenetic tree was constructed for 13 gamma-proteobacteria using a concatenated alignment of several hundred conserved orthologous proteins [48] .", [["gamma-proteobacteria", "GENE_OR_GENE_PRODUCT", 57, 77], ["13 gamma-proteobacteria", "PROTEIN", 54, 77], ["hundred conserved orthologous proteins", "PROTEIN", 120, 158], ["proteobacteria", "PROBLEM", 63, 77]]], ["Only two of the proteins had incongruent tree topologies in this analysis.", [["incongruent tree topologies", "PROBLEM", 29, 56], ["this analysis", "TEST", 60, 73], ["tree topologies", "OBSERVATION", 41, 56]]], ["A similar type of investigation was undertaken with Neisseria [49] , which revealed that the use of concatenated sequences buffered the distorting effect of recombination events and resulted in the resolution of clusters corresponding to the three most abundant species in the sample.", [["sample", "ANATOMY", 277, 283], ["concatenated sequences", "DNA", 100, 122], ["recombination events", "PROBLEM", 157, 177], ["abundant", "OBSERVATION_MODIFIER", 253, 261], ["species", "OBSERVATION", 262, 269]]], ["Genome sequence comparisons among members of Agrobacterium highlighted a broad range of intra-species divergence within very closely related but distinct species [50] [51] [52] .", [["intra-species divergence", "PROBLEM", 88, 112]]], ["Their data supported earlier claims by Majewski [53] that 'bacterial species experience a degree of sexual isolation from genetically divergent organisms since recombination occurs more frequently within species than between species'.", [["'bacterial species", "PROBLEM", 58, 76], ["sexual isolation", "PROBLEM", 100, 116], ["genetically divergent organisms", "PROBLEM", 122, 153]]], ["Konstantintidis and Tiedje [54] compared the gene content of 70 closely related bacterial genomes to identify whether species boundaries exist.", [["Konstantintidis", "CHEMICAL", 0, 15], ["Konstantintidis", "SIMPLE_CHEMICAL", 0, 15], ["bacterial genomes", "DNA", 80, 97]]], ["They found the levels of sequence similarity on the order of 94% corresponded to the traditional 70% DNA-DNA reassociation standard of the current species definition.", [["DNA", "CELLULAR_COMPONENT", 101, 104], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["DNA reassociation", "PROBLEM", 105, 122]]], ["As more extensive whole genome data come online, we can expect phylogenetic reconstructions to stabilize.", [["phylogenetic reconstructions", "TREATMENT", 63, 91]]], ["Some existing phylogenetic reconstructions will stand, and others will fall.Bacterial and Archaeal Divergence: Nothing Special?Finally, several recent studies have demonstrated that bacterial lineages follow bifurcating or vertical divergence [29, 30, [55] [56] [57] [58] .", [["Bacterial and Archaeal Divergence", "PROBLEM", 76, 109], ["several recent studies", "TEST", 136, 158], ["bacterial lineages", "PROBLEM", 182, 200], ["vertical divergence", "TEST", 223, 242], ["phylogenetic reconstructions", "OBSERVATION", 14, 42], ["Archaeal Divergence", "OBSERVATION", 90, 109], ["bacterial lineages", "OBSERVATION", 182, 200]]], ["Two studies in particular have shown that the dynamics of bifurcation are common and retrievable when considering bacterial lineages.", [["Two studies", "TEST", 0, 11], ["bacterial lineages", "PROBLEM", 114, 132], ["bifurcation", "OBSERVATION_MODIFIER", 58, 69], ["bacterial lineages", "OBSERVATION", 114, 132]]], ["Bobay and Ochman [29] showed that the footprints of divergence are easily detected in all domains of the tree of life.", [["tree", "ANATOMY_MODIFIER", 105, 109]]], ["Using measures of gene flow, they showed clearly that bacterial and archaeal lineages are no different from other organisms in showing discontinuities in gene flow.", [["gene flow", "TEST", 18, 27], ["bacterial and archaeal lineages", "PROBLEM", 54, 85], ["discontinuities in gene flow", "PROBLEM", 135, 163], ["archaeal lineages", "OBSERVATION", 68, 85], ["gene flow", "OBSERVATION", 154, 163]]], ["They took this result as evidence that discontinuity in genetic similarity during the divergence process in bacteria conforms to a biological species concept.", [["discontinuity in genetic similarity", "PROBLEM", 39, 74], ["the divergence process", "PROBLEM", 82, 104], ["bacteria", "PROBLEM", 108, 116]]], ["Jain et al. [30] used the average nucleotide identity (ANI), another method of assessing genomic similarity, to examine species divergence in thousands of genomes (involving billions of comparisons).", [["nucleotide", "CHEMICAL", 34, 44], ["nucleotide", "CHEMICAL", 34, 44]]], ["Intriguingly, they discovered an easily discernable and robust gap between 95% intra-species and 83% interspecies ANI values.", [["robust gap", "PROBLEM", 56, 66], ["intra-species", "TEST", 79, 92], ["robust", "OBSERVATION_MODIFIER", 56, 62], ["gap", "OBSERVATION_MODIFIER", 63, 66]]], ["This gap is again indicative of divergence in accordance with vertical divergence or splitting.Bacterial and Archaeal Divergence: Nothing Special?Other researchers argued for pluralism in how the divergence process is viewed.", [["vertical divergence", "PROBLEM", 62, 81], ["Bacterial and Archaeal Divergence", "PROBLEM", 95, 128], ["again indicative of", "UNCERTAINTY", 12, 31], ["divergence", "OBSERVATION", 32, 42], ["Archaeal Divergence", "OBSERVATION", 109, 128]]], ["Su\u00e1rez [59] suggested that speciation in the same mode as animals and plants can only be inferred if it can explain divergence better than a null hypothesis based on a random birth death process.", [["birth death", "DISEASE", 175, 186], ["a null hypothesis", "PROBLEM", 139, 156], ["a random birth death process", "PROBLEM", 166, 194]]], ["Their assumption is that selection drives speciation and should manifest itself in a statistically significant difference from the null hypothesis.", [["the null hypothesis", "PROBLEM", 127, 146], ["null hypothesis", "OBSERVATION", 131, 146]]], ["This argument, however, does not recognize random processes such as drift as a means to divergence and hence speciation.Tree Thinking, Concatenation and BacteriaWith the advent of genomic techniques, more and more gene partitions can and have been used in phylogenetic analysis.", [["BacteriaWith", "TREATMENT", 153, 165], ["genomic techniques", "TEST", 180, 198], ["phylogenetic analysis", "TEST", 256, 277]]], ["In essence, some researchers have suggested that gene sequences in a concatenated approach to phylogenetic systematics is a verificationist endeavor [17, 18] , the sole aim of which is to increase the appearance of support for a phylogenetic branching diagram [60] .", [["gene sequences", "TREATMENT", 49, 63]]], ["As Lienau and DeSalle [60] (p.", [["DeSalle [60]", "CHEMICAL", 14, 26]]], ["195) pointed out:Tree Thinking, Concatenation and Bacteria\"The goal of the total evidence approach to phylogenetic research is based in the idea of increasing explanatory power over background knowledge through test and corroboration, rather than to bolster support for nodes in a tree.", [["Bacteria", "PROBLEM", 50, 58], ["nodes", "PROBLEM", 270, 275], ["nodes", "OBSERVATION", 270, 275]]], ["In this context, the testing of phylogenetic data is a falsificationist endeavor that includes [italics added] the possibility of not rejecting the null hypothesis that there is no tree-like structure in molecular phylogenetic data.\"Tree Thinking, Concatenation and BacteriaIn addition, over the past three decades, phylogenetic studies have recognized the hypothetico-deductive nature of tree building.", [["tree", "ORGANISM_SUBDIVISION", 389, 393], ["the null hypothesis", "PROBLEM", 144, 163], ["phylogenetic studies", "TEST", 316, 336], ["no", "UNCERTAINTY", 178, 180]]], ["Maddison [61] recognized that lack of resolution could arise in nearly any phylogenetic analysis.", [["Maddison", "CHEMICAL", 0, 8]]], ["A hard polytomy is one that arises as the result of actual trifurcation or even polyfurcation events in the divergence of organisms.", [["A hard polytomy", "PROBLEM", 0, 15], ["actual trifurcation", "PROBLEM", 52, 71], ["polyfurcation events", "PROBLEM", 80, 100], ["hard", "OBSERVATION_MODIFIER", 2, 6], ["polytomy", "OBSERVATION", 7, 15], ["trifurcation", "OBSERVATION", 59, 71]]], ["A soft polytomy, on the other hand, is one where there simply are not enough data to support one bifurcating pattern over another.", [["soft polytomy", "OBSERVATION", 2, 15]]], ["If the support for a node is low or even nonexistent, then it can be for two reasons.", [["node", "ANATOMY", 21, 25], ["node", "MULTI-TISSUE_STRUCTURE", 21, 25], ["a node", "PROBLEM", 19, 25], ["node", "OBSERVATION", 21, 25]]], ["First, there simply may be no information in the dataset to resolve the node.", [["node", "ANATOMY", 72, 76], ["node", "MULTI-TISSUE_STRUCTURE", 72, 76], ["the node", "PROBLEM", 68, 76], ["may be no", "UNCERTAINTY", 20, 29], ["node", "OBSERVATION", 72, 76]]], ["In this case, there should be no conflicting signal amongst different sources of data.", [["conflicting signal", "PROBLEM", 33, 51]]], ["The conflicting signal will manifest itself as a node with low support.", [["node", "ANATOMY", 49, 53], ["a node with low support", "TREATMENT", 47, 70], ["node", "OBSERVATION", 49, 53]]], ["In addition, statistical approaches in the phylogenetic comparative method use a star phylogeny as a null hypothesis, explicitly testing for \"treeness\" [62, 63] .Tree Thinking, Concatenation and BacteriaWhile the suggestion that random data will produce bifurcating trees with relatively good support is true [64] [65] [66] , this phenomenon is very dependent on the number of taxa.", [["treeness", "DISEASE", 142, 150], ["a null hypothesis", "PROBLEM", 99, 116], ["random data", "TEST", 229, 240], ["very dependent", "PROBLEM", 345, 359], ["very dependent", "OBSERVATION_MODIFIER", 345, 359]]], ["As a simple demonstration of this problem, we have created several random phylogenetic datasets by transforming Darwin's On the Origin of Species into amino acid sequences, with assignment of hypothetical taxa to random blocks of text.", [["amino acid", "CHEMICAL", 151, 161], ["amino acid", "CHEMICAL", 151, 161], ["amino acid", "AMINO_ACID", 151, 161], ["amino acid sequences", "TEST", 151, 171]]], ["When matrices with 4, 8, 15, 20, and 40 taxa with 100 genes each (genes with length 100 amino acids) are generated in this way, phylogenetic analysis yields resolved trees.", [["amino acids", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "AMINO_ACID", 88, 99], ["4, 8, 15, 20, and 40 taxa", "DNA", 19, 44], ["length 100 amino acids", "TREATMENT", 77, 99], ["phylogenetic analysis", "TEST", 128, 149], ["resolved trees", "OBSERVATION", 157, 171]]], ["While matrices with 4 and 8 taxa show relatively high support at nodes, the effect erodes as more taxa are allowed to fill the \"fake\" phylogenetic matrix.", [["matrix", "CELLULAR_COMPONENT", 147, 153], ["relatively high support at nodes", "PROBLEM", 38, 70], ["nodes", "OBSERVATION", 65, 70]]], ["By the time 40 taxa are generated, parsimony trees are still resolved but with extremely low or no support measures at the majority of nodes in the tree ( Figure 1 ).", [["support measures", "TREATMENT", 99, 115], ["parsimony trees", "OBSERVATION", 35, 50], ["nodes", "OBSERVATION", 135, 140], ["tree", "ANATOMY_MODIFIER", 148, 152]]], ["This brings in to focus the need for assessment of robustness as a part of answering the question does a tree arise from a particular dataset?", [["assessment", "TEST", 37, 47], ["robustness", "PROBLEM", 51, 61]]], ["This leads us to three direct tests for a bacterial tree of life.", [["direct tests", "TEST", 23, 35], ["a bacterial tree of life", "TREATMENT", 40, 64]]], ["Red dots indicate nodes with BP between 66% and 85%.", [["nodes", "ANATOMY", 18, 23], ["nodes", "MULTI-TISSUE_STRUCTURE", 18, 23], ["Red dots", "TEST", 0, 8], ["nodes", "PROBLEM", 18, 23], ["BP", "TEST", 29, 31], ["nodes", "OBSERVATION", 18, 23]]], ["The green dots indicate nodes with BP between 50% and 65%.", [["nodes", "ANATOMY", 24, 29], ["green dots", "SIMPLE_CHEMICAL", 4, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 24, 29], ["BP", "PROTEIN", 35, 37], ["BP", "TEST", 35, 37], ["green dots", "OBSERVATION", 4, 14], ["nodes", "OBSERVATION", 24, 29]]], ["We first extracted the text from Darwin's On the Origin of Species.", [["Species", "OBSERVATION", 59, 66]]], ["The first 100 letters of the text were turned into a line corresponding to taxon 1, the next 100 letters are turned into a line corresponding to taxon 2, the next 100 letters are turned into a line corresponding to taxon 3 and the next 100 letters are turned into a line corresponding to taxon 4.", [["a line", "TREATMENT", 51, 57], ["taxon", "TEST", 75, 80], ["a line", "TREATMENT", 121, 127], ["taxon", "TEST", 145, 150], ["a line", "TREATMENT", 191, 197], ["taxon", "TEST", 215, 220], ["a line", "TREATMENT", 264, 270]]], ["The next step is to remove spaces and any letters in the alphabet that do not correspond to an amino acid.", [["amino acid", "CHEMICAL", 95, 105], ["amino acid", "CHEMICAL", 95, 105], ["amino acid", "AMINO_ACID", 95, 105], ["spaces", "PROBLEM", 27, 33], ["an amino acid", "TEST", 92, 105]]], ["These are replaced with ambiguous X's.", [["ambiguous X's", "PROBLEM", 24, 37]]], ["Next the individual lines for each partition are transformed into FASTA files and aligned using MAFFT [67] with default settings.", [["the individual lines", "TREATMENT", 5, 25], ["default settings", "TREATMENT", 112, 128]]], ["Finally, the matrices are formatted for phylogenetic analysis and analyzed using PAUP [68] .", [["phylogenetic analysis", "TEST", 40, 61], ["PAUP", "TEST", 81, 85]]], ["We used parsimony as an optimality criterion and weighted all characters equally.", [["an optimality criterion", "TEST", 21, 44]]], ["The searches were accomplished using 200 rounds of random taxon addition with tree bissection reconnection (TBR) branch swapping.", [["random taxon addition", "TREATMENT", 51, 72], ["tree bissection reconnection", "TREATMENT", 78, 106], ["branch", "ANATOMY_MODIFIER", 113, 119]]], ["We obtained bootstrap proportions for the trees shown here using the \"boot\" option in PAUP with 100 replicates.", [["bootstrap proportions", "TREATMENT", 12, 33], ["the trees", "TREATMENT", 38, 47], ["the \"boot\" option", "TREATMENT", 65, 82]]], ["The \"ithink\" matrix is available from the authors upon request.Three Simple Falsificationist Hypotheses that Test for the Existence of the Tree of LifeLienau et al. [26] proposed three simple falsification-prone hypotheses to test whether a tree of life can be rejected as a means of explaining the divergence of bacterial and archaeal lineages ( Table 1 ).", [["matrix", "CELLULAR_COMPONENT", 13, 19], ["bacterial and archaeal lineages", "CELL_TYPE", 313, 344], ["bacterial and archaeal lineages", "PROBLEM", 313, 344], ["archaeal lineages", "OBSERVATION", 327, 344]]], ["The last hypothesis in Table 1 is the most complex of the three because it requires the testing of several sub-hypotheses based on background knowledge that microbial systematists have established over the last century.", [["the testing", "TEST", 84, 95], ["microbial systematists", "PROBLEM", 157, 179]]], ["These largely revolve around monophyly of well-established groups of organisms and bacterial species and higher category boundaries established by systematists.", [["organisms", "PROBLEM", 69, 78], ["bacterial species", "PROBLEM", 83, 100], ["bacterial species", "OBSERVATION", 83, 100]]], ["Red dots indicate nodes with BP between 66% and 85%.", [["nodes", "ANATOMY", 18, 23], ["nodes", "MULTI-TISSUE_STRUCTURE", 18, 23], ["Red dots", "TEST", 0, 8], ["nodes", "PROBLEM", 18, 23], ["BP", "TEST", 29, 31], ["nodes", "OBSERVATION", 18, 23]]], ["The green dots indicate nodes with BP between 50% and 65%.", [["nodes", "ANATOMY", 24, 29], ["green dots", "SIMPLE_CHEMICAL", 4, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 24, 29], ["BP", "PROTEIN", 35, 37], ["BP", "TEST", 35, 37], ["green dots", "OBSERVATION", 4, 14], ["nodes", "OBSERVATION", 24, 29]]], ["We first extracted the text from Darwin's On the Origin of Species.", [["Species", "OBSERVATION", 59, 66]]], ["The first 100 letters of the text were turned into a line corresponding to taxon 1, the next 100 letters are turned into a line corresponding to taxon 2, the next 100 letters are turned into a line corresponding to taxon 3 and the next 100 letters are turned into a line corresponding to taxon 4.", [["a line", "TREATMENT", 51, 57], ["taxon", "TEST", 75, 80], ["a line", "TREATMENT", 121, 127], ["taxon", "TEST", 145, 150], ["a line", "TREATMENT", 191, 197], ["taxon", "TEST", 215, 220], ["a line", "TREATMENT", 264, 270]]], ["The next step is to remove spaces and any letters in the alphabet that do not correspond to an amino acid.", [["amino acid", "CHEMICAL", 95, 105], ["amino acid", "CHEMICAL", 95, 105], ["amino acid", "AMINO_ACID", 95, 105], ["spaces", "PROBLEM", 27, 33], ["an amino acid", "TEST", 92, 105]]], ["These are replaced with ambiguous X's.", [["ambiguous X's", "PROBLEM", 24, 37]]], ["Next the individual lines for each partition are transformed into FASTA files and aligned using MAFFT [67] with default settings.", [["the individual lines", "TREATMENT", 5, 25], ["default settings", "TREATMENT", 112, 128]]], ["Finally, the matrices are formatted for phylogenetic analysis and analyzed using PAUP [68] .", [["phylogenetic analysis", "TEST", 40, 61], ["PAUP", "TEST", 81, 85]]], ["We used parsimony as an optimality criterion and weighted all characters equally.", [["an optimality criterion", "TEST", 21, 44]]], ["The searches were accomplished using 200 rounds of random taxon addition with tree bissection reconnection (TBR) branch swapping.", [["random taxon addition", "TREATMENT", 51, 72], ["tree bissection reconnection", "TREATMENT", 78, 106], ["branch", "ANATOMY_MODIFIER", 113, 119]]], ["We obtained bootstrap proportions for the trees shown here using the \"boot\" option in PAUP with 100 replicates.", [["bootstrap proportions", "TREATMENT", 12, 33], ["the trees", "TREATMENT", 38, 47], ["the \"boot\" option", "TREATMENT", 65, 82]]], ["The \"ithink\" matrix is available from the authors upon request.Three Simple Falsificationist Hypotheses that Test for the Existence of the Tree of LifeLienau et al. [26] proposed three simple falsification-prone hypotheses to test whether a tree of life can be rejected as a means of explaining the divergence of bacterial and archaeal lineages ( Table 1 ).", [["matrix", "CELLULAR_COMPONENT", 13, 19], ["bacterial and archaeal lineages", "CELL_TYPE", 313, 344], ["bacterial and archaeal lineages", "PROBLEM", 313, 344], ["archaeal lineages", "OBSERVATION", 327, 344]]], ["The last hypothesis in Table 1 is the most complex of the three because it requires the testing of several sub-hypotheses based on background knowledge that microbial systematists have established over the last century.", [["the testing", "TEST", 84, 95], ["microbial systematists", "PROBLEM", 157, 179]]], ["These largely revolve around monophyly of well-established groups of organisms and bacterial species and higher category boundaries established by systematists.", [["organisms", "PROBLEM", 69, 78], ["bacterial species", "PROBLEM", 83, 100], ["bacterial species", "OBSERVATION", 83, 100]]], ["Three hypotheses that can be tested to examine the validity of a vertical tree of life.Hypothesis 1 A Massively Concatenated Matrix of Genome-Based Information Results in a Generally Unresolved Phylogenetic Tree.If this hypothesis can be rejected then,Hypothesis 2The Tree Generated from a Massively Concatenated Matrix is not Robust.Hypothesis 2If this hypothesis can be rejected then,Hypothesis 3The Robust Tree Generated from a Massively Concatenated Matrix does not Make Biological Sense (i.e., is in Conflict with Accepted Taxonomic Knowledge).Hypothesis 3If this hypothesis can be rejected then, No vertical tree of life exists.Hypothesis 3It is not surprising to us that all three levels of null hypotheses can be rejected [26, [69] [70] [71] [72] , indicating that the conclusion that a bacterial tree of life is a good explanation for how life has diverged is valid.", [["a Massively Concatenated Matrix", "TREATMENT", 288, 319], ["a Massively Concatenated Matrix", "TREATMENT", 429, 460], ["null hypotheses", "PROBLEM", 698, 713], ["Phylogenetic Tree", "OBSERVATION", 194, 211], ["not", "UNCERTAINTY", 323, 326], ["Robust", "OBSERVATION_MODIFIER", 327, 333]]], ["This does not mean that HGT and other lineage blurring processes do not occur.", [["HGT and other lineage blurring processes", "PROBLEM", 24, 64], ["lineage blurring", "OBSERVATION", 38, 54]]], ["On the other hand, this also does not imply that strictly bifurcating tree building methods obscure the role of HGT and lineage sorting (see below).Obscured Pattern or Obscured ProcessSeveral authors have claimed that tree-based phylogenetic analyses obscure the discovery of patterns that are of interest to evolutionary biologists.", [["Obscured Pattern", "PROBLEM", 148, 164], ["Obscured ProcessSeveral authors", "PROBLEM", 168, 199]]], ["The first is most relevant to this discussion and comes from the now classic Rokas et al. [73] study on yeast phylogenetics using a genome level dataset.", [["yeast", "SPECIES", 104, 109], ["yeast", "SPECIES", 104, 109], ["yeast phylogenetics", "TEST", 104, 123]]], ["A recent analysis of the yeast dataset disavowing a tree-based approach and preferring a network approach suggested that the disparity in gene tree topology may be the result of genome hybridization [74] .", [["yeast", "SPECIES", 25, 30], ["yeast", "SPECIES", 25, 30], ["A recent analysis", "TEST", 0, 17], ["the yeast dataset", "TEST", 21, 38], ["a network approach", "TREATMENT", 87, 105], ["the disparity in gene tree topology", "PROBLEM", 121, 156], ["genome hybridization", "PROBLEM", 178, 198]]], ["However, standard tree-based approaches [75] [76] [77] concluded that the incongruence of different gene geneologies as generated from the dataset is easily explained and expanded upon using a bifurcating framework.", [["gene geneologies", "DNA", 100, 116], ["different gene geneologies", "PROBLEM", 90, 116], ["a bifurcating framework", "TREATMENT", 191, 214]]], ["First, hidden support [76, 78, 79] can be used as an explanatory tool for the large amount of incongruence.", [["large", "OBSERVATION_MODIFIER", 78, 83], ["amount", "OBSERVATION_MODIFIER", 84, 90], ["incongruence", "OBSERVATION", 94, 106]]], ["Gatesy et al. [79] showed for the Rokas et al. [73] dataset that inappropriate outgroup choice can result in random rooting and result in seemingly incongruent phylogenies (see also [77] ).", [["seemingly incongruent phylogenies", "PROBLEM", 138, 171]]], ["In fact, Gatesy et al. [79] obtained the same unrooted network for all 106 genes in the dataset indicating that it is only when the unstable root is applied to the networks that incongruence appears.", [["root", "ANATOMY", 141, 145], ["root", "ORGAN", 141, 145], ["the unstable root", "PROBLEM", 128, 145]]], ["In addition, it depends on the network approach that is applied.", [["the network approach", "TREATMENT", 27, 47]]], ["They suggested that since the incidence of HGT varies among genes and groups of organisms, the impact or effect of HGT will then vary from phylogenetic problem to problem.", [["HGT varies among genes and groups of organisms", "PROBLEM", 43, 89], ["HGT", "TREATMENT", 115, 118]]], ["It is difficult to argue with this important observation, but a detailed examination of the impact of HGT on phylogenetic analysis in some specific examples can show some of the range of the effect HGT might have on phylogenetic analysis.Why a Tree of Life Infected with HGT Still BifurcatesBy examining the behavior of data in a phylogenetic context on a node-by-node and character-by-character basis, the impact of HGT on treelike structure can be examined.", [["node", "ANATOMY", 356, 360], ["-node", "MULTI-TISSUE_STRUCTURE", 363, 368], ["a detailed examination", "TEST", 62, 84], ["phylogenetic analysis", "TEST", 109, 130], ["phylogenetic analysis", "TEST", 216, 237], ["a node", "TEST", 354, 360], ["node", "OBSERVATION", 356, 360], ["node", "OBSERVATION", 364, 368]]], ["First, the proportion of HGT genes in phylogenetic analysis of these 160 genomes relative to non-HGT genes is about 1:7.", [["HGT genes", "DNA", 25, 34], ["160 genomes", "DNA", 69, 80], ["HGT genes", "DNA", 97, 106], ["phylogenetic analysis", "TEST", 38, 59]]], ["This ratio was tested at a wide range of E-value cutoffs and it appears to be immune to manipulation of cutoff values.", [["This ratio", "TEST", 0, 10], ["cutoff values", "TEST", 104, 117], ["appears to be", "UNCERTAINTY", 64, 77]]], ["Second, the consistency of a phylogenetic analysis is impacted by the removal of HGT genes.", [["HGT genes", "DNA", 81, 90], ["a phylogenetic analysis", "TEST", 27, 50], ["the removal of HGT genes", "TREATMENT", 66, 90], ["HGT genes", "OBSERVATION", 81, 90]]], ["This is a totally unexpected result, as the whole rationale for removing such genes is that they are inconsistent with an analysis.", [["an analysis", "TEST", 119, 130]]], ["Third, the removal of HGT genes decreases the resolution of a phylogenetic hypothesis at many nodes in an overall tree.", [["HGT genes", "DNA", 22, 31], ["the removal of HGT genes", "TREATMENT", 7, 31], ["a phylogenetic hypothesis", "PROBLEM", 60, 85], ["HGT genes", "OBSERVATION", 22, 31], ["resolution", "OBSERVATION_MODIFIER", 46, 56], ["phylogenetic hypothesis", "OBSERVATION", 62, 85], ["many", "OBSERVATION_MODIFIER", 89, 93], ["nodes", "OBSERVATION", 94, 99], ["tree", "ANATOMY_MODIFIER", 114, 118]]], ["This result is obtained because the HGT genes actually carry phylogenetic information relevant to the collapsing nodes.", [["nodes", "ANATOMY", 113, 118], ["collapsing nodes", "MULTI-TISSUE_STRUCTURE", 102, 118], ["HGT genes", "DNA", 36, 45], ["the collapsing nodes", "PROBLEM", 98, 118], ["collapsing", "OBSERVATION_MODIFIER", 102, 112], ["nodes", "OBSERVATION", 113, 118]]], ["Using similar approaches based on phylogenetic incongruence called Prunier, Abby et al. [71] examined over 350 genomes in 16 bacterial and archaeal phyla for over 12,000 orthologs.", [["archaeal phyla", "OBSERVATION", 139, 153]]], ["They pointed out that most branches in the tree of life they constructed experience an average of 5 to 10% HGT.", [["most", "ANATOMY_MODIFIER", 22, 26], ["branches", "ANATOMY_MODIFIER", 27, 35], ["tree", "ANATOMY_MODIFIER", 43, 47]]], ["Zamani-Dahaj [84] used a similar presence absence approach to Desalle et al. [83] for cyanobacteria and archaea and come to the conclusion that for cyanobacteria, about 15% and, for archaea, between 20% and 39% of genes show patterns of HGT. genes is that they are inconsistent with an analysis.", [["cyanobacteria", "PROBLEM", 86, 99], ["archaea", "PROBLEM", 104, 111], ["cyanobacteria", "PROBLEM", 148, 161], ["archaea", "TEST", 182, 189], ["an analysis", "TEST", 283, 294]]], ["Third, the removal of HGT genes decreases the resolution of a phylogenetic hypothesis at many nodes in an overall tree.", [["HGT genes", "DNA", 22, 31], ["the removal of HGT genes", "TREATMENT", 7, 31], ["a phylogenetic hypothesis", "PROBLEM", 60, 85], ["HGT genes", "OBSERVATION", 22, 31], ["resolution", "OBSERVATION_MODIFIER", 46, 56], ["phylogenetic hypothesis", "OBSERVATION", 62, 85], ["many", "OBSERVATION_MODIFIER", 89, 93], ["nodes", "OBSERVATION", 94, 99], ["tree", "ANATOMY_MODIFIER", 114, 118]]], ["This result is obtained because the HGT genes actually carry phylogenetic information relevant to the collapsing nodes.", [["nodes", "ANATOMY", 113, 118], ["collapsing nodes", "MULTI-TISSUE_STRUCTURE", 102, 118], ["HGT genes", "DNA", 36, 45], ["the collapsing nodes", "PROBLEM", 98, 118], ["collapsing", "OBSERVATION_MODIFIER", 102, 112], ["nodes", "OBSERVATION", 113, 118]]], ["Using similar approaches based on phylogenetic incongruence called Prunier, Abby et al. [71] examined over 350 genomes in 16 bacterial and archaeal phyla for over 12,000 orthologs.", [["archaeal phyla", "OBSERVATION", 139, 153]]], ["They pointed out that most branches in the tree of life they constructed experience an average of 5 to 10% HGT.", [["most", "ANATOMY_MODIFIER", 22, 26], ["branches", "ANATOMY_MODIFIER", 27, 35], ["tree", "ANATOMY_MODIFIER", 43, 47]]], ["Zamani-Dahaj [84] used a similar presence absence approach to Desalle et al. [83] for cyanobacteria and archaea and come to the conclusion that for cyanobacteria, about 15% and, for archaea, between 20% and 39% of genes show patterns of HGT.", [["cyanobacteria", "PROBLEM", 86, 99], ["archaea", "PROBLEM", 104, 111], ["cyanobacteria", "PROBLEM", 148, 161], ["archaea", "TEST", 182, 189]]], ["While there are some groups that experience a large amount of HGT, even these groups are not impacted phylogenetically, forcing them to conclude that \"the impact of LGT (HGT) on the branches of the tree of life is significant but not overwhelming\" [71, 85, 86] .", [["a large amount of HGT", "PROBLEM", 44, 65], ["LGT (HGT", "TREATMENT", 165, 173], ["large", "OBSERVATION_MODIFIER", 46, 51], ["amount", "OBSERVATION_MODIFIER", 52, 58], ["branches", "ANATOMY_MODIFIER", 182, 190], ["tree", "ANATOMY_MODIFIER", 198, 202]]], ["Green represents the total number of HGT families, blue represents the total number of noHGT gene families and the red line the total number of gene families at each E value.", [["HGT gene families", "DNA", 89, 106], ["HGT gene families", "TREATMENT", 89, 106], ["the red line", "TREATMENT", 111, 123], ["red line", "OBSERVATION", 115, 123]]], ["Most of the impact of HGT occurs at E values less than \u2212100 and the green arrows indicate the difference in nonHGT and total gene families; (B) the graph represents a plot of E value versus the consensus fork index (CFI), a measure of consistency of trees in a dataset.", [["the green arrows", "PROBLEM", 64, 80]]], ["To calculate the CFI, the concatenated tree was used as a standard; (C) the impact of removing HGT genes from the dataset on resolution of a phylogenetic tree.", [["CFI", "DNA", 17, 20], ["HGT genes", "DNA", 95, 104], ["removing HGT genes", "TREATMENT", 86, 104], ["tree", "OBSERVATION_MODIFIER", 39, 43], ["phylogenetic tree", "OBSERVATION", 141, 158]]], ["When HGT genes are removed from the dataset, basal nodes are deresolved.", [["basal nodes", "ANATOMY", 45, 56], ["basal nodes", "MULTI-TISSUE_STRUCTURE", 45, 56], ["HGT genes", "DNA", 5, 14], ["basal nodes", "PROBLEM", 45, 56], ["basal", "ANATOMY_MODIFIER", 45, 50], ["nodes", "OBSERVATION", 51, 56]]], ["It is difficult to argue with the premise of the tree of 1%.", [["tree", "ANATOMY_MODIFIER", 49, 53]]], ["Of course, if 30 genes are chosen for an analysis and there are 3000 genes in an average bacterium or archaeon genome, then 1% is correct.", [["archaeon genome", "DNA", 102, 117], ["an analysis", "TEST", 38, 49], ["archaeon genome", "TREATMENT", 102, 117], ["archaeon genome", "OBSERVATION", 102, 117]]], ["But some studies used the entire repertoire of proteins from the organisms under study for phylogenetic analysis, and the Lineau et al. [69] dataset shows that we can reject the three hypotheses listed in Table 1 .", [["some studies", "TEST", 4, 16], ["phylogenetic analysis", "TEST", 91, 112]]], ["Another example is from di Bonaventura et al. [88] , where a phylogeny of 14 species of Pasteurellaceae was placed into a phylogenetic context.", [["Pasteurellaceae", "ORGANISM", 88, 103], ["Pasteurellaceae", "PROBLEM", 88, 103], ["Pasteurellaceae", "OBSERVATION", 88, 103]]], ["Two datasets were considered in this studyfirst, all 3130 proteins were included regardless of taxonomic overlap, and second a matrix with 633 proteins where all fourteen Pasteruellaceae had the sequence.", [["matrix", "CELLULAR_COMPONENT", 127, 133], ["Pasteruellaceae", "CANCER", 171, 186], ["633 proteins", "PROTEIN", 139, 151], ["Pasteruellaceae", "PROTEIN", 171, 186], ["Two datasets", "TEST", 0, 12], ["taxonomic overlap", "PROBLEM", 95, 112]]], ["There are 11 nodes in the concatenated tree for both datasets that are recovered regardless of method and at 100% bootstrap support.", [["11 nodes in the concatenated tree", "PROBLEM", 10, 43], ["method", "TREATMENT", 95, 101], ["11", "OBSERVATION_MODIFIER", 10, 12], ["nodes", "OBSERVATION", 13, 18], ["tree", "ANATOMY_MODIFIER", 39, 43]]], ["Figure 3 shows the number of nodes agreeing with the concatenated trees graphed against the number of proteins in the two datasets for the node number in agreement.", [["nodes", "ANATOMY", 29, 34], ["node", "ANATOMY", 139, 143], ["nodes", "OBSERVATION", 29, 34], ["node", "OBSERVATION", 139, 143]]], ["The figure demonstrates rampant incongruence in both datasets.", [["rampant incongruence in both datasets", "PROBLEM", 24, 61], ["rampant", "OBSERVATION_MODIFIER", 24, 31], ["incongruence", "OBSERVATION", 32, 44], ["both datasets", "OBSERVATION", 48, 61]]], ["Yet a robust and taxonomically reasonable hypothesis is attained that mirrors the current taxonomy of the group.", [["robust", "OBSERVATION_MODIFIER", 6, 12]]], ["The concatenated phylogeny is the product of the interaction of all of the phylogenetic signal of all of the proteins in the datasets.", [["phylogeny", "OBSERVATION_MODIFIER", 17, 26]]], ["Green represents the total number of HGT families, blue represents the total number of noHGT gene families and the red line the total number of gene families at each E value.", [["HGT gene families", "DNA", 89, 106], ["HGT gene families", "TREATMENT", 89, 106], ["the red line", "TREATMENT", 111, 123], ["red line", "OBSERVATION", 115, 123]]], ["Most of the impact of HGT occurs at E values less than \u2212100 and the green arrows indicate the difference in nonHGT and total gene families; (B) the graph represents a plot of E value versus the consensus fork index (CFI), a measure of consistency of trees in a dataset.", [["the green arrows", "PROBLEM", 64, 80]]], ["To calculate the CFI, the concatenated tree was used as a standard; (C) the impact of removing HGT genes from the dataset on resolution of a phylogenetic tree.", [["CFI", "DNA", 17, 20], ["HGT genes", "DNA", 95, 104], ["removing HGT genes", "TREATMENT", 86, 104], ["tree", "OBSERVATION_MODIFIER", 39, 43], ["phylogenetic tree", "OBSERVATION", 141, 158]]], ["When HGT genes are removed from the dataset, basal nodes are deresolved.", [["basal nodes", "ANATOMY", 45, 56], ["basal nodes", "MULTI-TISSUE_STRUCTURE", 45, 56], ["HGT genes", "DNA", 5, 14], ["basal nodes", "PROBLEM", 45, 56], ["basal", "ANATOMY_MODIFIER", 45, 50], ["nodes", "OBSERVATION", 51, 56]]], ["Reference 84is available from the authors on request.Why a Tree of Life Infected with HGT Still BifurcatesWhile there are some groups that experience a large amount of HGT, even these groups are not impacted phylogenetically, forcing them to conclude that \"the impact of LGT (HGT) on the branches of the tree of life is significant but not overwhelming\" [71, 85, 86] .Why a Tree of Life Infected with HGT Still BifurcatesWe comment here too about the tree of 1%, first articulated by Dagan and Martin [87] .", [["LGT (HGT", "TREATMENT", 271, 279], ["Tree", "OBSERVATION_MODIFIER", 59, 63], ["large", "OBSERVATION_MODIFIER", 152, 157], ["amount", "OBSERVATION_MODIFIER", 158, 164], ["branches", "ANATOMY_MODIFIER", 288, 296], ["tree", "ANATOMY_MODIFIER", 304, 308]]], ["It is difficult to argue with the premise of the tree of 1%.", [["tree", "ANATOMY_MODIFIER", 49, 53]]], ["Of course, if 30 genes are chosen for an analysis and there are 3000 genes in an average bacterium or archaeon genome, then 1% is correct.", [["archaeon genome", "DNA", 102, 117], ["an analysis", "TEST", 38, 49], ["archaeon genome", "TREATMENT", 102, 117], ["archaeon genome", "OBSERVATION", 102, 117]]], ["But some studies used the entire repertoire of proteins from the organisms under study for phylogenetic analysis, and the Lineau et al. [69] dataset shows that we can reject the three hypotheses listed in Table 1 .", [["some studies", "TEST", 4, 16], ["phylogenetic analysis", "TEST", 91, 112]]], ["Another example is from di Bonaventura et al. [88] , where a phylogeny of 14 species of Pasteurellaceae was placed into a phylogenetic context.", [["Pasteurellaceae", "ORGANISM", 88, 103], ["Pasteurellaceae", "PROBLEM", 88, 103], ["Pasteurellaceae", "OBSERVATION", 88, 103]]], ["Two datasets were considered in this study-first, all 3130 proteins were included regardless of taxonomic overlap, and second a matrix with 633 proteins where all fourteen Pasteruellaceae had the sequence.", [["matrix", "CELLULAR_COMPONENT", 128, 134], ["Pasteruellaceae", "CANCER", 172, 187], ["633 proteins", "PROTEIN", 140, 152], ["Pasteruellaceae", "PROTEIN", 172, 187], ["Two datasets", "TEST", 0, 12], ["this study", "TEST", 32, 42], ["taxonomic overlap", "PROBLEM", 96, 113], ["taxonomic overlap", "OBSERVATION", 96, 113]]], ["There are 11 nodes in the concatenated tree for both datasets that are recovered regardless of method and at 100% bootstrap support.", [["11 nodes in the concatenated tree", "PROBLEM", 10, 43], ["method", "TREATMENT", 95, 101], ["11", "OBSERVATION_MODIFIER", 10, 12], ["nodes", "OBSERVATION", 13, 18], ["tree", "ANATOMY_MODIFIER", 39, 43]]], ["Figure 3 shows the number of nodes agreeing with the concatenated trees graphed against the number of proteins in the two datasets for the node number in agreement.", [["nodes", "ANATOMY", 29, 34], ["node", "ANATOMY", 139, 143], ["nodes", "OBSERVATION", 29, 34], ["node", "OBSERVATION", 139, 143]]], ["The figure demonstrates rampant incongruence in both datasets.", [["rampant incongruence in both datasets", "PROBLEM", 24, 61], ["rampant", "OBSERVATION_MODIFIER", 24, 31], ["incongruence", "OBSERVATION", 32, 44], ["both datasets", "OBSERVATION", 48, 61]]], ["Yet a robust and taxonomically reasonable hypothesis is attained that mirrors the current taxonomy of the group.", [["robust", "OBSERVATION_MODIFIER", 6, 12]]], ["The concatenated phylogeny is the product of the interaction of all of the phylogenetic signal of all of the proteins in the datasets.", [["phylogeny", "OBSERVATION_MODIFIER", 17, 26]]], ["An explanation for this seemingly strange result came from Lienau et al. [26] , who pointed out that even if incongruence at a node exists for a particular gene on a global level, there can be hidden support [75] for many of the other nodes in a phylogenetic hypothesis.", [["node", "ANATOMY", 127, 131], ["the other nodes", "PROBLEM", 225, 240], ["a phylogenetic hypothesis", "PROBLEM", 244, 269], ["node", "OBSERVATION", 127, 131], ["nodes", "OBSERVATION", 235, 240]]], ["The easiest way to picture this phenomenon is to think of mitochondrial and bacterial 16S ribosomal DNA.", [["mitochondrial", "ANATOMY", 58, 71], ["ribosomal", "ANATOMY", 90, 99], ["mitochondrial", "CELLULAR_COMPONENT", 58, 71], ["ribosomal", "CELLULAR_COMPONENT", 90, 99], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["mitochondrial and bacterial 16S ribosomal DNA", "DNA", 58, 103], ["mitochondrial and bacterial 16S ribosomal DNA", "PROBLEM", 58, 103], ["ribosomal DNA", "OBSERVATION", 90, 103]]], ["Using this gene to address the topology of the tree of life results in a tree radically incongruent with our background knowledge about the relationships of Archaea, Bacteria and Eukarya.", [["Bacteria", "CELLULAR_COMPONENT", 166, 174], ["Eukarya", "CELLULAR_COMPONENT", 179, 186], ["Archaea", "PROBLEM", 157, 164], ["Bacteria", "PROBLEM", 166, 174]]], ["The 16S tree places Eukarya within the bacterial clade and specifically close to the Proteobacteria.", [["the bacterial clade", "PROBLEM", 35, 54], ["tree", "OBSERVATION_MODIFIER", 8, 12], ["Proteobacteria", "OBSERVATION", 85, 99]]], ["However, when one looks at the hidden support 16S rDNA contributes to the accepted tree of life hypothesis, the hidden support is immense.", [["rDNA", "CELLULAR_COMPONENT", 50, 54], ["16S rDNA", "DNA", 46, 54]]], ["History before and after HGT is oftentimes kept intact.Concluding RemarksA representation of the history of life serves many purposes.", [["intact", "OBSERVATION", 48, 54]]], ["Phylogenetic trees are becoming increasingly important in community ecology, biogeography, hybrid zone analysis and even population genetics to name just a few evolutionary subdisciplines that are more and more reliant on phylogenies.", [["Phylogenetic trees", "PROBLEM", 0, 18], ["hybrid zone analysis", "TEST", 91, 111], ["trees", "OBSERVATION", 13, 18]]], ["It is therefore incumbent upon scientists to use the most accurate approaches to represent the pattern of divergence of life on Earth.Concluding RemarksChallenges to the tree of life have been raised on two major fronts as a result of genome level sequencing.", [["genome level sequencing", "TEST", 235, 258], ["tree", "ANATOMY_MODIFIER", 170, 174]]], ["Incomplete lineage sorting ISL [58] and HGT [11] [12] [13] [14] [15] [16] 18, 20, 21] have both been suggested as \"treebusters\" at certain levels of divergence amongst organisms.", [["HGT", "TEST", 40, 43], ["lineage", "OBSERVATION_MODIFIER", 11, 18], ["ISL", "OBSERVATION_MODIFIER", 27, 30]]], ["It is true that ISL and HGT disrupt vertical signals and they are both extremely interesting evolutionary processes that deserve attention and focus in both phylogenetic and evolutionary studies.", [["evolutionary studies", "TEST", 174, 194], ["ISL", "OBSERVATION", 16, 19], ["vertical signals", "OBSERVATION", 36, 52]]], ["The extent of their impact on vertically evolving and bifurcating lineages has been assumed to be substantial enough that new paradigms to replace the tree of life have been suggested [1] .", [["extent", "OBSERVATION_MODIFIER", 4, 10], ["bifurcating lineages", "OBSERVATION", 54, 74], ["assumed to be", "UNCERTAINTY", 84, 97], ["substantial", "OBSERVATION_MODIFIER", 98, 109], ["new", "OBSERVATION_MODIFIER", 122, 125]]], ["We suggest that beyond supposedly high levels of HGT, bacteria and archaea play by the same evolutionary rules that involve mutation, recombination, drift and selection.", [["bacteria", "PROBLEM", 54, 62], ["mutation", "PROBLEM", 124, 132]]], ["There is nothing really special about their divergence other than HGT, and if HGT either exists at a lower level than is thought or can be shown to be surmountable in the context of phylogenetic analysis, then there is no reason to \"uproot\" the tree of life.", [["HGT", "PROBLEM", 78, 81], ["phylogenetic analysis", "TEST", 182, 203], ["no reason", "UNCERTAINTY", 219, 228]]], ["Attempts at empirically determining the level of HGT in datasets range between below 15% [71, 83, 84] and the high set by the tree of 1%.", [["tree", "ANATOMY_MODIFIER", 126, 130]]], ["If the tree of life is a \"tree of 1%\" then the rest-99%can be used as a limit of non-vertical information [12, 13] of the genes in bacterial and archaeal An explanation for this seemingly strange result came from Lienau et al. [26] , who pointed out that even if incongruence at a node exists for a particular gene on a global level, there can be hidden support [75] for many of the other nodes in a phylogenetic hypothesis.", [["node", "ANATOMY", 281, 285], ["the genes in bacterial", "PROBLEM", 118, 140], ["the other nodes", "PROBLEM", 379, 394], ["a phylogenetic hypothesis", "PROBLEM", 398, 423], ["tree", "OBSERVATION_MODIFIER", 7, 11], ["node", "OBSERVATION", 281, 285], ["nodes", "OBSERVATION", 389, 394]]], ["The easiest way to picture this phenomenon is to think of mitochondrial and bacterial 16S ribosomal DNA.", [["mitochondrial", "ANATOMY", 58, 71], ["ribosomal", "ANATOMY", 90, 99], ["mitochondrial", "CELLULAR_COMPONENT", 58, 71], ["ribosomal", "CELLULAR_COMPONENT", 90, 99], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["mitochondrial and bacterial 16S ribosomal DNA", "DNA", 58, 103], ["mitochondrial and bacterial 16S ribosomal DNA", "PROBLEM", 58, 103], ["ribosomal DNA", "OBSERVATION", 90, 103]]], ["Using this gene to address the topology of the tree of life results in a tree radically incongruent with our background knowledge about the relationships of Archaea, Bacteria and Eukarya.", [["Bacteria", "CELLULAR_COMPONENT", 166, 174], ["Eukarya", "CELLULAR_COMPONENT", 179, 186], ["Archaea", "PROBLEM", 157, 164], ["Bacteria", "PROBLEM", 166, 174]]], ["The 16S tree places Eukarya within the bacterial clade and specifically close to the Proteobacteria.", [["the bacterial clade", "PROBLEM", 35, 54], ["tree", "OBSERVATION_MODIFIER", 8, 12], ["Proteobacteria", "OBSERVATION", 85, 99]]], ["However, when one looks at the hidden support 16S rDNA contributes to the accepted tree of life hypothesis, the hidden support is immense.", [["rDNA", "CELLULAR_COMPONENT", 50, 54], ["16S rDNA", "DNA", 46, 54]]], ["History before and after HGT is oftentimes kept intact.Concluding RemarksA representation of the history of life serves many purposes.", [["intact", "OBSERVATION", 48, 54]]], ["Phylogenetic trees are becoming increasingly important in community ecology, biogeography, hybrid zone analysis and even population genetics to name just a few evolutionary subdisciplines that are more and more reliant on phylogenies.", [["Phylogenetic trees", "PROBLEM", 0, 18], ["hybrid zone analysis", "TEST", 91, 111], ["trees", "OBSERVATION", 13, 18]]], ["It is therefore incumbent upon scientists to use the most accurate approaches to represent the pattern of divergence of life on Earth.Concluding RemarksChallenges to the tree of life have been raised on two major fronts as a result of genome level sequencing.", [["genome level sequencing", "TEST", 235, 258], ["tree", "ANATOMY_MODIFIER", 170, 174]]], ["Incomplete lineage sorting ISL [58] and HGT [11] [12] [13] [14] [15] [16] 18, 20, 21] have both been suggested as \"treebusters\" at certain levels of divergence amongst organisms.", [["HGT", "TEST", 40, 43], ["lineage", "OBSERVATION_MODIFIER", 11, 18], ["ISL", "OBSERVATION_MODIFIER", 27, 30]]], ["It is true that ISL and HGT disrupt vertical signals and they are both extremely interesting evolutionary processes that deserve attention and focus in both phylogenetic and evolutionary studies.", [["evolutionary studies", "TEST", 174, 194], ["ISL", "OBSERVATION", 16, 19], ["vertical signals", "OBSERVATION", 36, 52]]], ["The extent of their impact on vertically evolving and bifurcating lineages has been assumed to be substantial enough that new paradigms to replace the tree of life have been suggested [1] .", [["extent", "OBSERVATION_MODIFIER", 4, 10], ["bifurcating lineages", "OBSERVATION", 54, 74], ["assumed to be", "UNCERTAINTY", 84, 97], ["substantial", "OBSERVATION_MODIFIER", 98, 109], ["new", "OBSERVATION_MODIFIER", 122, 125]]], ["We suggest that beyond supposedly high levels of HGT, bacteria and archaea play by the same evolutionary rules that involve mutation, recombination, drift and selection.", [["bacteria", "PROBLEM", 54, 62], ["mutation", "PROBLEM", 124, 132]]], ["There is nothing really special about their divergence other than HGT, and if HGT either exists at a lower level than is thought or can be shown to be surmountable in the context of phylogenetic analysis, then there is no reason to \"uproot\" the tree of life.", [["HGT", "PROBLEM", 78, 81], ["phylogenetic analysis", "TEST", 182, 203], ["no reason", "UNCERTAINTY", 219, 228]]], ["Attempts at empirically determining the level of HGT in datasets range between below 15% [71, 83, 84] and the high set by the tree of 1%.", [["tree", "ANATOMY_MODIFIER", 126, 130]]], ["If the tree of life is a \"tree of 1%\" then the rest-99%-can be used as a limit of non-vertical information [12, 13] of the genes in bacterial and archaeal datasets.", [["the genes in bacterial and archaeal datasets", "PROBLEM", 119, 163], ["tree", "OBSERVATION_MODIFIER", 7, 11], ["archaeal datasets", "OBSERVATION", 146, 163]]], ["If we consider those estimates made from presence/absence approaches, the frequency of potential HGT tops out at 35% for archaea and lower for other lineages.", [["potential HGT tops", "TREATMENT", 87, 105], ["archaea", "PROBLEM", 121, 128]]], ["We simply suggest that it is not pervasive enough to fell a bifurcating tree of life.Concluding RemarksMany readers will be asking why not just use networks to do our analyses in the first place.", [["bifurcating", "OBSERVATION_MODIFIER", 60, 71], ["tree", "OBSERVATION_MODIFIER", 72, 76]]], ["Such methods can detect tree-like structures very simply and because they are more flexible in their interpretation, they should be preferred over strictly bifurcating trees.", [["tree-like structures", "PROBLEM", 24, 44]]], ["We suggest that this approach puts the cart before the horse because using the tree of life as a null hypothesis to examine the impact of HGT and lineage sorting in the tree of life makes fewer and simpler assumptions than assuming a network.", [["horse", "ORGANISM", 55, 60], ["a null hypothesis", "PROBLEM", 95, 112], ["tree", "ANATOMY_MODIFIER", 169, 173]]], ["In fact, we contend that phenomena such as specific HGT events in an evolutionary context are not discoverable without a tree of life.", [["phenomena", "PROBLEM", 25, 34], ["specific HGT events", "PROBLEM", 43, 62]]], ["By accepting a concatenated hypothesis for the tree of life, a baseline bifurcating pattern is discovered.", [["a concatenated hypothesis", "PROBLEM", 13, 38], ["a baseline bifurcating pattern", "PROBLEM", 61, 91], ["bifurcating", "OBSERVATION_MODIFIER", 72, 83]]], ["This baseline pattern can then be used to interpret any fragment of DNA, gene or cluster of genes as being in line with vertical history or horizontal transfer [71] .", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["any fragment of DNA", "PROBLEM", 52, 71]]], ["In fact, a tree of life offers what we might call more explanatory power than any other method of evolutionary analysis, because a bifurcating tree makes fewer assumptions about the divergence process as first proposed by Darwin in his Principle of Divergence.Concluding RemarksWe point out that species and speciation in bacteria would not be interpretable in a biological context without a bifurcating tree of life.", [["evolutionary analysis", "TEST", 98, 119], ["species", "PROBLEM", 296, 303], ["speciation in bacteria", "PROBLEM", 308, 330]]], ["As we note above, bacteria and archaea play by the same evolutionary rules as eukarya.", [["bacteria", "PROBLEM", 18, 26], ["archaea", "PROBLEM", 31, 38]]], ["Mutation, selection and drift result in genotypic and phenotypic clustering that simply would not result with a tree of 1%.", [["genotypic and phenotypic clustering", "PROBLEM", 40, 75]]], ["Again, we may turn to Darwin's perspective, \"Why is not all nature in confusion, instead of the species being, as we see them, well defined? [90] ?\"", [["confusion", "DISEASE", 70, 79], ["confusion", "PROBLEM", 70, 79]]], ["Although Darwin was referring to eukaryotes, numerous studies have revealed clusters of bacterial isolates that share complex phenotypes, and these clusters are often designated as species [89, [91] [92] [93] [94] .", [["numerous studies", "TEST", 45, 61], ["bacterial isolates", "PROBLEM", 88, 106], ["complex phenotypes", "PROBLEM", 118, 136], ["bacterial isolates", "OBSERVATION", 88, 106]]], ["In fact, Cohan used the existence of these clusters as evidence of bacterial species.", [["bacterial species", "PROBLEM", 67, 84], ["evidence of", "UNCERTAINTY", 55, 66], ["bacterial species", "OBSERVATION", 67, 84]]], ["\"Bacterial diversity is organized into discrete phenotypic and genetic clusters . . . and these clusters are recognized as species.\" [95] .", [["Bacterial diversity", "PROBLEM", 1, 20], ["Bacterial diversity", "OBSERVATION", 1, 20]]], ["Lan and Reeves [96] proposed the core genome hypothesis (CGH), which starts with the biological species concept [23] and acknowledges the potential impact of HGT on bacterial species.", [["the core genome hypothesis", "PROBLEM", 29, 55], ["HGT on bacterial species", "PROBLEM", 158, 182], ["bacterial species", "OBSERVATION", 165, 182]]], ["The CGH predicts that a subset of bacterial genes, the core, is present in all, or nearly all, individuals within a species.", [["bacterial genes", "DNA", 34, 49], ["bacterial genes", "PROBLEM", 34, 49], ["bacterial genes", "OBSERVATION", 34, 49], ["core", "OBSERVATION_MODIFIER", 55, 59], ["all", "OBSERVATION_MODIFIER", 75, 78]]], ["These are the genes that provide the defining characteristics of a species and are assumed to experience primarily purifying selection, to remove deleterious mutations, and to maintain existing functions.", [["a species", "PROBLEM", 65, 74], ["deleterious mutations", "PROBLEM", 146, 167]]], ["As a species evolves, its core genome will evolve as a complex of co-evolved functions.Concluding RemarksThe CGH has dramatically influenced how bacteriologists think about the nature of bacterial species.", [["core genome", "DNA", 26, 37], ["bacterial species", "PROBLEM", 187, 204], ["bacterial species", "OBSERVATION", 187, 204]]], ["Prior to the CGH, the strongest argument against the recognition of bacterial \"species\" was the simple observation of HGT between bacterial lineages.", [["bacterial lineages", "CELL_TYPE", 130, 148], ["the CGH", "TEST", 9, 16], ["bacterial \"species", "PROBLEM", 68, 86], ["HGT between bacterial lineages", "PROBLEM", 118, 148], ["bacterial lineages", "OBSERVATION", 130, 148]]], ["The fact that bacterial species gene pools may not be tightly closed was enough reason for many microbiologists to conclude bacterial species could not survive such exchange.", [["bacterial species gene pools", "PROBLEM", 14, 42], ["bacterial species", "PROBLEM", 124, 141], ["bacterial species", "OBSERVATION", 14, 31]]], ["This contradicts the fact that bacteria exist in phenotypic clusters, which many microbiologists recognize as species.", [["bacteria", "PROBLEM", 31, 39], ["phenotypic clusters", "PROBLEM", 49, 68], ["bacteria", "OBSERVATION", 31, 39], ["phenotypic clusters", "OBSERVATION", 49, 68]]], ["Even more compelling, it is becoming clear that these well-defined phenotypic clusters correspond to underlying genotype clusters [97] [98] [99] .Concluding RemarksTaxonomy of bacteria and archaea would be impossible too.", [["these well-defined phenotypic clusters", "PROBLEM", 48, 86], ["underlying genotype clusters", "PROBLEM", 101, 129], ["bacteria", "PROBLEM", 176, 184], ["archaea", "PROBLEM", 189, 196], ["clear", "OBSERVATION", 37, 42], ["bacteria", "OBSERVATION", 176, 184]]], ["Without bifurcation, divergence in a biological context and every scientific endeavor that uses such divergence becomes meaningless.", [["bifurcation", "PROBLEM", 8, 19], ["bifurcation", "OBSERVATION_MODIFIER", 8, 19]]]], "PMC2291564": [["IntroductionThe field of bioinformatics has enjoyed significant growth in China.", [["significant", "OBSERVATION_MODIFIER", 52, 63], ["growth", "OBSERVATION_MODIFIER", 64, 70]]], ["As shown in Figure 1A, this number has been increasing significantly over the past decade.", [["increasing", "OBSERVATION_MODIFIER", 44, 54], ["significantly", "OBSERVATION_MODIFIER", 55, 68]]], ["The number of all publications from China indexed in PubMed has also been increasing (Figure 1B), but if we plot the percentage of bioinformatics publications from China among all PubMed publications from China, we observe that the percentage itself has been increasing rapidly (Figure 1C), indicating that the contribution of bioinformatics research is becoming more significant within the life sciences in China.", [["all", "OBSERVATION_MODIFIER", 14, 17], ["publications", "OBSERVATION", 18, 30], ["increasing", "OBSERVATION_MODIFIER", 74, 84], ["increasing", "OBSERVATION_MODIFIER", 259, 269]]], ["Additionally, the number of PubMed publications from China has also been growing faster than the total number of PubMed publications (Figure 1B versus 1E).", [["growing", "OBSERVATION_MODIFIER", 73, 80], ["faster", "OBSERVATION_MODIFIER", 81, 87]]], ["Furthermore, we observe that, very interestingly, for each year starting from 2003, the percentage of bioinformatics publications among all PubMed publications is greater in China than worldwide (Figure 1C versus 1F), indicating that bioinformatics as a field within the life sciences is enjoying a faster growth rate in China than elsewhere in the world.IntroductionThese numbers and trends, although only rough estimates, are fascinating and deserve a closer look.", [["greater", "OBSERVATION_MODIFIER", 163, 170]]], ["Due to the nature of personal perspectives and space limitations, what we present is by no means exhaustive, but merely suggestive.The Early YearsChina had a late and rather sluggish start in bioinformatics, largely due to lack of institutional support for bioinformatics and governmental funding during the early years.", [["space limitations", "PROBLEM", 47, 64], ["institutional support", "TREATMENT", 231, 252], ["governmental funding", "TREATMENT", 276, 296]]], ["Fascinated by computable and predictable characteristics of biological systems, he first studied protein structures and then devoted himself to the analysis of DNA and protein sequences.", [["DNA", "CELLULAR_COMPONENT", 160, 163], ["DNA and protein sequences", "DNA", 160, 185], ["the analysis", "TEST", 144, 156], ["DNA and protein sequences", "TEST", 160, 185]]], ["In visualizing very long DNA sequences, including the complete genomes of several bacteria and yeast and segments of human genome, his group observed fractal-like patterns [1]; subsequently they proposed the description of a genome using statistics of K-strings (by counting a series of K-tuples in a linear sequence of symbols), enabling a new paradigm for phylogenetic analysis without sequence alignments [2].", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["human", "ORGANISM", 117, 122], ["long DNA sequences", "DNA", 20, 38], ["human genome", "DNA", 117, 129], ["K-strings", "DNA", 252, 261], ["K-tuples", "DNA", 287, 295], ["yeast", "SPECIES", 95, 100], ["human", "SPECIES", 117, 122], ["yeast", "SPECIES", 95, 100], ["human", "SPECIES", 117, 122], ["very long DNA sequences", "PROBLEM", 15, 38], ["several bacteria", "PROBLEM", 74, 90], ["yeast and segments of human genome", "PROBLEM", 95, 129], ["K-strings", "PROBLEM", 252, 261], ["K-tuples", "TREATMENT", 287, 295], ["phylogenetic analysis", "TEST", 358, 379], ["several", "OBSERVATION_MODIFIER", 74, 81], ["bacteria", "OBSERVATION", 82, 90], ["human genome", "OBSERVATION", 117, 129]]], ["His group later created the concept of Z-curve to display DNA composition dynamics in geometric spaces [4],[5].", [["His", "CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["Z-curve", "TEST", 39, 46]]], ["Z-curve has been successfully applied to genome sequence analyses such as prediction of coding genes in yeast genome [6], isochores in human genome [7], and replication origins in archaeal genomes [8].", [["human", "ORGANISM", 135, 140], ["coding genes", "DNA", 88, 100], ["yeast genome", "DNA", 104, 116], ["isochores", "DNA", 122, 131], ["human genome", "DNA", 135, 147], ["archaeal genomes", "DNA", 180, 196], ["yeast", "SPECIES", 104, 109], ["human", "SPECIES", 135, 140], ["yeast", "SPECIES", 104, 109], ["human", "SPECIES", 135, 140], ["Z-curve", "TREATMENT", 0, 7], ["genome sequence analyses", "TEST", 41, 65], ["coding genes in yeast genome", "PROBLEM", 88, 116], ["isochores in human genome", "PROBLEM", 122, 147], ["yeast genome", "OBSERVATION", 104, 116], ["archaeal genomes", "OBSERVATION", 180, 196]]], ["His group identified hundreds of novel small noncoding RNAs in the nematode C. elegans and characterized their sequence features and expression patterns [11],[13].", [["nematode", "ORGANISM", 67, 75], ["C. elegans", "ORGANISM", 76, 86], ["small noncoding RNAs", "RNA", 39, 59], ["C. elegans", "SPECIES", 76, 86], ["C. elegans", "SPECIES", 76, 86], ["novel small noncoding RNAs", "PROBLEM", 33, 59], ["small", "OBSERVATION_MODIFIER", 39, 44], ["noncoding RNAs", "OBSERVATION", 45, 59]]], ["A few other early scientists with important contributions include Yanda Li [18]\u2013[24], Luhua Lai [25]\u2013[34], Yunyu Shi [35], Liaofu Luo [36]\u2013[40], Dafu Ding [41]\u2013[43], and Zhirong Sun [44]\u2013[48].The Early YearsIn the early to mid-1990s, many Chinese biologists were still not familiar with international biological databases, and some in remote cities did not even have reliable Internet connections to overseas Web sites.", [["Li", "CHEMICAL", 72, 74], ["Dafu Ding [41]\u2013[43]", "SIMPLE_CHEMICAL", 145, 164], ["Yanda Li", "TEST", 66, 74], ["Luhua Lai", "TEST", 86, 95], ["Liaofu Luo", "TEST", 123, 133], ["Dafu Ding", "TEST", 145, 154], ["Zhirong Sun", "TEST", 170, 181], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["From them, many Chinese scientists received their first exposure to biological data and analysis tools.", [["biological data", "TEST", 68, 83], ["analysis tools", "TEST", 88, 102]]], ["Through close collaboration with the NCBI, EBI, and EMBnet, Luo's group continues to maintain the largest online bioinformatics resource in China at http://www.cbi.pku.edu.cn.The Internet Boom and the Genomic BoomTwo significant developments in the second half of the 1990s proved critical to the expansion of bioinformatics in China.", [["significant", "OBSERVATION_MODIFIER", 217, 228]]], ["It was not until 1994 that full TCP/IP Internet connection between China and the rest of the world was established.", [["TCP", "CHEMICAL", 32, 35]]], ["At that time, the only established connection was an existing link, a dial-up X.25 connection, between the Institute of High-Energy Physics (IHEP) in Beijing and the Stanford Linear Accelerator Center (SLAC) at Stanford University.", [["the Stanford Linear Accelerator Center (SLAC", "TREATMENT", 162, 206]]], ["On May 17, 1994, the official connection to FIX-West was announced, and the U.S.-based Energy Sciences Network (ESnet) agreed to carry China IP traffic.", [["FIX", "GENE_OR_GENE_PRODUCT", 44, 47], ["FIX", "PROTEIN", 44, 47]]], ["Despite the late start, China caught up quickly with the worldwide Internet boom and established fast and broad Internet connections which were critical for biological data exchange.The Internet Boom and the Genomic BoomAt about the same time, the genomic boom in the late 1990s to early 2000s exemplified by the Human Genome Project [49] started to generate huge and exponentially growing amounts of data.", [["Human", "ORGANISM", 313, 318], ["Human", "SPECIES", 313, 318]]], ["After earlier efforts such as sequencing of full-length cDNAs [50], Chinese scientists officially participated in the Human Genome Project in 1999 and sequenced 1% of the human genome [9],[49].", [["Human", "ORGANISM", 118, 123], ["human", "ORGANISM", 171, 176], ["cDNAs", "DNA", 56, 61], ["human genome", "DNA", 171, 183], ["Human", "SPECIES", 118, 123], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176]]], ["Since then the Chinese genome centers have independently sequenced several large genomes including those of rice (Oryza sativa L. ssp. indica) [51], silkworm (Bombyx mori) [52], and numerous microbial genomes such as that of Thermoanaerobacter tengcongensis, a rod-shaped, gram-negative, anaerobic eubacterium isolated from a freshwater hot spring in Tengchong, China [53].The Internet Boom and the Genomic BoomData is a major driving force for bioinformatics\u2014it demands new methods for data storage and analyses and motivated the computational discovery of biological patterns.", [["rice", "ORGANISM", 108, 112], ["Oryza sativa", "ORGANISM", 114, 126], ["L.", "ORGANISM", 127, 129], ["ssp.", "ORGANISM", 130, 134], ["indica", "ORGANISM", 135, 141], ["silkworm (", "ORGANISM", 149, 159], ["Bombyx mori", "ORGANISM", 159, 170], ["Thermoanaerobacter tengcongensis", "ORGANISM", 225, 257], ["rice", "SPECIES", 108, 112], ["Oryza sativa", "SPECIES", 114, 126], ["L. ssp.", "SPECIES", 127, 134], ["indica", "SPECIES", 135, 141], ["silkworm", "SPECIES", 149, 157], ["Bombyx mori", "SPECIES", 159, 170], ["Thermoanaerobacter tengcongensis", "SPECIES", 225, 257], ["rice", "SPECIES", 108, 112], ["Oryza sativa L. ssp.", "SPECIES", 114, 134], ["indica", "SPECIES", 135, 141], ["silkworm", "SPECIES", 149, 157], ["Bombyx mori", "SPECIES", 159, 170], ["Thermoanaerobacter tengcongensis", "SPECIES", 225, 257], ["numerous microbial genomes", "PROBLEM", 182, 208], ["Thermoanaerobacter tengcongensis", "PROBLEM", 225, 257], ["gram", "TEST", 273, 277], ["anaerobic eubacterium", "PROBLEM", 288, 309], ["data storage", "TEST", 487, 499], ["large", "OBSERVATION_MODIFIER", 75, 80], ["microbial genomes", "OBSERVATION", 191, 208]]], ["In all genomic projects, bioinformatics teams played significant roles in data analysis.", [["data analysis", "TEST", 74, 87]]], ["Databases were created to store the genomic data, for instance BGI-RIS [54] and SilkDB [55] for rice and silkworm genomic sequence data and related biological information, and ChickVD [56] for chicken genomic sequence variations.", [["chicken", "ORGANISM", 193, 200], ["rice and silkworm genomic sequence", "DNA", 96, 130], ["chicken genomic sequence", "DNA", 193, 217], ["rice", "SPECIES", 96, 100], ["chicken", "SPECIES", 193, 200], ["rice", "SPECIES", 96, 100], ["silkworm", "SPECIES", 105, 113], ["chicken", "SPECIES", 193, 200], ["silkworm genomic sequence data", "TEST", 105, 135], ["chicken genomic sequence variations", "PROBLEM", 193, 228]]], ["Methods and software packages were developed to analyze the huge amount of genomic data, including for instance BGF, an ab initio gene prediction method developed for the rice genome based on Hidden Markov Model (HMM) and dynamic programming [57], a nonsupervised gene prediction algorithm for bacterial and archaeal genomes [58], and a method for genome comparison using Gene Ontology (GO) with statistical testing [59].Present Day: A Diversified LandscapeSince the end of the 1990s, bioinformatics in China has experienced significant growth fueled by not only the aforementioned Internet and genomic boom but also by official institutional support, steadily increasing government funding, and very importantly, a growing number of Chinese scientists returning to China after formal overseas training and research experience in bioinformatics and genomics.", [["BGF", "GENE_OR_GENE_PRODUCT", 112, 115], ["BGF", "PROTEIN", 112, 115], ["rice genome", "DNA", 171, 182], ["bacterial and archaeal genomes", "DNA", 294, 324], ["rice", "SPECIES", 171, 175], ["rice", "SPECIES", 171, 175], ["software packages", "TREATMENT", 12, 29], ["an ab initio gene prediction method", "TREATMENT", 117, 152], ["the rice genome", "TREATMENT", 167, 182], ["a nonsupervised gene prediction algorithm", "TREATMENT", 248, 289], ["bacterial and archaeal genomes", "PROBLEM", 294, 324], ["statistical testing", "TEST", 396, 415], ["formal overseas training", "TREATMENT", 778, 802], ["archaeal genomes", "OBSERVATION", 308, 324], ["increasing", "OBSERVATION_MODIFIER", 661, 671]]], ["Today the field is characterized by a great variety of biological questions addressed and the close collaborations between computational scientists and bench biologists, with a full spectrum of focuses ranging from providing resources and services, developing databases and algorithms, to generating hypotheses and making biological discoveries.Present Day: A Diversified LandscapeProviding biological data resources and services is still an important part of bioinformatics.", [["algorithms", "TEST", 274, 284]]], ["Furthermore, many new primary databases with raw data and value-added secondary databases were created by Chinese scientists (Table 1), and many locally developed methods were implemented and incorporated into Web servers (Table 2).", [["value", "TEST", 58, 63], ["new", "OBSERVATION_MODIFIER", 18, 21]]], ["These databases and tools address a broad range of biological questions and are open to the entire international scientific community, and are enjoyed by a large worldwide user base.Present Day: A Diversified LandscapeIndependently or in collaboration with bench scientists, bioinformatics scientists have played significant roles in important biological discoveries.", [["These databases", "TEST", 0, 15], ["large", "OBSERVATION_MODIFIER", 156, 161]]], ["In 2003, China and many other countries suffered from the severe acute respiratory syndrome (SARS) epidemic.", [["acute respiratory syndrome", "DISEASE", 65, 91], ["SARS", "DISEASE", 93, 97], ["the severe acute respiratory syndrome", "PROBLEM", 54, 91], ["epidemic", "PROBLEM", 99, 107], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91]]], ["A team of bioinformaticians quickly joined the Chinese SARS Molecular Epidemiology Consortium, led by Guo-Ping Zhao, to sequence and analyze SARS coronavirus genomic sequences derived from the early, middle, and late phases of the SARS epidemic as well as viral sequences from palm civets.", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 231, 235], ["palm", "ORGANISM_SUBDIVISION", 277, 281], ["SARS coronavirus genomic sequences", "DNA", 141, 175], ["viral sequences", "DNA", 256, 271], ["SARS coronavirus", "SPECIES", 141, 157], ["SARS coronavirus genomic sequences", "TEST", 141, 175], ["the SARS epidemic", "PROBLEM", 227, 244], ["viral sequences", "TEST", 256, 271], ["middle", "ANATOMY_MODIFIER", 200, 206]]], ["Their work uncovered the molecular evolution of the SARS coronavirus and the viral invasion from animal to human [60],[61].", [["SARS coronavirus", "DISEASE", 52, 68], ["SARS coronavirus", "ORGANISM", 52, 68], ["human", "ORGANISM", 107, 112], ["coronavirus", "SPECIES", 57, 68], ["human", "SPECIES", 107, 112], ["SARS coronavirus", "SPECIES", 52, 68], ["human", "SPECIES", 107, 112], ["the SARS coronavirus", "PROBLEM", 48, 68], ["the viral invasion", "PROBLEM", 73, 91], ["viral invasion", "OBSERVATION", 77, 91]]], ["Another group proposed a mathematical model to estimate the evolution rate of the SARS coronavirus genome (0.16 base/day) and the time of the last common ancestor of the sequenced SARS strains (August or September of 2002) [62].", [["SARS", "DISEASE", 82, 86], ["SARS", "DISEASE", 180, 184], ["SARS coronavirus genome", "DNA", 82, 105], ["SARS coronavirus", "SPECIES", 82, 98], ["the SARS coronavirus genome", "PROBLEM", 78, 105], ["the sequenced SARS strains", "PROBLEM", 166, 192]]], ["To identify potential anti-viral drug targets, proteomic and bioinformatic methods were used to investigate key SARS viral proteins including structural proteins [63], spike protein [64], and 3C-like proteinase [30].", [["spike protein [64]", "GENE_OR_GENE_PRODUCT", 168, 186], ["3C-like proteinase", "GENE_OR_GENE_PRODUCT", 192, 210], ["SARS viral proteins", "PROTEIN", 112, 131], ["structural proteins", "PROTEIN", 142, 161], ["spike protein [64], and 3C-like proteinase", "PROTEIN", 168, 210], ["anti-viral drug targets", "TREATMENT", 22, 45], ["bioinformatic methods", "TEST", 61, 82], ["key SARS viral proteins", "PROBLEM", 108, 131], ["structural proteins", "TEST", 142, 161], ["spike protein", "TEST", 168, 181], ["3C", "TEST", 192, 194], ["proteinase", "TEST", 200, 210], ["anti-viral drug", "OBSERVATION", 22, 37]]], ["Genomic packaging signals, which may be used to design antisense RNA and RNA interfere (RNAi) drugs treating SARS, were predicted by comparative genomics methods [65].", [["SARS", "DISEASE", 109, 113], ["antisense RNA", "RNA", 55, 68], ["antisense RNA", "TREATMENT", 55, 68], ["RNAi) drugs", "TREATMENT", 88, 99], ["SARS", "PROBLEM", 109, 113], ["packaging signals", "OBSERVATION", 8, 25]]], ["The three-dimensional structure of 3C-like proteinase was constructed by homology modeling, based on which virtual screening of chemical databases was performed to search for potential inhibitors [31].", [["3C-like proteinase", "GENE_OR_GENE_PRODUCT", 35, 53], ["3C-like proteinase", "PROTEIN", 35, 53], ["3C-like proteinase", "TREATMENT", 35, 53], ["virtual screening", "TEST", 107, 124], ["chemical databases", "TEST", 128, 146]]], ["Chinese SARS patients were statistically studied to elucidate the association of symptom combinations with different outcome and therapeutic effects [66] and the association between mannose-binding lectin gene polymorphisms and susceptibility to SARS virus infection [67].Present Day: A Diversified LandscapeThe large Chinese population provided invaluable resources for genetic studies.", [["SARS", "DISEASE", 8, 12], ["SARS virus infection", "DISEASE", 246, 266], ["mannose", "CHEMICAL", 182, 189], ["patients", "ORGANISM", 13, 21], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 182, 204], ["SARS virus", "ORGANISM", 246, 256], ["mannose-binding lectin gene polymorphisms", "DNA", 182, 223], ["patients", "SPECIES", 13, 21], ["SARS virus", "SPECIES", 246, 256], ["symptom", "PROBLEM", 81, 88], ["mannose-binding lectin gene polymorphisms", "PROBLEM", 182, 223], ["SARS virus infection", "PROBLEM", 246, 266], ["genetic studies", "TEST", 371, 386], ["Diversified", "OBSERVATION_MODIFIER", 287, 298], ["Landscape", "OBSERVATION", 299, 308], ["large", "OBSERVATION_MODIFIER", 312, 317]]], ["Patient and control groups were genotyped to establish associations between genetic variations and susceptibility to diseases such as esophageal squamous cell carcinoma [68], hepatocellular carcinoma in a particularly high-risk region of China [69], hypertension [70], and coronary heart disease [71].", [["esophageal squamous cell carcinoma", "ANATOMY", 134, 168], ["hepatocellular carcinoma", "ANATOMY", 175, 199], ["coronary", "ANATOMY", 273, 281], ["heart", "ANATOMY", 282, 287], ["esophageal squamous cell carcinoma", "DISEASE", 134, 168], ["hepatocellular carcinoma", "DISEASE", 175, 199], ["hypertension", "DISEASE", 250, 262], ["coronary heart disease", "DISEASE", 273, 295], ["esophageal squamous cell carcinoma", "CANCER", 134, 168], ["hepatocellular carcinoma", "CANCER", 175, 199], ["heart", "ORGAN", 282, 287], ["Patient", "SPECIES", 0, 7], ["genetic variations", "PROBLEM", 76, 94], ["susceptibility to diseases", "PROBLEM", 99, 125], ["esophageal squamous cell carcinoma", "PROBLEM", 134, 168], ["hepatocellular carcinoma", "PROBLEM", 175, 199], ["hypertension", "PROBLEM", 250, 262], ["coronary heart disease", "PROBLEM", 273, 295], ["esophageal", "ANATOMY", 134, 144], ["squamous cell carcinoma", "OBSERVATION", 145, 168], ["hepatocellular", "ANATOMY", 175, 189], ["carcinoma", "OBSERVATION", 190, 199], ["hypertension", "OBSERVATION", 250, 262], ["coronary heart", "ANATOMY", 273, 287], ["disease", "OBSERVATION", 288, 295]]], ["A link between an Asian-enriched SNP in human sialidase and severe adverse reactions to the anti-viral drug Tamiflu (oseltamivir carboxylate) was proposed and confirmed by bioinformatic methods and enzymatic assays [72].", [["SNP", "CHEMICAL", 33, 36], ["Tamiflu", "CHEMICAL", 108, 115], ["oseltamivir carboxylate", "CHEMICAL", 117, 140], ["Tamiflu", "CHEMICAL", 108, 115], ["oseltamivir carboxylate", "CHEMICAL", 117, 140], ["human", "ORGANISM", 40, 45], ["sialidase", "GENE_OR_GENE_PRODUCT", 46, 55], ["Tamiflu", "SIMPLE_CHEMICAL", 108, 115], ["oseltamivir carboxylate", "SIMPLE_CHEMICAL", 117, 140], ["Asian-enriched SNP", "DNA", 18, 36], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["an Asian-enriched SNP in human sialidase", "TREATMENT", 15, 55], ["severe adverse reactions", "PROBLEM", 60, 84], ["the anti-viral drug Tamiflu", "TREATMENT", 88, 115], ["oseltamivir carboxylate)", "TREATMENT", 117, 141], ["enzymatic assays", "TEST", 198, 214], ["severe", "OBSERVATION_MODIFIER", 60, 66]]], ["A number of interesting works studied the migration history of Chinese and East Asian populations by the sequencing and phylogentic analysis of Y-chromosomes [73]\u2013[77].", [["Y-chromosomes", "DNA", 144, 157], ["the sequencing", "TEST", 101, 115], ["phylogentic analysis", "TEST", 120, 140], ["Y-chromosomes", "TEST", 144, 157]]], ["As more and more genetic data were generated, new algorithms continued to be developed, for instance a Java-based method to analyze linkage disequilibrium [79], software for haplotype block partition and htSNPs selection [80], a method to detect human recombination hotspots based on a multiple-hotspot model and an approximate log-likelihood ratio test [81], and an SVM-based method that used new sequence and structure features to predict the possible disease association of nonsynonmous SNPs with increased accuracy [82].Present Day: A Diversified LandscapeThe increasing number of completely and partially sequenced genomes have enabled the study of the evolution of genomes and gene families.", [["human", "ORGANISM", 246, 251], ["human recombination hotspots", "DNA", 246, 274], ["nonsynonmous SNPs", "DNA", 477, 494], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["new algorithms", "PROBLEM", 46, 60], ["linkage disequilibrium", "PROBLEM", 132, 154], ["haplotype block partition", "TREATMENT", 174, 199], ["an SVM", "TEST", 364, 370], ["new sequence", "TEST", 394, 406], ["nonsynonmous SNPs", "PROBLEM", 477, 494], ["the study", "TEST", 641, 650], ["nonsynonmous SNPs", "OBSERVATION", 477, 494], ["increased", "OBSERVATION_MODIFIER", 500, 509], ["Diversified", "OBSERVATION_MODIFIER", 539, 550], ["Landscape", "OBSERVATION", 551, 560], ["increasing", "OBSERVATION_MODIFIER", 564, 574], ["number", "OBSERVATION_MODIFIER", 575, 581]]], ["Of particular interest to many Chinese scientists is the study of the evolution of plants, largely due to the country's longstanding strength in plant biology and partly due to its dedication to the sequencing of the rice genome.", [["rice genome", "DNA", 217, 228], ["rice", "SPECIES", 217, 221], ["rice", "SPECIES", 217, 221], ["the study", "TEST", 53, 62]]], ["Two groups had studied the collinearity of duplicated genes along rice chromosomes and discovered that the rice genome had undergone an ancient whole-genome duplication 70 million years ago and a recent segmental duplication involving Chromosomes 11 and 12 five million years ago [83],[84].", [["chromosomes", "ANATOMY", 71, 82], ["rice chromosomes", "CELLULAR_COMPONENT", 66, 82], ["rice chromosomes", "DNA", 66, 82], ["rice genome", "DNA", 107, 118], ["rice", "SPECIES", 66, 70], ["rice", "SPECIES", 107, 111], ["rice", "SPECIES", 66, 70], ["rice", "SPECIES", 107, 111], ["an ancient whole-genome duplication", "TREATMENT", 133, 168], ["a recent segmental duplication involving Chromosomes", "PROBLEM", 194, 246], ["segmental", "ANATOMY_MODIFIER", 203, 212], ["duplication", "OBSERVATION", 213, 224]]], ["Their findings settled previous disputes over whether rice was an ancient aneuploid or an ancient polyploidy, bringing the two contradictory sides to agreement in the form of a graciously co-authored Commentary [85].", [["rice", "SPECIES", 54, 58], ["rice", "SPECIES", 54, 58], ["an ancient aneuploid", "PROBLEM", 63, 83], ["an ancient polyploidy", "PROBLEM", 87, 108], ["ancient polyploidy", "OBSERVATION", 90, 108]]], ["In addition to whole genomes, the evolution of many important plant gene families was also studied in detail, such as transcription factor families [86] and enzymes [87].", [["plant gene families", "DNA", 62, 81], ["transcription factor families", "PROTEIN", 118, 147], ["enzymes", "PROTEIN", 157, 164], ["enzymes", "TEST", 157, 164]]], ["A group studied the origination of new genes in rice and found a surprisingly high number of retrogenes as well as chimeric genes originated by retroposition, suggesting that retroposition is an important mechanism that governs gene evolution in rice and other grass species [88].", [["rice", "ORGANISM", 48, 52], ["rice", "ORGANISM_SUBDIVISION", 246, 250], ["retrogenes", "DNA", 93, 103], ["chimeric genes", "DNA", 115, 129], ["rice", "SPECIES", 48, 52], ["rice", "SPECIES", 246, 250], ["rice", "SPECIES", 48, 52], ["rice", "SPECIES", 246, 250]]], ["Several groups had proposed interesting theories about the genetic code (amino acid codons and stop codons) [36],[37],[40],[90],[91].Present Day: A Diversified LandscapeWhen and where genes in a genome are transcribed and translated and how this expression of genes and proteins is regulated are important biological questions that had interested numerous scientists for decades.", [["amino acid", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 73, 83], ["amino acid", "AMINO_ACID", 73, 83], ["the genetic code (amino acid codons", "TREATMENT", 55, 90]]], ["A first step to study this important question is to measure and compare the expression level of mRNAs.", [["mRNAs", "RNA", 96, 101]]], ["Several Chinese groups had developed algorithms for microarray experiments including designing probes [92], processing raw data by an integrated pipeline [93], detecting differentially expressed genes by relative entropy [94], identifying clusters of co-expressed genes by Hidden Markov Models [47], and finding disease-related genes by an ensemble decision approach [95].", [["co-expressed genes", "DNA", 251, 269], ["disease-related genes", "DNA", 312, 333], ["microarray experiments", "TEST", 52, 74]]], ["Transcription factors bind to upstream regions of genes to regulate their transcription.", [["Transcription factors", "PROTEIN", 0, 21], ["upstream regions", "DNA", 30, 46], ["Transcription factors bind", "PROBLEM", 0, 26]]], ["About 2,000 transcription factors (\u223c10% of the genomes) were identified in each of the three sequenced plant genomes, Arabidopsis, rice, and populus, by combining similarity and motif-based approaches [96]\u2013[98].", [["populus", "ANATOMY", 141, 148], ["rice", "ORGANISM_SUBDIVISION", 131, 135], ["transcription factors", "PROTEIN", 12, 33], ["plant genomes", "DNA", 103, 116], ["Arabidopsis", "SPECIES", 118, 129], ["rice", "SPECIES", 131, 135], ["Arabidopsis", "SPECIES", 118, 129], ["rice", "SPECIES", 131, 135], ["plant genomes", "OBSERVATION", 103, 116]]], ["A new method was developed to identify potential transcription factor binding sites in the upstream regions of genes by searching for over-represented cis-elements with Position Weight Matrix\u2013based similarity scores [48].", [["transcription factor binding sites", "DNA", 49, 83], ["upstream regions", "DNA", 91, 107], ["cis-elements", "DNA", 151, 163], ["A new method", "TREATMENT", 0, 12], ["potential transcription factor binding sites", "PROBLEM", 39, 83], ["Position Weight Matrix\u2013based similarity scores", "TEST", 169, 215]]], ["Another method uncovered the patterns of conservation, genomic distribution, and co-factor binding of transcription factor binding sites given ChIP-chip tiling array data [99].", [["transcription factor binding sites", "DNA", 102, 136], ["transcription factor binding sites", "PROBLEM", 102, 136], ["genomic distribution", "OBSERVATION", 55, 75]]], ["A new four-component statistical model was proposed to improve accuracy of the identification of translation initiation sites in microbial genomes [100].", [["translation initiation sites", "DNA", 97, 125], ["translation initiation sites", "TREATMENT", 97, 125], ["new", "OBSERVATION_MODIFIER", 2, 5], ["microbial genomes", "OBSERVATION", 129, 146]]], ["Alternative splicing adds great variety to the proteome.", [["Alternative splicing", "TREATMENT", 0, 20], ["great variety", "OBSERVATION_MODIFIER", 26, 39]]], ["A new method, named Splicing Variant Analysis Platform (SVAP, http://svap.cbi.pku.edu.cn), could identify alternatively spliced isoforms from EST data ten times faster than other existing methods.", [["A new method", "TREATMENT", 0, 12], ["EST data", "TEST", 142, 150]]], ["Increased prediction accuracy of splice sites was achieved by using quadratic discriminant analysis with diversity measure or by introducing a competition mechanism of splice sites selection [22],[101].", [["splice sites", "DNA", 33, 45], ["splice sites", "DNA", 168, 180], ["splice sites", "PROBLEM", 33, 45], ["quadratic discriminant analysis", "TEST", 68, 99], ["diversity measure", "TREATMENT", 105, 122], ["splice sites", "OBSERVATION", 33, 45]]], ["An interesting work identified 2,695 newly evolved exons in rodents and calculated the new exon origination rate at about 2.71\u00d710\u22123 per gene per million years; they suggested that most new exons might originate through \u201cexonization\u201d of intronic sequences and appear to be alternative exons that are expressed at low levels [102].Present Day: A Diversified LandscapeMore recently, several Chinese bioinformatics groups had made progress in studying the regulation of transcription and translation by microRNAs, noncoding RNAs, and natural antisense transcripts.", [["exons", "DNA", 51, 56], ["exons", "DNA", 189, 194], ["intronic sequences", "DNA", 236, 254], ["exons", "DNA", 284, 289], ["microRNAs, noncoding RNAs", "RNA", 499, 524], ["natural antisense transcripts", "RNA", 530, 559], ["intronic sequences", "TEST", 236, 254], ["alternative exons", "PROBLEM", 272, 289], ["new", "OBSERVATION_MODIFIER", 87, 90]]], ["New computational methods were developed to identify precursor and mature microRNAs by sequence features, hair-pin structural features, and cross-species conservations [18],[20],[103],[104].", [["[20]", "SIMPLE_CHEMICAL", 173, 177], ["New computational methods", "TEST", 0, 25], ["sequence features", "TEST", 87, 104], ["pin structural features", "PROBLEM", 111, 134], ["pin structural", "OBSERVATION_MODIFIER", 111, 125]]], ["MicroRNAs in Chlamydomonas reinhardtii, a unicellular green alga, were identified in reads obtained by the highly parallel 454 pyrosequencing technology; the results suggested that the miRNA pathway may be an ancient mechanism of gene regulation that evolved prior to the emergence of multicellularity [105].", [["green alga", "ANATOMY", 54, 64], ["Chlamydomonas reinhardtii", "ORGANISM", 13, 38], ["green alga", "ORGANISM", 54, 64], ["Chlamydomonas reinhardtii", "SPECIES", 13, 38], ["Chlamydomonas reinhardtii", "SPECIES", 13, 38], ["MicroRNAs in Chlamydomonas reinhardtii", "PROBLEM", 0, 38], ["a unicellular green alga", "PROBLEM", 40, 64], ["the miRNA pathway", "PROBLEM", 181, 198], ["gene regulation", "PROBLEM", 230, 245], ["Chlamydomonas reinhardtii", "OBSERVATION", 13, 38]]], ["To study the expression profile of microRNAs, two methods were developed using data from EST sequencing and SAGE-based total RNA clones, respectively [19],[106].", [["microRNAs", "DNA", 35, 44], ["EST sequencing", "TEST", 89, 103], ["SAGE", "TEST", 108, 112]]], ["Longer noncoding RNAs were also studied extensively.", [["noncoding RNAs", "RNA", 7, 21], ["Longer noncoding RNAs", "PROBLEM", 0, 21]]], ["Hundreds of novel noncoding RNAs were identified in C. elegans first by a cloning strategy and then by a whole-genome tiling array technology [11],[12].", [["C. elegans", "ORGANISM", 52, 62], ["noncoding RNAs", "RNA", 18, 32], ["C. elegans", "SPECIES", 52, 62], ["C. elegans", "SPECIES", 52, 62], ["novel noncoding RNAs", "TREATMENT", 12, 32], ["a cloning strategy", "TREATMENT", 72, 90], ["noncoding RNAs", "OBSERVATION", 18, 32]]], ["The expression of intron-encoded noncoding RNAs was profiled using a custom-designed microarray combining noncoding RNAs and their host genes, and many noncoding RNAs were found to be independently transcribed with ncRNA-specific promoter elements [10].", [["intron-encoded noncoding RNAs", "RNA", 18, 47], ["noncoding RNAs", "RNA", 106, 120], ["host genes", "DNA", 131, 141], ["noncoding RNAs", "RNA", 152, 166], ["ncRNA", "DNA", 215, 220], ["promoter elements", "DNA", 230, 247], ["intron-encoded noncoding RNAs", "PROBLEM", 18, 47], ["a custom-designed microarray combining noncoding RNAs", "TREATMENT", 67, 120]]], ["To facilitate future studies, new databases were created to catalogue noncoding RNAs and noncoding RNA\u2013protein interactions [13],[14], and new algorithms were developed to accurately predict the protein-coding potential of a given transcript and the secondary structure of an RNA [107],[108].", [["noncoding RNAs", "RNA", 70, 84], ["future studies", "TEST", 14, 28], ["new databases", "TEST", 30, 43], ["new algorithms", "TEST", 139, 153]]], ["Many RNAs function through an antisense mechanism.", [["an antisense mechanism", "TREATMENT", 27, 49], ["RNAs function", "OBSERVATION", 5, 18]]], ["Several Chinese groups have identified cis- and trans-natural antisense transcripts at the whole-genome scale and found that they are highly abundant and have interesting features of function, expression, and evolution [109]\u2013[111].Present Day: A Diversified LandscapeResearch at the protein level is gaining increasing momentum thanks in part to China's recognition of protein sciences as one of the major research areas to promote and support in the next 20 years.", [["cis- and trans-natural antisense transcripts", "RNA", 39, 83], ["cis", "TEST", 39, 42], ["A Diversified LandscapeResearch at the protein level", "TREATMENT", 244, 296], ["protein sciences", "TREATMENT", 369, 385], ["increasing", "OBSERVATION_MODIFIER", 308, 318]]], ["An interesting new method achieved rapid multiple alignment of protein three-dimensional structures by the use of conformational letters, which were defined as discretized states of 3D segmental structural states [117].", [["new", "OBSERVATION_MODIFIER", 15, 18], ["rapid", "OBSERVATION_MODIFIER", 35, 40], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["alignment", "OBSERVATION_MODIFIER", 50, 59]]], ["Several effective scoring functions and algorithms were developed for the docking of protein with small compounds [28],[29],[33],[34].", [["[29],[33]", "SIMPLE_CHEMICAL", 119, 128], ["small compounds", "PROBLEM", 98, 113]]], ["In the field of proteomics, China joined the Human Proteome Organization (HUPO) with a special focus on the study of the human liver proteome, led by Fuchu He [118],[119].", [["liver proteome", "ANATOMY", 127, 141], ["Human", "ORGANISM", 45, 50], ["human", "ORGANISM", 121, 126], ["liver", "ORGAN", 127, 132], ["Human", "SPECIES", 45, 50], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["the study", "TEST", 104, 113], ["liver", "ANATOMY", 127, 132]]], ["The fetal and adult liver proteomes were extensively profiled using mass spectrometry technologies [120]\u2013[122].", [["fetal", "ANATOMY", 4, 9], ["liver proteomes", "ANATOMY", 20, 35], ["fetal", "ANATOMICAL_SYSTEM", 4, 9], ["liver", "ORGAN", 20, 25], ["The fetal and adult liver proteomes", "PROBLEM", 0, 35], ["mass spectrometry technologies", "TEST", 68, 98], ["fetal", "ANATOMY", 4, 9], ["liver", "ANATOMY", 20, 25]]], ["Driven by the need to identify peptides and proteins from mass spectrometry data, new algorithms were developed with increased accuracy [15], [16], [123]\u2013[126].", [["[16], [123]\u2013", "SIMPLE_CHEMICAL", 142, 154], ["mass spectrometry data", "TEST", 58, 80], ["new algorithms", "TEST", 82, 96], ["increased accuracy", "PROBLEM", 117, 135]]], ["Computational prediction of subcellular localizations of proteins is an important problem in proteomics, and several good methods had been developed in China using a variety of classification methods such as Support Vector Machine [44],[45], fuzzy k-NN method [23], and an integrated meta-approach [127].", [["subcellular", "ANATOMY", 28, 39], ["subcellular localizations of proteins", "PROBLEM", 28, 65], ["fuzzy k", "TEST", 242, 249]]], ["Another method predicted the protein submitochondria locations by hybridizing pseudo-amino acid composition with physicochemical features of segmented sequence [24].", [["-amino acid", "CHEMICAL", 84, 95], ["pseudo-amino acid", "CHEMICAL", 78, 95], ["-amino acid", "SIMPLE_CHEMICAL", 84, 95], ["hybridizing pseudo-amino acid composition", "PROBLEM", 66, 107]]], ["Protein\u2013protein interactions were under intense study.", [["intense study", "TEST", 40, 53]]], ["They were predicted from sequence features [128], Gene Ontology annotations [129],[130], and integration of 27 heterogeneous genomic, proteomic, and functional annotation datasets [27].", [["sequence features", "TEST", 25, 42], ["Gene Ontology annotations", "TEST", 50, 75], ["proteomic", "TEST", 134, 143], ["heterogeneous", "OBSERVATION_MODIFIER", 111, 124]]], ["The protein\u2013protein interfaces were studied in detail, such as the potential of mean force used in the ranking of the binding energies of different protein\u2013protein complexes [25] and the hydrogen bond, hydrophobic and vdW interactions used to estimate the individual contribution of each interfacial residue to the binding [26].", [["hydrogen", "CHEMICAL", 187, 195], ["protein\u2013protein complexes", "PROTEIN", 148, 173], ["The protein\u2013protein interfaces", "TEST", 0, 30], ["mean force", "PROBLEM", 80, 90], ["hydrophobic and vdW interactions", "PROBLEM", 202, 234], ["each interfacial residue", "PROBLEM", 283, 307]]], ["A recent paper reported the design of nonnatural protein\u2013protein interaction pairs by key residues grafting [27].", [["nonnatural protein\u2013protein interaction pairs", "PROTEIN", 38, 82], ["nonnatural protein\u2013protein interaction pairs", "TREATMENT", 38, 82], ["key residues grafting", "TREATMENT", 86, 107]]], ["The topology of the protein\u2013protein interaction network in yeast was analyzed using a spectral method derived from graph theory to uncover hidden topological structures such as quasi-cliques and quasi-bipartites [131], and visualized as a clustering tree [17].", [["protein\u2013protein interaction network", "PROTEIN", 20, 55], ["yeast", "SPECIES", 59, 64], ["yeast", "SPECIES", 59, 64], ["a spectral method", "TREATMENT", 84, 101]]], ["Metabolic pathways were identified using the KEGG Othology as an alternative controlled vocabulary [132].Present Day: A Diversified LandscapeInteresting progress had been made in the systems biology studies of biological networks.", [["biological networks", "MULTI-TISSUE_STRUCTURE", 210, 229], ["the KEGG Othology", "TEST", 41, 58]]], ["The global dynamical properties and stabilities of the networks had been studied.", [["global", "OBSERVATION_MODIFIER", 4, 10], ["dynamical properties", "OBSERVATION", 11, 31], ["stabilities", "OBSERVATION_MODIFIER", 36, 47]]], ["In particular, the yeast cell-cycle network and the Drosophila segment polarity network appeared to be highly robust [133],[134].", [["cell", "ANATOMY", 25, 29], ["cell", "CELL", 25, 29], ["yeast", "SPECIES", 19, 24], ["Drosophila", "SPECIES", 52, 62], ["yeast", "SPECIES", 19, 24], ["the yeast cell", "TEST", 15, 29], ["the Drosophila segment polarity network", "TEST", 48, 87], ["yeast cell", "OBSERVATION", 19, 29]]], ["The protein interaction networks of Saccharomyces cerevisiae, Caenorhabditis elegans, and Drosophila melanogaster were found to have a scale-free and high-degree clustering nature with a small-world property with similar diameter at 4\u20135 [135].", [["Saccharomyces cerevisiae", "ORGANISM", 36, 60], ["Caenorhabditis elegans", "ORGANISM", 62, 84], ["Drosophila melanogaster", "ORGANISM", 90, 113], ["protein interaction networks", "PROTEIN", 4, 32], ["Saccharomyces cerevisiae", "SPECIES", 36, 60], ["Caenorhabditis elegans", "SPECIES", 62, 84], ["Drosophila melanogaster", "SPECIES", 90, 113], ["Saccharomyces cerevisiae", "SPECIES", 36, 60], ["Caenorhabditis elegans", "SPECIES", 62, 84], ["Drosophila melanogaster", "SPECIES", 90, 113], ["Saccharomyces cerevisiae", "TREATMENT", 36, 60], ["Caenorhabditis elegans", "PROBLEM", 62, 84], ["Drosophila melanogaster", "PROBLEM", 90, 113], ["a scale", "TEST", 133, 140], ["high-degree clustering nature", "PROBLEM", 150, 179], ["high-degree", "OBSERVATION_MODIFIER", 150, 161], ["small", "OBSERVATION_MODIFIER", 187, 192], ["similar", "OBSERVATION_MODIFIER", 213, 220], ["diameter", "OBSERVATION_MODIFIER", 221, 229]]], ["Key proteins, subgraphs, and modules were identified and analyzed in the signal transduction networks [136], transcriptional regulation networks in yeast [137], and protein\u2013protein interaction networks during fruitfly and human brain aging [138],[139].", [["brain", "ANATOMY", 228, 233], ["human", "ORGANISM", 222, 227], ["brain", "ORGAN", 228, 233], ["transcriptional regulation networks", "PROTEIN", 109, 144], ["protein\u2013protein interaction networks", "PROTEIN", 165, 201], ["yeast", "SPECIES", 148, 153], ["human", "SPECIES", 222, 227], ["yeast", "SPECIES", 148, 153], ["human", "SPECIES", 222, 227], ["transcriptional regulation networks", "TREATMENT", 109, 144], ["human brain aging", "TEST", 222, 239]]], ["Simulation analysis of the energy metabolism network in mammalian myocardia revealed that the systemic states of metabolic networks did not always remain optimal, but might become suboptimal when a transient perturbation occurs [140].", [["myocardia", "ANATOMY", 66, 75], ["Simulation analysis", "TEST", 0, 19], ["mammalian myocardia", "TEST", 56, 75], ["a transient perturbation", "PROBLEM", 196, 220]]], ["Finally, the dynamic properties of the arachidonic acid metabolic network which includes several targets for anti-inflammatory drugs was analyzed using ordinary differential equations, and the flux balance in the network was found to be important for efficient and safe drug design [141].Present Day: A Diversified LandscapeThe bioinformatics discipline has grown too broad to be reviewed comprehensively in any one article.", [["arachidonic acid", "CHEMICAL", 39, 55], ["arachidonic acid", "CHEMICAL", 39, 55], ["arachidonic acid", "SIMPLE_CHEMICAL", 39, 55], ["the arachidonic acid metabolic network", "PROBLEM", 35, 73], ["anti-inflammatory drugs", "TREATMENT", 109, 132], ["ordinary differential equations", "TEST", 152, 183], ["the flux balance", "TEST", 189, 205], ["Diversified", "OBSERVATION_MODIFIER", 303, 314], ["Landscape", "OBSERVATION", 315, 324]]], ["Just to give two examples of interesting areas of bioinformatics research that we did not adequately review here: first, a small group of researchers in China have made progress in computational neurobiology, including proposing a computational model as a neurodecoder based on synchronous oscillation in the visual cortex [142] and a simulation study on the Ca2+-independent but voltage-dependent exocytosis and endocytosis in dorsal root ganglion neurons [143]; second, many groups have developed databases and methods of imaging, such as the digital image datasets of Chinese Visible Human (a male and a female) [144], a high-resolution anatomical rat atlas [145], and methods for optical molecular imaging [146].Education: A New Generation of Locally Trained BioinformaticiansBioinformatics talent in China is reaching a critical mass.", [["visual cortex", "ANATOMY", 309, 322], ["dorsal root ganglion neurons", "ANATOMY", 428, 456], ["Ca2", "CHEMICAL", 359, 362], ["Ca2", "CHEMICAL", 359, 362], ["Ca2+-", "SIMPLE_CHEMICAL", 359, 364], ["dorsal root ganglion neurons", "CELL", 428, 456], ["Human", "ORGANISM", 587, 592], ["rat", "ORGANISM", 651, 654], ["Ca2", "PROTEIN", 359, 362], ["dorsal root ganglion neurons", "CELL_TYPE", 428, 456], ["Human", "SPECIES", 587, 592], ["rat", "SPECIES", 651, 654], ["synchronous oscillation", "PROBLEM", 278, 301], ["a simulation study", "TEST", 333, 351], ["the Ca2", "TEST", 355, 362], ["voltage-dependent exocytosis", "PROBLEM", 380, 408], ["endocytosis in dorsal root ganglion neurons", "PROBLEM", 413, 456], ["imaging", "TEST", 524, 531], ["optical molecular imaging", "TEST", 684, 709], ["a critical mass", "PROBLEM", 823, 838], ["small", "OBSERVATION_MODIFIER", 123, 128], ["synchronous oscillation", "OBSERVATION", 278, 301], ["visual cortex", "ANATOMY", 309, 322], ["dorsal", "ANATOMY_MODIFIER", 428, 434], ["root ganglion", "ANATOMY", 435, 448], ["mass", "OBSERVATION", 834, 838]]], ["Although a slight majority of the graduates (15 out of 28, or 54%) still chose to pursue postdoctoral positions overseas, the remaining had decided to stay in China, with nine working in academia and four in industry.", [["slight", "OBSERVATION_MODIFIER", 11, 17], ["majority", "OBSERVATION_MODIFIER", 18, 26]]], ["Many other Chinese universities are now offering bioinformatics degree programs at the PhD, Master's, and even Bachelor's levels (see list in Table 3).", [["bioinformatics degree programs", "TREATMENT", 49, 79]]], ["In addition to formal degree programs, many university courses and ad hoc workshops have been offered to train bench biologists on how to use bioinformatic databases and tools.The Future: Promises and ChallengesToday bioinformatics research in China still lags behind the best in the world.", [["formal degree programs", "TREATMENT", 15, 37], ["bioinformatic databases", "TEST", 142, 165]]], ["However, it is catching up quickly, and several positive factors suggest a bright future.", [["several positive factors", "PROBLEM", 40, 64]]], ["First, the aforementioned critical mass of bioinformaticians will be a driving force for the future development of bioinformatics in China.", [["mass", "OBSERVATION", 35, 39]]], ["Second, life science research at large is gaining momentum in China and progressing quickly.", [["large", "OBSERVATION_MODIFIER", 33, 38]]], ["Third, China's total funding for scientific research has been steadily increasing in the past five years, reaching 1.40% of her GDP in 2006 and a total annual R&D expenditure of 300 billion Yuan (or US$38.5 billion) [147].", [["GDP", "CHEMICAL", 128, 131], ["steadily", "OBSERVATION_MODIFIER", 62, 70], ["increasing", "OBSERVATION_MODIFIER", 71, 81]]], ["The recent national goal for R&D growth has been set to an incremental annual increase of 20%.", [["R&D growth", "PROBLEM", 29, 39], ["increase", "OBSERVATION_MODIFIER", 78, 86]]], ["Last but not least, China is investing heavily in its computing infrastructure, including the China Grid initiated by the Ministry of Education and the China National Grid (CNGrid) initiated by Chinese Academy of Sciences, both supported largely by the Ministry of Science and Technology.", [["not", "UNCERTAINTY", 9, 12], ["least", "OBSERVATION_MODIFIER", 13, 18]]], ["Scientists returning from overseas often face a salary reduction, reverse culture shock, and a different funding system and application process.", [["shock", "DISEASE", 82, 87], ["a salary reduction", "TREATMENT", 46, 64], ["reverse culture shock", "PROBLEM", 66, 87], ["a different funding system", "PROBLEM", 93, 119], ["application process", "TREATMENT", 124, 143], ["culture shock", "OBSERVATION", 74, 87]]], ["No similar initiatives exist in China yet.", [["similar", "OBSERVATION_MODIFIER", 3, 10], ["initiatives", "OBSERVATION", 11, 22]]], ["There is also no official professional bioinformatics society in China.", [["no", "UNCERTAINTY", 14, 16]]], ["More noticeable perhaps is the lack of a Chinese national center for bioinformation, the equivalent of the US National Center for Biotechnology Information (NCBI) that is the central repository and information hub for biological data and tools.", [["biological data", "TEST", 218, 233]]], ["As China is generating a large and growing amount of biological data, a Chinese national center with a dedicated budget and staff could more effectively collect and store the local data and exchange it with the international scientific community.", [["large", "OBSERVATION_MODIFIER", 25, 30], ["growing", "OBSERVATION_MODIFIER", 35, 42], ["amount", "OBSERVATION_MODIFIER", 43, 49]]]], "PMC7101927": [["IntroductionInvasive aspergillosis is a life-threatening major infection in immunosuppressed patients.", [["Invasive aspergillosis", "ANATOMY", 12, 34], ["Invasive aspergillosis", "DISEASE", 12, 34], ["infection", "DISEASE", 63, 72], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["IntroductionInvasive aspergillosis", "PROBLEM", 0, 34], ["immunosuppressed patients", "TREATMENT", 76, 101], ["Invasive", "OBSERVATION_MODIFIER", 12, 20], ["aspergillosis", "OBSERVATION", 21, 34], ["major", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72]]], ["The lungs are the most commonly affected organ in invasive aspergillosis.", [["lungs", "ANATOMY", 4, 9], ["organ", "ANATOMY", 41, 46], ["invasive aspergillosis", "ANATOMY", 50, 72], ["aspergillosis", "DISEASE", 59, 72], ["lungs", "ORGAN", 4, 9], ["organ", "ORGAN", 41, 46], ["aspergillosis", "CANCER", 59, 72], ["invasive aspergillosis", "PROBLEM", 50, 72], ["lungs", "ANATOMY", 4, 9], ["invasive", "OBSERVATION_MODIFIER", 50, 58], ["aspergillosis", "OBSERVATION", 59, 72]]], ["Gastrointestinal invasive aspergillosis is usually seen as a part of a disseminated infection and rarely as an isolated organ infection [1].", [["Gastrointestinal invasive aspergillosis", "ANATOMY", 0, 39], ["organ", "ANATOMY", 120, 125], ["Gastrointestinal invasive aspergillosis", "DISEASE", 0, 39], ["infection", "DISEASE", 84, 93], ["organ infection", "DISEASE", 120, 135], ["organ", "ORGAN", 120, 125], ["Gastrointestinal invasive aspergillosis", "PROBLEM", 0, 39], ["a disseminated infection", "PROBLEM", 69, 93], ["an isolated organ infection", "PROBLEM", 108, 135], ["invasive", "OBSERVATION_MODIFIER", 17, 25], ["aspergillosis", "OBSERVATION", 26, 39], ["disseminated", "OBSERVATION_MODIFIER", 71, 83], ["infection", "OBSERVATION", 84, 93], ["organ", "ANATOMY", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["This report presents a case of isolated invasive Aspergillus gastritis developing without disseminated aspergillosis in a patient with no predisposing factors, such as immunosuppression.Case reportA 13-year-old female patient being followed-up for arthrogryposis multiplex congenita, mild mental retardation and pectus excavatum presented with a 2-day history of abdominal pain, abdominal swelling and vomiting gastric content.", [["abdominal", "ANATOMY", 363, 372], ["abdominal", "ANATOMY", 379, 388], ["gastric", "ANATOMY", 411, 418], ["Aspergillus gastritis", "DISEASE", 49, 70], ["aspergillosis", "DISEASE", 103, 116], ["arthrogryposis multiplex congenita", "DISEASE", 248, 282], ["mental retardation", "DISEASE", 289, 307], ["pectus excavatum", "DISEASE", 312, 328], ["abdominal pain", "DISEASE", 363, 377], ["abdominal swelling", "DISEASE", 379, 397], ["vomiting", "DISEASE", 402, 410], ["Aspergillus gastritis", "PATHOLOGICAL_FORMATION", 49, 70], ["patient", "ORGANISM", 122, 129], ["female", "ORGANISM", 211, 217], ["patient", "ORGANISM", 218, 225], ["abdominal", "ORGANISM_SUBDIVISION", 363, 372], ["abdominal", "ORGANISM_SUBDIVISION", 379, 388], ["gastric", "ORGAN", 411, 418], ["patient", "SPECIES", 122, 129], ["patient", "SPECIES", 218, 225], ["isolated invasive Aspergillus gastritis", "PROBLEM", 31, 70], ["disseminated aspergillosis", "PROBLEM", 90, 116], ["predisposing factors", "PROBLEM", 138, 158], ["immunosuppression", "TREATMENT", 168, 185], ["arthrogryposis multiplex congenita", "PROBLEM", 248, 282], ["mild mental retardation", "PROBLEM", 284, 307], ["pectus excavatum", "PROBLEM", 312, 328], ["abdominal pain", "PROBLEM", 363, 377], ["abdominal swelling", "PROBLEM", 379, 397], ["vomiting gastric content", "PROBLEM", 402, 426], ["invasive", "OBSERVATION_MODIFIER", 40, 48], ["Aspergillus gastritis", "OBSERVATION", 49, 70], ["without", "UNCERTAINTY", 82, 89], ["disseminated", "OBSERVATION_MODIFIER", 90, 102], ["aspergillosis", "OBSERVATION", 103, 116], ["congenita", "OBSERVATION", 273, 282], ["mild", "OBSERVATION_MODIFIER", 284, 288], ["mental retardation", "OBSERVATION", 289, 307], ["pectus excavatum", "OBSERVATION", 312, 328], ["abdominal", "ANATOMY", 363, 372], ["pain", "OBSERVATION", 373, 377], ["abdominal", "ANATOMY", 379, 388], ["swelling", "OBSERVATION", 389, 397], ["gastric", "ANATOMY", 411, 418], ["content", "OBSERVATION", 419, 426]]], ["Physical examination revealed widespread abdominal tenderness that was more prominent in the epigastric region while a standing abdominal X-ray showed a large, dilated gastric air pocket.", [["abdominal", "ANATOMY", 41, 50], ["epigastric region", "ANATOMY", 93, 110], ["abdominal", "ANATOMY", 128, 137], ["gastric air pocket", "ANATOMY", 168, 186], ["abdominal tenderness", "DISEASE", 41, 61], ["abdominal", "ORGANISM_SUBDIVISION", 41, 50], ["epigastric", "ORGAN", 93, 103], ["gastric air", "MULTI-TISSUE_STRUCTURE", 168, 179], ["Physical examination", "TEST", 0, 20], ["widespread abdominal tenderness", "PROBLEM", 30, 61], ["a standing abdominal X-ray", "TEST", 117, 143], ["a large, dilated gastric air pocket", "PROBLEM", 151, 186], ["widespread", "OBSERVATION_MODIFIER", 30, 40], ["abdominal", "ANATOMY", 41, 50], ["tenderness", "OBSERVATION", 51, 61], ["more prominent", "OBSERVATION_MODIFIER", 71, 85], ["epigastric", "ANATOMY", 93, 103], ["region", "ANATOMY_MODIFIER", 104, 110], ["abdominal", "ANATOMY", 128, 137], ["large", "OBSERVATION_MODIFIER", 153, 158], ["dilated", "OBSERVATION", 160, 167], ["gastric", "ANATOMY", 168, 175], ["air pocket", "OBSERVATION", 176, 186]]], ["Laboratory test results showed urea 163 mg/dl (range 0\u201350 mg/dl), BUN 76 mg/dl (range 0\u201323 mg/dl), uric acid 15.4 mg/dl (range 0\u20136.1 mg/dl), CRP 79.5 mg/dl (range 0\u20138 mg/dl), leukocyte 20300/\u03bcl (range 4900\u20139100/\u03bcl), and potassium 2.96 mEq/l (3.1\u20135.5 mEq/l).", [["leukocyte", "ANATOMY", 175, 184], ["urea", "CHEMICAL", 31, 35], ["uric acid", "CHEMICAL", 99, 108], ["potassium", "CHEMICAL", 220, 229], ["urea", "CHEMICAL", 31, 35], ["uric acid", "CHEMICAL", 99, 108], ["potassium", "CHEMICAL", 220, 229], ["urea", "SIMPLE_CHEMICAL", 31, 35], ["BUN", "SIMPLE_CHEMICAL", 66, 69], ["uric acid", "SIMPLE_CHEMICAL", 99, 108], ["CRP", "GENE_OR_GENE_PRODUCT", 141, 144], ["leukocyte", "CELL", 175, 184], ["potassium", "SIMPLE_CHEMICAL", 220, 229], ["CRP", "PROTEIN", 141, 144], ["Laboratory test", "TEST", 0, 15], ["urea", "TEST", 31, 35], ["BUN", "TEST", 66, 69], ["uric acid", "TEST", 99, 108], ["CRP", "TEST", 141, 144], ["leukocyte", "TEST", 175, 184], ["potassium", "TEST", 220, 229]]], ["Other laboratory test results were normal.", [["Other laboratory test", "TEST", 0, 21], ["normal", "OBSERVATION", 35, 41]]], ["Abdominal ultrasonography demonstrated grade I hydronephrosis, increased mesenteric echo, mesenteric lymphadenopathies 1 cm in size, duodenal wall edema and ascites while the epigastric region could not be evaluated because of the presence of abundant gas.", [["Abdominal", "ANATOMY", 0, 9], ["mesenteric", "ANATOMY", 73, 83], ["mesenteric", "ANATOMY", 90, 100], ["duodenal wall", "ANATOMY", 133, 146], ["ascites", "ANATOMY", 157, 164], ["epigastric region", "ANATOMY", 175, 192], ["hydronephrosis", "DISEASE", 47, 61], ["lymphadenopathies", "DISEASE", 101, 118], ["duodenal wall edema", "DISEASE", 133, 152], ["ascites", "DISEASE", 157, 164], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 73, 83], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 90, 100], ["duodenal wall edema", "PATHOLOGICAL_FORMATION", 133, 152], ["Abdominal ultrasonography", "TEST", 0, 25], ["grade I hydronephrosis", "PROBLEM", 39, 61], ["increased mesenteric echo", "PROBLEM", 63, 88], ["mesenteric lymphadenopathies", "PROBLEM", 90, 118], ["duodenal wall edema", "PROBLEM", 133, 152], ["ascites", "PROBLEM", 157, 164], ["abundant gas", "PROBLEM", 243, 255], ["grade I", "OBSERVATION_MODIFIER", 39, 46], ["hydronephrosis", "OBSERVATION", 47, 61], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["mesenteric", "ANATOMY", 73, 83], ["mesenteric", "ANATOMY", 90, 100], ["lymphadenopathies", "OBSERVATION", 101, 118], ["1 cm", "OBSERVATION_MODIFIER", 119, 123], ["size", "OBSERVATION_MODIFIER", 127, 131], ["duodenal", "ANATOMY", 133, 141], ["wall", "ANATOMY_MODIFIER", 142, 146], ["edema", "OBSERVATION", 147, 152], ["ascites", "OBSERVATION", 157, 164], ["epigastric", "ANATOMY", 175, 185], ["abundant", "OBSERVATION_MODIFIER", 243, 251], ["gas", "OBSERVATION", 252, 255]]], ["A nasogastric catheter brought up retention material.", [["nasogastric", "ANATOMY", 2, 13], ["A nasogastric catheter", "TREATMENT", 0, 22], ["nasogastric", "ANATOMY", 2, 13], ["catheter", "OBSERVATION", 14, 22], ["retention material", "OBSERVATION", 34, 52]]], ["Acute abdomen was considered and the patient was taken to surgery after preoperative preparation.", [["abdomen", "ANATOMY", 6, 13], ["abdomen", "ORGAN", 6, 13], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["Acute abdomen", "PROBLEM", 0, 13], ["surgery", "TREATMENT", 58, 65], ["preoperative preparation", "TREATMENT", 72, 96], ["abdomen", "ANATOMY", 6, 13]]], ["Laparotomy was performed with a supraumbilical incision and seropurulent free fluid was seen in the abdomen together with a 6 \u00d7 3 cm necrotic area close to the gastric fundus in the large curvature (Fig. 1).", [["supraumbilical", "ANATOMY", 32, 46], ["abdomen", "ANATOMY", 100, 107], ["necrotic area", "ANATOMY", 133, 146], ["gastric fundus", "ANATOMY", 160, 174], ["necrotic", "DISEASE", 133, 141], ["fluid", "ORGANISM_SUBSTANCE", 78, 83], ["abdomen", "ORGAN", 100, 107], ["gastric fundus", "MULTI-TISSUE_STRUCTURE", 160, 174], ["Laparotomy", "TREATMENT", 0, 10], ["a supraumbilical incision", "TREATMENT", 30, 55], ["seropurulent free fluid", "PROBLEM", 60, 83], ["a 6 \u00d7 3 cm necrotic area", "PROBLEM", 122, 146], ["supraumbilical", "OBSERVATION_MODIFIER", 32, 46], ["incision", "OBSERVATION", 47, 55], ["seropurulent", "OBSERVATION_MODIFIER", 60, 72], ["free", "OBSERVATION_MODIFIER", 73, 77], ["fluid", "OBSERVATION", 78, 83], ["abdomen", "ANATOMY", 100, 107], ["6 \u00d7 3 cm", "OBSERVATION_MODIFIER", 124, 132], ["necrotic", "OBSERVATION_MODIFIER", 133, 141], ["area", "OBSERVATION", 142, 146], ["gastric fundus", "ANATOMY", 160, 174], ["large", "OBSERVATION_MODIFIER", 182, 187], ["curvature", "OBSERVATION_MODIFIER", 188, 197], ["Fig", "OBSERVATION_MODIFIER", 199, 202]]], ["The necrotic region was excised and the gastric defect repaired.", [["necrotic region", "ANATOMY", 4, 19], ["gastric", "ANATOMY", 40, 47], ["necrotic", "DISEASE", 4, 12], ["gastric defect", "DISEASE", 40, 54], ["necrotic region", "TISSUE", 4, 19], ["gastric", "ORGAN", 40, 47], ["The necrotic region", "PROBLEM", 0, 19], ["the gastric defect", "PROBLEM", 36, 54], ["necrotic", "OBSERVATION_MODIFIER", 4, 12], ["gastric", "ANATOMY", 40, 47], ["defect repaired", "OBSERVATION", 48, 63]]], ["Oral intake was started on the 5th postoperative day and the patient was discharged on the 11th day with no problems.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["problems", "PROBLEM", 108, 116]]]], "PMC6160892": [["IBV vaccines and challenge viruses ::: MATERIALS AND METHODSThree live, attenuated vaccines, H120 (Guangdong Dahuanong Animal Health Products Co., Ltd., Guangzhou, China), 4/91 (MSD Animal Health (Shanghai) Trading Co., Ltd., Shanghai, China) andLDT3-A (QYH Biotech Co., Ltd., Beijing, China) were purchased commercially.", [["H120", "CHEMICAL", 93, 97], ["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["H120", "SPECIES", 93, 97], ["IBV vaccines", "TREATMENT", 0, 12], ["attenuated vaccines", "TREATMENT", 72, 91]]], ["Each vaccine was reconstituted according to the manufacturer\u2019s instructions.", [["Each vaccine", "TREATMENT", 0, 12]]], ["According to our previous description[12, 20], H120 (Massachusetts serotype) and 4/91 (793B serotype) vaccines were designated as serotype 3 andserotype 5, respectively.", [["H120", "GENE_OR_GENE_PRODUCT", 47, 51], ["Massachusetts serotype", "ORGANISM", 53, 75], ["4/91 (793B serotype", "ORGANISM", 81, 100], ["serotype) vaccines", "TREATMENT", 92, 110]]], ["The serotype of LDT3-A vaccine was different from Mass-type vaccines and other vaccines used in China [13].", [["LDT3-A", "CHEMICAL", 16, 22], ["LDT3-A", "ORGANISM", 16, 22], ["The serotype of LDT3", "TREATMENT", 0, 20], ["A vaccine", "TREATMENT", 21, 30], ["Mass-type vaccines", "TREATMENT", 50, 68], ["other vaccines", "TREATMENT", 73, 87]]], ["IBV localisolates GX-YL5, GX-GL11079 and GX-NN09032 belonging to serotype 1, 2 and 5, respectively, were isolated from Guangxi, China and were currently the representative dominant serotypes insouthern China [10, 18].", [["IBV localisolates", "ORGANISM", 0, 17], ["GX-YL5", "GENE_OR_GENE_PRODUCT", 18, 24], ["GX-GL11079", "ORGANISM", 26, 36], ["GX-NN09032", "ORGANISM", 41, 51], ["serotype 1", "ORGANISM", 65, 75], ["5", "ORGANISM", 83, 84], ["IBV", "SPECIES", 0, 3], ["IBV localisolates GX-YL5", "SPECIES", 0, 24], ["IBV", "TEST", 0, 3], ["GX", "TEST", 26, 28], ["GX", "TEST", 41, 43], ["serotype", "TEST", 65, 73]]], ["GX-YL5, GX-GL11079 and GX-NN09032 strains were propagated in 10-day-old specificpathogen free (SPF) chicken embryos and the 50% tracheal organ culture infection dose (TOC-ID50) was determined as previously described for the quantification of the viruses[12].Chickens ::: MATERIALS AND METHODSThe SPF white leghorn chickens used in this study were hatched in our facilities (Guangxi University, Nanning, China) from fertile SPF eggs (Beijing Merial Vital Laboratory AnimalTechnology Co., Ltd., Beijing, China).", [["embryos", "ANATOMY", 108, 115], ["tracheal organ", "ANATOMY", 128, 142], ["infection", "DISEASE", 151, 160], ["TOC-ID50", "CHEMICAL", 167, 175], ["GX-YL5", "GENE_OR_GENE_PRODUCT", 0, 6], ["GX-GL11079", "GENE_OR_GENE_PRODUCT", 8, 18], ["GX-NN09032 strains", "CELL", 23, 41], ["chicken", "ORGANISM", 100, 107], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 108, 115], ["Chickens", "ORGANISM", 258, 266], ["chickens", "ORGANISM", 314, 322], ["GX-YL5, GX-GL11079 and GX-NN09032 strains", "DNA", 0, 41], ["chicken", "SPECIES", 100, 107], ["Chickens", "SPECIES", 258, 266], ["chickens", "SPECIES", 314, 322], ["chicken", "SPECIES", 100, 107], ["white leghorn chickens", "SPECIES", 300, 322], ["GX", "TEST", 0, 2], ["GX", "TEST", 8, 10], ["GL11079", "TEST", 11, 18], ["GX", "TEST", 23, 25], ["strains", "PROBLEM", 34, 41], ["chicken embryos", "TREATMENT", 100, 115], ["tracheal organ culture", "TEST", 128, 150], ["the viruses", "PROBLEM", 242, 253], ["METHODSThe SPF white leghorn chickens", "TREATMENT", 285, 322], ["this study", "TEST", 331, 341], ["GX", "ANATOMY", 8, 10], ["tracheal organ", "ANATOMY", 128, 142], ["viruses", "OBSERVATION", 246, 253]]], ["The birds were reared in separate isolators following animal welfare guidelines and under strict biosecurity measures.", [["birds", "ORGANISM", 4, 9], ["animal welfare guidelines", "TREATMENT", 54, 79], ["strict biosecurity measures", "TREATMENT", 90, 117]]], ["Animal experiments were approvedby the Animal Care & Welfare Committee of Guangxi University (approval number GXU2016-011) and were performed in accordance with animal ethics guidelines and approved protocols.Experimental design ::: MATERIALS AND METHODSSeven-day-old SPF birds were randomly divided into five groups, which were named as H120 group, 4/91 group, LDT3-A group, non-vaccinated group and blank control group, respectively.", [["LDT3-A", "CHEMICAL", 362, 368], ["SPF", "ORGANISM", 268, 271], ["birds", "ORGANISM", 272, 277], ["LDT3-A", "SIMPLE_CHEMICAL", 362, 368], ["LDT3", "TEST", 362, 366]]], ["Therewere 12 birds in the blank control group and 36 birds in the other four groups.", [["birds", "ORGANISM", 13, 18]]], ["Birds in the groups of H120, 4/91 and LDT3-A were vaccinated by eye and nose drop with H120, 4/91 and LDT3-Aattenuated vaccines, respectively, at the manufacturer\u2019s recommended dose.", [["eye", "ANATOMY", 64, 67], ["nose", "ANATOMY", 72, 76], ["LDT3-A", "CELL", 38, 44], ["eye", "ORGAN", 64, 67], ["nose", "ORGANISM_SUBDIVISION", 72, 76], ["H120", "TEST", 23, 27], ["LDT3", "TEST", 38, 42], ["nose drop", "TEST", 72, 81], ["H120", "TEST", 87, 91], ["LDT3", "TEST", 102, 106], ["eye", "ANATOMY", 64, 67], ["nose", "ANATOMY", 72, 76]]], ["Birds in the non-vaccinated group were treated with sterile phosphate-buffered saline in the same manner and thosein the blank control group received nothing.", [["phosphate", "CHEMICAL", 60, 69], ["thosein", "CHEMICAL", 109, 116], ["phosphate", "CHEMICAL", 60, 69], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 60, 85], ["sterile phosphate-buffered saline", "TREATMENT", 52, 85], ["thosein the blank control group", "TREATMENT", 109, 140]]], ["Blood samples were collected from 10 birds in each group prior to inoculation (0 day) and at 7, 14 and 21 post-inoculation (dpi) of the vaccinesfor detection of IBV-specific antibody and quantity analysis of CD4+ and CD8+ T lymphocytes.", [["Blood samples", "ANATOMY", 0, 13], ["CD4+ and CD8+ T lymphocytes", "ANATOMY", 208, 235], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["IBV", "ORGANISM", 161, 164], ["CD4", "GENE_OR_GENE_PRODUCT", 208, 211], ["CD8", "GENE_OR_GENE_PRODUCT", 217, 220], ["CD4", "PROTEIN", 208, 211], ["CD8+ T lymphocytes", "CELL_TYPE", 217, 235], ["IBV", "SPECIES", 161, 164], ["Blood samples", "TEST", 0, 13], ["the vaccinesfor detection", "TEST", 132, 157], ["IBV", "TEST", 161, 164], ["specific antibody", "TEST", 165, 182], ["quantity analysis", "TEST", 187, 204], ["CD4", "TEST", 208, 211], ["CD8", "TEST", 217, 220]]], ["At 21 dpi birds in the H120, 4/91, LDT3-A and non-vaccinated groups weredivided randomly into three groups of 12 birds each and challenged via eye and nose drop with 0.2 ml of 104 TOC-ID50 of IBV GX-YL5, GX-GL11079 andGX-NN09032 strains, respectively.", [["H120", "ANATOMY", 23, 27], ["eye", "ANATOMY", 143, 146], ["nose", "ANATOMY", 151, 155], ["TOC-ID50", "CHEMICAL", 180, 188], ["LDT3-A", "CELL", 35, 41], ["birds", "ORGANISM", 113, 118], ["eye", "ORGAN", 143, 146], ["nose", "ORGANISM_SUBDIVISION", 151, 155], ["IBV", "ORGANISM", 192, 195], ["GX-YL5", "SIMPLE_CHEMICAL", 196, 202], ["GX-GL11079", "SIMPLE_CHEMICAL", 204, 214], ["andGX-NN09032", "CELL", 215, 228], ["IBV", "SPECIES", 192, 195], ["LDT3", "TEST", 35, 39], ["TOC", "TEST", 180, 183], ["IBV GX", "TEST", 192, 198], ["GX", "TEST", 204, 206], ["andGX", "TEST", 215, 220], ["eye", "ANATOMY", 143, 146], ["nose", "ANATOMY", 151, 155]]], ["Birds in the blank control group received no challenge virus.", [["challenge virus", "PROBLEM", 45, 60], ["blank", "ANATOMY", 13, 18]]], ["Clinical signs were observed and recorded daily.", [["Clinical signs", "TEST", 0, 14]]], ["At 5 days post-challenge (dpc), the birds ineach group were humanely killed and necropsied.", [["birds", "ORGANISM", 36, 41]]], ["The trachea and kidney samples were collected from each bird aseptically for the detection of viral loads.", [["trachea", "ANATOMY", 4, 11], ["kidney samples", "ANATOMY", 16, 30], ["trachea", "MULTI-TISSUE_STRUCTURE", 4, 11], ["kidney samples", "CANCER", 16, 30], ["viral loads", "PROBLEM", 94, 105], ["trachea", "ANATOMY", 4, 11], ["kidney", "ANATOMY", 16, 22], ["viral loads", "OBSERVATION", 94, 105]]], ["The dead birds were also necropsiedto confirm the infection of IBV.Detection of IBV-specific antibody ::: MATERIALS AND METHODSA portion of the blood samples collected above were used to detect the IBV-specific antibody using a commercial enzyme-linked immunosorbent assay (ELISA) kit (IDEXX Laboratory, Inc.,Westbrook, ME, U.S.A.) following the manufacturer\u2019s instructions.Quantification of CD4+ and CD8+ T lymphocytes in peripheral blood ::: MATERIALS AND METHODSPeripheral blood mononuclear cells were isolated from another portion of the blood samples collected above and then used to analyze the percentages of the CD4+ andCD8+ T lymphocytes by flow cytometry.", [["blood samples", "ANATOMY", 144, 157], ["CD4+", "ANATOMY", 392, 396], ["T lymphocytes", "ANATOMY", 406, 419], ["peripheral blood", "ANATOMY", 423, 439], ["METHODSPeripheral blood mononuclear cells", "ANATOMY", 458, 499], ["blood samples", "ANATOMY", 542, 555], ["CD4+ andCD8+ T lymphocytes", "ANATOMY", 620, 646], ["infection", "DISEASE", 50, 59], ["birds", "ORGANISM", 9, 14], ["IBV", "ORGANISM", 63, 66], ["IBV", "ORGANISM", 80, 83], ["blood samples", "ORGANISM_SUBSTANCE", 144, 157], ["IBV", "ORGANISM", 198, 201], ["CD4", "GENE_OR_GENE_PRODUCT", 392, 395], ["CD8", "GENE_OR_GENE_PRODUCT", 401, 404], ["T lymphocytes", "CELL", 406, 419], ["peripheral blood", "ORGANISM_SUBSTANCE", 423, 439], ["METHODSPeripheral blood mononuclear cells", "CELL", 458, 499], ["blood samples", "ORGANISM_SUBSTANCE", 542, 555], ["CD4", "GENE_OR_GENE_PRODUCT", 620, 623], ["CD8", "GENE_OR_GENE_PRODUCT", 628, 631], ["IBV-specific antibody", "PROTEIN", 80, 101], ["IBV-specific antibody", "PROTEIN", 198, 219], ["CD4", "PROTEIN", 392, 395], ["CD8", "PROTEIN", 401, 404], ["T lymphocytes", "CELL_TYPE", 406, 419], ["METHODSPeripheral blood mononuclear cells", "CELL_TYPE", 458, 499], ["CD4", "PROTEIN", 620, 623], ["CD8+ T lymphocytes", "CELL_TYPE", 628, 646], ["IBV", "SPECIES", 63, 66], ["IBV", "SPECIES", 80, 83], ["IBV", "SPECIES", 198, 201], ["The dead birds", "PROBLEM", 0, 14], ["the infection of IBV", "PROBLEM", 46, 66], ["IBV", "TEST", 80, 83], ["the blood samples", "TEST", 140, 157], ["the IBV", "TEST", 194, 201], ["specific antibody", "TEST", 202, 219], ["a commercial enzyme", "TEST", 226, 245], ["immunosorbent assay", "TEST", 253, 272], ["CD4", "TEST", 392, 395], ["CD8", "PROBLEM", 401, 404], ["peripheral blood", "TEST", 423, 439], ["METHODSPeripheral blood mononuclear cells", "TEST", 458, 499], ["the blood samples", "TEST", 538, 555], ["the CD4", "TEST", 616, 623], ["flow cytometry", "TEST", 650, 664], ["infection", "OBSERVATION", 50, 59], ["CD4", "OBSERVATION", 392, 395], ["lymphocytes", "OBSERVATION", 408, 419], ["peripheral", "ANATOMY_MODIFIER", 423, 433], ["blood", "ANATOMY", 434, 439], ["mononuclear cells", "OBSERVATION", 482, 499], ["blood", "ANATOMY", 542, 547], ["CD4", "OBSERVATION", 620, 623], ["flow cytometry", "OBSERVATION", 650, 664]]], ["1 \u00d7 106 cells were stained with Mouse Anti-Chicken CD4-PE and CD8a-FITC antibodies (Wuhan AmyJet Scientific Inc., Wuhan, China).All staining reactions were conducted following the manufacturers\u2019 protocols.", [["cells", "ANATOMY", 8, 13], ["FITC", "CHEMICAL", 67, 71], ["cells", "CELL", 8, 13], ["Mouse", "ORGANISM", 32, 37], ["CD4-PE", "GENE_OR_GENE_PRODUCT", 51, 57], ["CD8a-FITC antibodies", "GENE_OR_GENE_PRODUCT", 62, 82], ["1 \u00d7 106 cells", "CELL_LINE", 0, 13], ["Mouse Anti-Chicken CD4", "PROTEIN", 32, 54], ["PE", "PROTEIN", 55, 57], ["CD8a-FITC antibodies", "PROTEIN", 62, 82], ["Mouse", "SPECIES", 32, 37], ["Mouse", "SPECIES", 32, 37], ["Mouse Anti-Chicken CD4", "TEST", 32, 54], ["PE", "PROBLEM", 55, 57], ["CD8a-FITC antibodies", "TEST", 62, 82], ["All staining reactions", "PROBLEM", 128, 150], ["PE", "OBSERVATION", 55, 57]]], ["Then the fluorescence positive cells were analyzed by a BD AccuriTM C6 Flow Cytometer (Becton,Dickinson and Co., NJ, U.S.A.).Detection of viral loads in trachea and kidney ::: MATERIALS AND METHODSViral RNA was extracted from trachea and kidney samples of each bird at 5 dpc using EasyPure RNA Purification Kit (TransGen Biotech, Beijing, China).", [["cells", "ANATOMY", 31, 36], ["trachea", "ANATOMY", 153, 160], ["kidney", "ANATOMY", 165, 171], ["trachea", "ANATOMY", 226, 233], ["kidney samples", "ANATOMY", 238, 252], ["cells", "CELL", 31, 36], ["trachea", "MULTI-TISSUE_STRUCTURE", 153, 160], ["kidney", "ORGAN", 165, 171], ["trachea", "MULTI-TISSUE_STRUCTURE", 226, 233], ["kidney samples", "MULTI-TISSUE_STRUCTURE", 238, 252], ["fluorescence positive cells", "CELL_LINE", 9, 36], ["METHODSViral RNA", "RNA", 190, 206], ["the fluorescence positive cells", "PROBLEM", 5, 36], ["viral loads in trachea and kidney", "PROBLEM", 138, 171], ["METHODSViral RNA", "TREATMENT", 190, 206], ["viral loads", "OBSERVATION", 138, 149], ["trachea", "ANATOMY", 153, 160], ["kidney", "ANATOMY", 165, 171], ["METHODSViral RNA", "OBSERVATION", 190, 206], ["trachea", "ANATOMY", 226, 233], ["kidney", "ANATOMY", 238, 244]]], ["First-strand cDNA was synthesized usingrandom hexamers (TaKaRa, Tokyo, Japan).", [["-strand cDNA", "DNA", 5, 17]]], ["The IBV viral loads in trachea and kidney samples were detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) targetingthe nucleocapsid (N) gene according to our previous description [8].Statistical analysis ::: MATERIALS AND METHODSAll data were shown as mean values \u00b1 standard error (mean \u00b1 SE).", [["trachea", "ANATOMY", 23, 30], ["kidney samples", "ANATOMY", 35, 49], ["IBV", "ORGANISM", 4, 7], ["trachea", "MULTI-TISSUE_STRUCTURE", 23, 30], ["kidney samples", "CANCER", 35, 49], ["reverse transcriptase polymerase chain reaction (qRT-PCR) targetingthe nucleocapsid (N) gene", "DNA", 80, 172], ["IBV", "SPECIES", 4, 7], ["The IBV viral loads in trachea and kidney samples", "TEST", 0, 49], ["quantitative reverse transcriptase polymerase chain reaction", "PROBLEM", 67, 127], ["qRT", "TEST", 129, 132], ["METHODSAll data", "TEST", 254, 269], ["mean values", "TEST", 284, 295], ["viral loads", "OBSERVATION", 8, 19], ["trachea", "ANATOMY", 23, 30], ["kidney", "ANATOMY", 35, 41]]], ["Statistical analysis was performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, U.S.A.), and significant differences(P<0.05) were determined by the Student\u2019s t-test.", [["Statistical analysis", "TEST", 0, 20], ["SPSS version", "TEST", 41, 53], ["significant", "OBSERVATION_MODIFIER", 97, 108]]], ["P values less than 0.05 (P<0.05) were regarded as significantand those less than 0.01 (P<0.01) were regarded as highly significant.Antibody responses to IBV following vaccination ::: RESULTSThe birds in all the three vaccinated groups produced antibodies against IBV at 7dpi and the antibody levels continued to rise from 7 to 21 dpi, especially in the LDT3-A group (Fig. 1).", [["IBV", "ORGANISM", 153, 156], ["birds", "ORGANISM", 194, 199], ["IBV", "ORGANISM", 263, 266], ["antibodies", "PROTEIN", 244, 254], ["IBV", "SPECIES", 153, 156], ["IBV", "SPECIES", 263, 266], ["P values", "TEST", 0, 8], ["antibodies", "TREATMENT", 244, 254], ["IBV", "PROBLEM", 263, 266], ["the antibody levels", "TEST", 279, 298]]], ["The antibody levels of vaccinated groups were significantly higher (P<0.05 or P<0.01) than those of non-vaccinated groups from 7 to 21 dpi.At 21 dpi, the LDT3-A group showed the highest antibody level (P<0.01), while the H120 group showed a medium level and the 4/91 group presented the lowest level(P<0.05).CD4+ and CD8+ T lymphocytes in peripheral blood of vaccinated chickens ::: RESULTSThe percentages of CD4+ and CD8+ T lymphocytes in all the three vaccinated groups showed different upward trends and were significantly higher(P<0.05 or P<0.01) than those of the non-vaccinated groups within 21 dpi (Fig. 2).", [["CD4+", "ANATOMY", 308, 312], ["CD8+ T lymphocytes", "ANATOMY", 317, 335], ["peripheral blood", "ANATOMY", 339, 355], ["CD4+", "ANATOMY", 409, 413], ["T lymphocytes", "ANATOMY", 423, 436], ["LDT3-A", "GENE_OR_GENE_PRODUCT", 154, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 308, 311], ["CD8", "GENE_OR_GENE_PRODUCT", 317, 320], ["peripheral blood", "ORGANISM_SUBSTANCE", 339, 355], ["chickens", "ORGANISM", 370, 378], ["CD4", "GENE_OR_GENE_PRODUCT", 409, 412], ["CD8", "GENE_OR_GENE_PRODUCT", 418, 421], ["T lymphocytes", "CELL", 423, 436], ["LDT3", "PROTEIN", 154, 158], ["CD4", "PROTEIN", 308, 311], ["CD8+ T lymphocytes", "CELL_TYPE", 317, 335], ["CD4", "PROTEIN", 409, 412], ["CD8", "PROTEIN", 418, 421], ["T lymphocytes", "CELL_TYPE", 423, 436], ["chickens", "SPECIES", 370, 378], ["chickens", "SPECIES", 370, 378], ["The antibody levels", "TEST", 0, 19], ["vaccinated groups", "TEST", 23, 40], ["the LDT3", "TEST", 150, 158], ["the highest antibody level", "TEST", 174, 200], ["CD4", "TEST", 308, 311], ["CD8", "TEST", 317, 320], ["lymphocytes", "TEST", 324, 335], ["CD4", "TEST", 409, 412], ["CD8", "TEST", 418, 421], ["T lymphocytes", "TEST", 423, 436], ["different upward trends", "PROBLEM", 479, 502], ["CD8+ T lymphocytes", "OBSERVATION", 317, 335], ["peripheral", "ANATOMY_MODIFIER", 339, 349], ["blood", "ANATOMY", 350, 355], ["CD4", "OBSERVATION", 409, 412], ["lymphocytes", "OBSERVATION", 425, 436], ["different", "OBSERVATION_MODIFIER", 479, 488], ["upward", "OBSERVATION_MODIFIER", 489, 495], ["significantly", "OBSERVATION_MODIFIER", 512, 525], ["higher", "OBSERVATION_MODIFIER", 526, 532]]], ["At 7 dpi, the 4/91 and H120 groups showed the highest CD4+ and CD8+ T lymphocyte percentages, respectively.", [["CD4+", "ANATOMY", 54, 58], ["CD8+ T lymphocyte", "ANATOMY", 63, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD4", "PROTEIN", 54, 57], ["CD8", "PROTEIN", 63, 66], ["CD8", "TEST", 63, 66]]], ["At 14 dpi, the H120 and 4/91 groups had the highest(P<0.05) CD4+ and CD8+ T lymphocyte percentages, respectively.", [["H120", "ANATOMY", 15, 19], ["CD4+", "ANATOMY", 60, 64], ["CD8+ T lymphocyte", "ANATOMY", 69, 86], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD4", "PROTEIN", 60, 63], ["CD8", "PROTEIN", 69, 72], ["the H120", "TEST", 11, 19], ["CD4", "TEST", 60, 63], ["CD8", "TEST", 69, 72]]], ["At 21 dpi, the percentages of CD4+ and CD8+ T lymphocytes inthe 4/91 group were the highest, and those in the H120 group were the lowest.Clinical signs and gross lesions in birds challenged with IBV ::: RESULTSAt 2\u20135 dpc, there were birds in the vaccinated groups exhibited gasping, coughing, sneezing, tracheal rale and nasal discharge and some looked depressed with anorexia, ruffled feathers, dryclaw and wet droppings.", [["CD4+", "ANATOMY", 30, 34], ["T lymphocytes", "ANATOMY", 44, 57], ["gross lesions", "ANATOMY", 156, 169], ["tracheal", "ANATOMY", 303, 311], ["nasal", "ANATOMY", 321, 326], ["coughing", "DISEASE", 283, 291], ["sneezing", "DISEASE", 293, 301], ["depressed", "DISEASE", 353, 362], ["anorexia", "DISEASE", 368, 376], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["T lymphocytes", "CELL", 44, 57], ["H120", "CANCER", 110, 114], ["gross lesions", "PATHOLOGICAL_FORMATION", 156, 169], ["birds", "ORGANISM", 173, 178], ["IBV", "ORGANISM", 195, 198], ["birds", "ORGANISM", 233, 238], ["nasal", "ORGANISM_SUBDIVISION", 321, 326], ["CD4", "PROTEIN", 30, 33], ["CD8", "PROTEIN", 39, 42], ["T lymphocytes", "CELL_TYPE", 44, 57], ["IBV", "SPECIES", 195, 198], ["the percentages", "TEST", 11, 26], ["CD4", "TEST", 30, 33], ["CD8", "TEST", 39, 42], ["T lymphocytes", "TEST", 44, 57], ["Clinical signs", "TEST", 137, 151], ["gross lesions", "PROBLEM", 156, 169], ["gasping", "PROBLEM", 274, 281], ["coughing", "PROBLEM", 283, 291], ["sneezing", "PROBLEM", 293, 301], ["tracheal rale and nasal discharge", "PROBLEM", 303, 336], ["some looked depressed", "PROBLEM", 341, 362], ["anorexia", "PROBLEM", 368, 376], ["ruffled feathers", "PROBLEM", 378, 394], ["dryclaw", "PROBLEM", 396, 403], ["wet droppings", "PROBLEM", 408, 421], ["CD4", "OBSERVATION", 30, 33], ["highest", "OBSERVATION_MODIFIER", 84, 91], ["gross", "OBSERVATION_MODIFIER", 156, 161], ["lesions", "OBSERVATION", 162, 169], ["gasping", "OBSERVATION", 274, 281], ["tracheal", "ANATOMY", 303, 311], ["nasal", "ANATOMY", 321, 326], ["anorexia", "OBSERVATION", 368, 376], ["ruffled feathers", "OBSERVATION", 378, 394]]], ["Some even exhibited severe respiratory distress and eventually died.", [["respiratory", "ANATOMY", 27, 38], ["respiratory distress", "DISEASE", 27, 47], ["severe respiratory distress", "PROBLEM", 20, 47], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["respiratory distress", "OBSERVATION", 27, 47]]], ["And all the birds in the non-vaccinated group showed much more severe clinical signs than thosein the vaccinated groups.", [["birds", "ORGANISM", 12, 17]]], ["In the necropsy at 5 dpc, the kidneys of the birds challenged with GX-YL5 strain were swollen and pale, and showed a white sludge of urate deposition, and somebirds showed trachitis with exudates.", [["kidneys", "ANATOMY", 30, 37], ["urate", "CHEMICAL", 133, 138], ["trachitis", "DISEASE", 172, 181], ["urate", "CHEMICAL", 133, 138], ["kidneys", "ORGAN", 30, 37], ["birds", "ORGANISM", 45, 50], ["GX-YL5", "GENE_OR_GENE_PRODUCT", 67, 73], ["urate", "SIMPLE_CHEMICAL", 133, 138], ["GX-YL5 strain", "TEST", 67, 80], ["swollen", "PROBLEM", 86, 93], ["a white sludge of urate deposition", "PROBLEM", 115, 149], ["trachitis", "PROBLEM", 172, 181], ["exudates", "PROBLEM", 187, 195], ["kidneys", "ANATOMY", 30, 37], ["swollen", "OBSERVATION", 86, 93], ["pale", "OBSERVATION_MODIFIER", 98, 102], ["urate deposition", "OBSERVATION", 133, 149], ["trachitis", "OBSERVATION", 172, 181], ["exudates", "OBSERVATION", 187, 195]]], ["The birds challenged with GX-GL11079 and GX-NN09032 strains exhibited more exudates in the trachea.", [["exudates", "ANATOMY", 75, 83], ["trachea", "ANATOMY", 91, 98], ["GX-GL11079", "CHEMICAL", 26, 36], ["birds", "ORGANISM", 4, 9], ["GX-GL11079", "SIMPLE_CHEMICAL", 26, 36], ["GX-NN09032", "SIMPLE_CHEMICAL", 41, 51], ["trachea", "ORGAN", 91, 98], ["GX", "TEST", 26, 28], ["GX", "TEST", 41, 43], ["strains", "PROBLEM", 52, 59], ["exudates in the trachea", "PROBLEM", 75, 98], ["more", "OBSERVATION_MODIFIER", 70, 74], ["exudates", "OBSERVATION", 75, 83], ["trachea", "ANATOMY", 91, 98]]], ["No clinical signs or gross lesions were observed inany birds in the blank control group.The immune protection rates of each group against the challenge ::: RESULTSThe morbidity, mortality and protective rate of the experiment groups at 5 dpc were summarized in Table 1.", [["gross lesions", "ANATOMY", 21, 34], ["gross lesions", "PATHOLOGICAL_FORMATION", 21, 34], ["clinical signs", "PROBLEM", 3, 17], ["gross lesions", "PROBLEM", 21, 34], ["The immune protection rates", "TREATMENT", 88, 115], ["gross", "OBSERVATION_MODIFIER", 21, 26], ["lesions", "OBSERVATION", 27, 34]]], ["The results showed that the protection rates of H120, 4/91 and LDT3-A vaccines against the infection of GX-YL5, GX-GL11079 and GX-NN09032 strains were 41.7\u201358.3%, 75.0\u201383.7%and 66.7\u201375.0%, respectively.", [["LDT3-A", "CHEMICAL", 63, 69], ["infection", "DISEASE", 91, 100], ["H120", "SIMPLE_CHEMICAL", 48, 52], ["LDT3-A vaccines", "ORGANISM", 63, 78], ["GX-YL5", "ORGANISM", 104, 110], ["GX-GL11079", "ORGANISM", 112, 122], ["GX-NN09032 strains", "ORGANISM", 127, 145], ["the protection rates", "TEST", 24, 44], ["H120", "TEST", 48, 52], ["LDT3", "TEST", 63, 67], ["A vaccines", "TREATMENT", 68, 78], ["the infection", "PROBLEM", 87, 100], ["GX", "TEST", 112, 114], ["GX", "TEST", 127, 129], ["strains", "TEST", 138, 145], ["infection", "OBSERVATION", 91, 100]]], ["The protection rate of the 4/91 group against the challenge of GX-NN09032 strain was the highest (83.7%).", [["GX-NN09032", "CHEMICAL", 63, 73], ["GX-NN09032", "SIMPLE_CHEMICAL", 63, 73], ["The protection rate", "TEST", 0, 19]]], ["As expected, no protection was observed in thenon-vaccinated group.", [["protection", "TREATMENT", 16, 26], ["no", "UNCERTAINTY", 13, 15]]], ["No morbidity and mortality were observed in any birds in the blank control group.The viral loads in the trachea and kidney of birds challenged with IBV ::: RESULTSThe viral loads in trachea and kidney of vaccinated groups were significantly (P<0.01) lower than those of the non-vaccinated group at 5 dpc (Fig. 3).", [["trachea", "ANATOMY", 104, 111], ["kidney", "ANATOMY", 116, 122], ["trachea", "ANATOMY", 182, 189], ["kidney", "ANATOMY", 194, 200], ["trachea", "ORGAN", 104, 111], ["kidney", "ORGAN", 116, 122], ["birds", "ORGANISM", 126, 131], ["IBV", "ORGANISM", 148, 151], ["trachea", "MULTI-TISSUE_STRUCTURE", 182, 189], ["kidney", "ORGAN", 194, 200], ["IBV", "SPECIES", 148, 151], ["morbidity", "PROBLEM", 3, 12], ["mortality", "PROBLEM", 17, 26], ["The viral loads in the trachea", "PROBLEM", 81, 111], ["RESULTSThe viral loads in trachea and kidney of vaccinated groups", "TEST", 156, 221], ["morbidity", "OBSERVATION", 3, 12], ["viral loads", "OBSERVATION", 85, 96], ["trachea", "ANATOMY", 104, 111], ["kidney", "ANATOMY", 116, 122], ["viral loads", "OBSERVATION", 167, 178], ["trachea", "ANATOMY", 182, 189], ["kidney", "ANATOMY", 194, 200], ["vaccinated", "OBSERVATION", 204, 214]]], ["In all vaccinated groups, the viral loads in the trachea were higher than those in the kidney.", [["trachea", "ANATOMY", 49, 56], ["kidney", "ANATOMY", 87, 93], ["trachea", "ORGAN", 49, 56], ["kidney", "ORGAN", 87, 93], ["the viral loads", "TEST", 26, 41], ["viral loads", "OBSERVATION", 30, 41], ["trachea", "ANATOMY", 49, 56], ["higher", "OBSERVATION_MODIFIER", 62, 68], ["kidney", "ANATOMY", 87, 93]]], ["The viral loads in the trachea and kidney of the vaccinated groups at every timepoints showed the same pattern, that was the H120 group was higher than that of the LDT3-A group and the LDT3-A group was higher than that of the 4/91 group.", [["trachea", "ANATOMY", 23, 30], ["kidney", "ANATOMY", 35, 41], ["LDT3-A", "CHEMICAL", 164, 170], ["LDT3-A", "CHEMICAL", 185, 191], ["trachea", "MULTI-TISSUE_STRUCTURE", 23, 30], ["kidney", "ORGAN", 35, 41], ["LDT3-A", "CANCER", 164, 170], ["LDT3-A", "SIMPLE_CHEMICAL", 185, 191], ["The viral loads", "TEST", 0, 15], ["the LDT3", "TEST", 160, 168], ["the LDT3", "TEST", 181, 189], ["viral loads", "OBSERVATION", 4, 15], ["trachea", "ANATOMY", 23, 30], ["kidney", "ANATOMY", 35, 41]]], ["The viral loads in trachea andkidney of the 4/91 group challenged with the same serotype strain GX-NN09032 maintained a low level of less than 102 copies/\u00b5l and were significantly lower thanthose of the H120 group and the LDT3-A group at 5 dpc.", [["trachea andkidney", "ANATOMY", 19, 36], ["GX-NN09032", "CHEMICAL", 96, 106], ["LDT3-A", "CHEMICAL", 222, 228], ["trachea andkidney", "MULTI-TISSUE_STRUCTURE", 19, 36], ["GX-NN09032", "SIMPLE_CHEMICAL", 96, 106], ["LDT3-A", "GENE_OR_GENE_PRODUCT", 222, 228], ["The viral loads in trachea andkidney", "TEST", 0, 36], ["viral loads", "OBSERVATION", 4, 15], ["trachea", "ANATOMY", 19, 26], ["low level", "OBSERVATION_MODIFIER", 120, 129]]], ["None of the viruses was detected in the trachea or kidney samples from the blank control group.DISCUSSIONLive attenuated vaccines play a key role in the control of IB, but limited or no cross-protection confers between serotypes of IBVs.", [["trachea", "ANATOMY", 40, 47], ["kidney samples", "ANATOMY", 51, 65], ["IBVs", "DISEASE", 232, 236], ["trachea", "MULTI-TISSUE_STRUCTURE", 40, 47], ["kidney samples", "CANCER", 51, 65], ["IBVs", "CANCER", 232, 236], ["the viruses", "PROBLEM", 8, 19], ["DISCUSSIONLive attenuated vaccines", "TREATMENT", 95, 129], ["IBVs", "TREATMENT", 232, 236], ["viruses", "OBSERVATION", 12, 19], ["trachea", "ANATOMY", 40, 47], ["kidney", "ANATOMY", 51, 57]]], ["Therefore, it is extremely critical to choose theappropriate IBV vaccines in practice.", [["IBV", "ORGANISM", 61, 64], ["IBV", "SPECIES", 61, 64], ["theappropriate IBV vaccines", "TREATMENT", 46, 73]]], ["Little is known about the protection conferred by the commonly used live attenuated vaccines H120, 4/91 and LDT3-A against IBV prevalent local strains insouthern China.", [["H120, 4/91 and LDT3-A", "CHEMICAL", 93, 114], ["H120", "SIMPLE_CHEMICAL", 93, 97], ["4/91", "SIMPLE_CHEMICAL", 99, 103], ["LDT3-A", "ORGANISM", 108, 114], ["IBV", "ORGANISM", 123, 126], ["IBV", "SPECIES", 123, 126], ["live attenuated vaccines", "TREATMENT", 68, 92]]], ["In the present study, significantly higher antibody levels and percentages of CD4+, CD8+ T lymphocytes in vaccinated groups compared to the non-vaccinatedgroups within 21 dpi indicated that the vaccines H120, 4/91 and LDT3-A could stimulate the immunized chickens to produce humoral and cellular immunity that potentially resist or eliminate theinfection of IBV.", [["CD4+, CD8+ T lymphocytes", "ANATOMY", 78, 102], ["non-vaccinatedgroups", "ANATOMY", 140, 160], ["cellular", "ANATOMY", 287, 295], ["LDT3-A", "CHEMICAL", 218, 224], ["CD4", "GENE_OR_GENE_PRODUCT", 78, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["LDT3-A", "SIMPLE_CHEMICAL", 218, 224], ["chickens", "ORGANISM", 255, 263], ["cellular", "CELL", 287, 295], ["IBV", "ORGANISM", 358, 361], ["CD4", "PROTEIN", 78, 81], ["CD8", "PROTEIN", 84, 87], ["T lymphocytes", "CELL_TYPE", 89, 102], ["chickens", "SPECIES", 255, 263], ["chickens", "SPECIES", 255, 263], ["IBV", "SPECIES", 358, 361], ["the present study", "TEST", 3, 20], ["significantly higher antibody levels", "PROBLEM", 22, 58], ["percentages", "TEST", 63, 74], ["CD4", "TEST", 78, 81], ["CD8", "TEST", 84, 87], ["T lymphocytes in vaccinated groups", "PROBLEM", 89, 123], ["the vaccines H120", "TEST", 190, 207], ["LDT3", "TEST", 218, 222], ["the immunized chickens", "TREATMENT", 241, 263], ["humoral and cellular immunity", "PROBLEM", 275, 304], ["IBV", "PROBLEM", 358, 361]]], ["However, at 5 dpc, the protection rates of H120, 4/91 and LDT3-A vaccines against the challenges of the three prevalent IBV isolates were 41.7\u201358.3%, 75\u201383.7% and 66.7\u201375.0%,respectively.", [["LDT3-A", "CHEMICAL", 58, 64], ["LDT3-A vaccines", "ORGANISM", 58, 73], ["IBV", "ORGANISM", 120, 123], ["IBV", "SPECIES", 120, 123], ["the protection rates", "TEST", 19, 39], ["LDT3", "TREATMENT", 58, 62], ["A vaccines", "TREATMENT", 63, 73], ["IBV isolates", "TEST", 120, 132]]], ["Hence, none of the three attenuated vaccines could provide complete protection against all the current prevalent isolates, but vaccine 4/91 offered the best immune protection ofthe three and vaccine LDT3-A had better protection than the H120 vaccine.DISCUSSIONA previous report showed that the best protection against challenge is achieved by a vaccine containing a homologous strain [7].", [["LDT3-A", "CHEMICAL", 199, 205], ["H120", "CHEMICAL", 237, 241], ["LDT3-A", "SIMPLE_CHEMICAL", 199, 205], ["H120", "SPECIES", 237, 241], ["the three attenuated vaccines", "TREATMENT", 15, 44], ["vaccine", "TREATMENT", 127, 134], ["vaccine LDT3", "TREATMENT", 191, 203], ["the H120 vaccine", "TREATMENT", 233, 249], ["a vaccine", "TREATMENT", 343, 352], ["a homologous strain", "PROBLEM", 364, 383]]], ["In this study, theattenuated vaccine H120 (serotype 3) provided poor protection against IBV GX-YL5 (serotype 1), GX-GL11079 (serotype 2) and GX-NN09032 (serotype 5) strains with the low protection rate of 41.7,58.3 and 58.3%, respectively.", [["H120", "CHEMICAL", 37, 41], ["serotype 3", "ORGANISM", 43, 53], ["IBV", "ORGANISM", 88, 91], ["GX-YL5", "ORGANISM", 92, 98], ["serotype 1", "ORGANISM", 100, 110], ["GX-GL11079", "ORGANISM", 113, 123], ["serotype 2", "ORGANISM", 125, 135], ["GX-NN09032 (serotype 5", "ORGANISM", 141, 163], ["H120", "SPECIES", 37, 41], ["IBV GX-YL5", "SPECIES", 88, 98], ["this study", "TEST", 3, 13], ["theattenuated vaccine H120 (serotype", "TREATMENT", 15, 51], ["IBV GX", "TEST", 88, 94], ["serotype", "TEST", 100, 108], ["GX", "TEST", 113, 115], ["serotype", "TEST", 125, 133], ["GX", "TEST", 141, 143], ["serotype", "TEST", 153, 161], ["strains", "PROBLEM", 165, 172], ["the low protection rate", "TEST", 178, 201]]], ["The vaccine 4/91 (serotype 5) has provided lower protection rate against the challenge with GX-GL11079 (serotype 2, 75.0%) compared to GX-NN09032 (serotype 5,83.7%).", [["GX-GL11079", "CHEMICAL", 92, 102], ["GX-NN09032", "CHEMICAL", 135, 145], ["serotype 5", "ORGANISM", 18, 28], ["GX-GL11079", "ORGANISM", 92, 102], ["GX-NN09032", "SIMPLE_CHEMICAL", 135, 145], ["GX-NN09032", "SPECIES", 135, 145], ["The vaccine", "TREATMENT", 0, 11], ["lower protection rate", "TREATMENT", 43, 64], ["GX", "TEST", 92, 94], ["serotype", "TEST", 104, 112], ["GX", "TEST", 135, 137], ["serotype", "TEST", 147, 155]]], ["Interestingly, the vaccine 4/91 (serotype 5) provided the same protection rate (83.7%) against the challenge with isolate GX-YL5 (serotype 1) and GX-NN09032 (serotype 5), but the viralloads of trachea and kidney from GX-NN09032 challenged birds were always lower than those from GX-YL5 challenged birds.", [["trachea", "ANATOMY", 193, 200], ["kidney", "ANATOMY", 205, 211], ["serotype 5", "ORGANISM", 33, 43], ["GX-YL5", "ORGANISM", 122, 128], ["serotype 1", "ORGANISM", 130, 140], ["GX-NN09032", "ORGANISM", 146, 156], ["serotype 5", "ORGANISM", 158, 168], ["trachea", "ORGAN", 193, 200], ["kidney", "ORGAN", 205, 211], ["GX-NN09032", "ORGANISM", 217, 227], ["birds", "ORGANISM", 239, 244], ["GX-YL5", "ORGANISM", 279, 285], ["birds", "ORGANISM", 297, 302], ["the vaccine", "TREATMENT", 15, 26], ["GX", "TEST", 146, 148], ["GX", "TEST", 217, 219], ["trachea", "ANATOMY", 193, 200], ["kidney", "ANATOMY", 205, 211], ["GX", "ANATOMY", 217, 219]]], ["Therefore, our data indicated that the vaccine 4/91 had a greaterability to inhibit the replication and reduce the shedding of a homologous serotype virus than a heterologous serotype virus; the vaccine H120 provided poor protection against the heterologousserotype viruses.", [["4/91", "CHEMICAL", 47, 51], ["H120", "CHEMICAL", 203, 207], ["serotype virus", "ORGANISM", 140, 154], ["heterologous serotype virus", "ORGANISM", 162, 189], ["heterologousserotype viruses", "ORGANISM", 245, 273], ["heterologous serotype virus", "SPECIES", 162, 189], ["serotype virus", "SPECIES", 175, 189], ["H120", "SPECIES", 203, 207], ["our data", "TEST", 11, 19], ["the vaccine", "TREATMENT", 35, 46], ["the replication", "TREATMENT", 84, 99], ["a homologous serotype virus", "PROBLEM", 127, 154], ["a heterologous serotype virus", "PROBLEM", 160, 189], ["the vaccine", "TREATMENT", 191, 202], ["the heterologousserotype viruses", "PROBLEM", 241, 273], ["viruses", "OBSERVATION", 266, 273]]], ["These findings support the necessity of developing new vaccines whose antigenicity match the antigenic profile of current prevalent IBV variants in the region.DISCUSSIONAccording to the requirements in China, the clinical protection offered by a compliant IB vaccine must be not less than 80% against a virulent challenge [13].", [["IBV", "ORGANISM", 132, 135], ["IBV", "SPECIES", 132, 135], ["new vaccines", "TREATMENT", 51, 63], ["a compliant IB vaccine", "TREATMENT", 244, 266], ["new", "OBSERVATION_MODIFIER", 51, 54], ["IBV variants", "OBSERVATION", 132, 144], ["region", "ANATOMY_MODIFIER", 152, 158]]], ["Previous studies demonstrated that the H120 vaccine couldn\u2019t provide sufficient protection against the field isolates in China [6, 13,14,15, 24].", [["H120", "CHEMICAL", 39, 43], ["Previous studies", "TEST", 0, 16], ["the H120 vaccine", "TREATMENT", 35, 51]]], ["The latest report showedthat a novel recombinant virulent IBV strain was isolated from an H120- and 4/91-IBV-vaccinated flock in China [27].", [["IBV", "ORGANISM", 58, 61], ["4/91-IBV", "ORGANISM", 100, 108], ["IBV", "SPECIES", 58, 61], ["a novel recombinant virulent IBV strain", "PROBLEM", 29, 68], ["an H120", "TEST", 87, 94], ["IBV-vaccinated flock", "TREATMENT", 105, 125]]], ["In our study, the attenuated vaccine4/91 could not provide complete protection against IBV GX-NN09032 strain even though they shared the same serotype [20].", [["vaccine4/91", "CHEMICAL", 29, 40], ["vaccine4/91", "SIMPLE_CHEMICAL", 29, 40], ["IBV", "ORGANISM", 87, 90], ["GX-NN09032 strain", "ORGANISM", 91, 108], ["IBV GX-NN09032 strain", "SPECIES", 87, 108], ["our study", "TEST", 3, 12], ["the attenuated vaccine4/91", "TREATMENT", 14, 40], ["IBV GX", "TEST", 87, 93], ["NN09032 strain", "PROBLEM", 94, 108]]], ["The reason for this may be thata single vaccine dose of a monovalent vaccine could not provide sufficient immunity with complete protection to birds.", [["single vaccine dose", "TREATMENT", 33, 52], ["a monovalent vaccine", "TREATMENT", 56, 76]]], ["Therefore, in an attempt to provide broader protection to chickens, theprime-boost vaccination program in combination with application of two different IBV vaccines (\u201clive + live\u201d or \u201clive + inactivated\u201d) should be performed for the birds in southern China.", [["chickens", "ORGANISM", 58, 66], ["IBV", "ORGANISM", 152, 155], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 58, 66], ["IBV", "SPECIES", 152, 155], ["broader protection to chickens", "TREATMENT", 36, 66], ["theprime-boost vaccination program", "TREATMENT", 68, 102], ["two different IBV vaccines", "TREATMENT", 138, 164]]], ["Inother countries, it has also been showed that vaccination with two antigenically distinct live-attenuated vaccines can achieved a broad cross-protection against multiple different IBV types[5, 21, 22].", [["IBV", "ORGANISM", 182, 185], ["IBV", "SPECIES", 182, 185], ["vaccination", "TREATMENT", 48, 59], ["attenuated vaccines", "TREATMENT", 97, 116], ["a broad cross-protection", "TREATMENT", 130, 154], ["multiple different IBV types", "PROBLEM", 163, 191]]], ["Further investigation will be necessary to determine whichcombination of H120, 4/91 and LDT3-A vaccines could provide the most effective protection against the prevalent local strains in southern China.DISCUSSIONIn summary, the present study indicated that the commercial attenuated vaccines H120, 4/91 and LDT3-A could not provide complete protection against the prevalent isolates of IBV in southernChina.", [["LDT3-A", "CHEMICAL", 88, 94], ["H120, 4/91 and LDT3-A", "CHEMICAL", 292, 313], ["LDT3-A vaccines", "ORGANISM", 88, 103], ["LDT3-A", "SIMPLE_CHEMICAL", 307, 313], ["IBV", "ORGANISM", 386, 389], ["IBV", "SPECIES", 386, 389], ["Further investigation", "TEST", 0, 21], ["H120", "TEST", 73, 77], ["LDT3-A vaccines", "TREATMENT", 88, 103], ["the present study", "TEST", 224, 241], ["the commercial attenuated vaccines", "TREATMENT", 257, 291], ["LDT3", "TEST", 307, 311]]], ["The 4/91 vaccine demonstrated the best immune protection against the IBV strains prevalent in southern China, while LDT3-A vaccine was less protective and H120 vaccine provided theleast protection.", [["LDT3-A", "CHEMICAL", 116, 122], ["H120", "CHEMICAL", 155, 159], ["IBV", "ORGANISM", 69, 72], ["LDT3-A", "ORGANISM", 116, 122], ["IBV", "SPECIES", 69, 72], ["H120", "SPECIES", 155, 159], ["The 4/91 vaccine", "TREATMENT", 0, 16], ["the IBV strains", "PROBLEM", 65, 80], ["LDT3-A vaccine", "TREATMENT", 116, 130], ["H120 vaccine", "TREATMENT", 155, 167], ["theleast protection", "TREATMENT", 177, 196]]], ["The results also stressed the necessity of developing new vaccines containing a homologous serotype strain and the prime-boost vaccination schedules in combination withapplication of two different IBV vaccine strains.CONFLICT OF INTERESTThe authors declare no conflicts of interest.", [["IBV", "ORGANISM", 197, 200], ["IBV", "SPECIES", 197, 200], ["new vaccines", "TREATMENT", 54, 66], ["a homologous serotype strain", "TREATMENT", 78, 106], ["the prime-boost vaccination schedules", "TREATMENT", 111, 148], ["two different IBV vaccine strains", "TREATMENT", 183, 216]]]], "6d19115a7ff62523eabe683d40f8e9a46224bd2c": [["Dear Editor,In late February 2020 the Lombardy region (Italy) was dramatically hit by a new infectious coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2).", [["infectious coronavirus disease", "DISEASE", 92, 122], ["COVID-19", "CHEMICAL", 124, 132], ["acute respiratory syndrome coronavirus", "DISEASE", 155, 193], ["coronavirus", "ORGANISM", 103, 114], ["Sars-CoV-2", "ORGANISM", 197, 207], ["severe acute respiratory syndrome coronavirus", "SPECIES", 148, 193], ["a new infectious coronavirus disease", "PROBLEM", 86, 122], ["COVID", "TEST", 124, 129], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 144, 193], ["CoV", "TEST", 202, 205], ["new", "OBSERVATION_MODIFIER", 88, 91], ["infectious coronavirus disease", "OBSERVATION", 92, 122], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory syndrome coronavirus", "OBSERVATION", 161, 193]]], ["COVID-19 is paucisymptomatic in the majority of patients but can lead to acute respiratory distress syndrome (ARDS) in up to 30% of cases and to death in 3 to 5% of cases [1] .Dear Editor,Accumulating evidence suggests that severe COVID-19 manifestations are sustained by a \"cytokine storm\" triggered by Sars-CoV-2 mediated inflammasome activation [2, 3] .", [["respiratory", "ANATOMY", 79, 90], ["acute respiratory distress syndrome", "DISEASE", 73, 108], ["ARDS", "DISEASE", 110, 114], ["death", "DISEASE", 145, 150], ["patients", "ORGANISM", 48, 56], ["Sars-CoV-2", "GENE_OR_GENE_PRODUCT", 304, 314], ["cytokine", "PROTEIN", 275, 283], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 0, 5], ["paucisymptomatic", "PROBLEM", 12, 28], ["acute respiratory distress syndrome", "PROBLEM", 73, 108], ["ARDS", "PROBLEM", 110, 114], ["severe COVID-19 manifestations", "PROBLEM", 224, 254], ["a \"cytokine storm", "PROBLEM", 272, 289], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory distress", "OBSERVATION", 79, 99], ["severe", "OBSERVATION_MODIFIER", 224, 230]]], ["Of note, this hyper-inflammatory state is typically preceded by 5 to 10 days of spiking fever that takes over mild influenza-like symptoms, suggesting that, after a first phase characterized by viral spread, COVID-19 might progress to an uncontrolled cytokine release syndrome [1] [2] [3] .Dear Editor,COVID-19 was aggressively faced by the Italian healthcare authorities with restrictive containment measures but, despite that, Lombardy still records 11.337 deaths, 12.043 hospitalized individuals, and 1.073 critically ill patients at the time of writing [www.salute.gov.it].", [["fever", "DISEASE", 88, 93], ["influenza-like symptoms", "DISEASE", 115, 138], ["COVID-19", "CHEMICAL", 208, 216], ["deaths", "DISEASE", 459, 465], ["critically ill", "DISEASE", 510, 524], ["COVID-19", "CHEMICAL", 208, 216], ["patients", "ORGANISM", 525, 533], ["cytokine", "PROTEIN", 251, 259], ["patients", "SPECIES", 525, 533], ["this hyper-inflammatory state", "PROBLEM", 9, 38], ["spiking fever", "PROBLEM", 80, 93], ["mild influenza-like symptoms", "PROBLEM", 110, 138], ["viral spread", "PROBLEM", 194, 206], ["an uncontrolled cytokine release syndrome", "PROBLEM", 235, 276], ["restrictive containment measures", "TREATMENT", 377, 409], ["inflammatory", "OBSERVATION", 20, 32], ["mild", "OBSERVATION_MODIFIER", 110, 114], ["influenza", "OBSERVATION", 115, 124], ["restrictive containment", "OBSERVATION", 377, 400]]], ["Because these numbers exceed the maximum capacity of available intensive care units (ICU), patients are asked to stay at home until advanced respiratory impairment, thus increasing the lethality of COVID-19 [4] .", [["respiratory", "ANATOMY", 141, 152], ["respiratory impairment", "DISEASE", 141, 163], ["COVID-19", "CHEMICAL", 198, 206], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["advanced respiratory impairment", "PROBLEM", 132, 163], ["COVID", "TEST", 198, 203]]], ["In shortage of ICU beds, treating patients at risk of developing hyper-inflammatory ARDS in outpatient settings becomes, therefore, imperative in order to impact disease course and to relieve the pressure on hospitals' structures.", [["ARDS", "DISEASE", 84, 88], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["developing hyper-inflammatory ARDS", "PROBLEM", 54, 88], ["disease course", "TREATMENT", 162, 176], ["the pressure on hospitals' structures", "PROBLEM", 192, 229], ["hyper", "OBSERVATION", 65, 70], ["inflammatory", "OBSERVATION_MODIFIER", 71, 83], ["ARDS", "OBSERVATION", 84, 88], ["pressure", "OBSERVATION_MODIFIER", 196, 204]]], ["Yet, in the absence of effective antiviral therapies and reliable predictors of negative disease progression, this neglected category of patients can rely only on supportive measures while awaiting for clinical deterioration and transportation to emergency departments.Journal Pre-proofWe herein report the favourable outcome of 9 domiciliary consecutive COVID-19 patients treated with a loading dose of 1mg oral colchicine 12 hours apart followed by 1mg daily colchicine until third day of axillary temperature < 37.5\u00b0C. Colchicine was started after a median of 8 days (range 6-13) from COVID-19 onset and after 3 to 5 days of spiking fever despite acetaminophen or antibiotic treatment.", [["oral", "ANATOMY", 408, 412], ["axillary", "ANATOMY", 491, 499], ["colchicine", "CHEMICAL", 413, 423], ["colchicine", "CHEMICAL", 461, 471], ["Colchicine", "CHEMICAL", 522, 532], ["fever", "DISEASE", 636, 641], ["acetaminophen", "CHEMICAL", 650, 663], ["colchicine", "CHEMICAL", 413, 423], ["colchicine", "CHEMICAL", 461, 471], ["Colchicine", "CHEMICAL", 522, 532], ["acetaminophen", "CHEMICAL", 650, 663], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 364, 372], ["oral", "ORGANISM_SUBDIVISION", 408, 412], ["colchicine", "SIMPLE_CHEMICAL", 413, 423], ["colchicine", "SIMPLE_CHEMICAL", 461, 471], ["axillary", "ORGAN", 491, 499], ["Colchicine", "SIMPLE_CHEMICAL", 522, 532], ["acetaminophen", "SIMPLE_CHEMICAL", 650, 663], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 364, 372], ["effective antiviral therapies", "TREATMENT", 23, 52], ["negative disease progression", "PROBLEM", 80, 108], ["supportive measures", "TREATMENT", 163, 182], ["clinical deterioration", "PROBLEM", 202, 224], ["a loading dose", "TREATMENT", 386, 400], ["1mg oral colchicine", "TREATMENT", 404, 423], ["colchicine", "TREATMENT", 461, 471], ["axillary temperature", "TEST", 491, 511], ["C. Colchicine", "TREATMENT", 519, 532], ["COVID", "TEST", 588, 593], ["spiking fever", "PROBLEM", 628, 641], ["acetaminophen", "TREATMENT", 650, 663], ["antibiotic treatment", "TREATMENT", 667, 687], ["axillary", "ANATOMY", 491, 499]]], ["As shown in Figure 1 , colchicine led to defervescence within 72 hours in all patients.", [["colchicine", "CHEMICAL", 23, 33], ["defervescence", "DISEASE", 41, 54], ["colchicine", "CHEMICAL", 23, 33], ["colchicine", "SIMPLE_CHEMICAL", 23, 33], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["colchicine", "TREATMENT", 23, 33]]], ["Only one patient was hospitalized because of persisting dyspnea and discharged after four days of low-flow oxygen therapy.", [["dyspnea", "DISEASE", 56, 63], ["oxygen", "CHEMICAL", 107, 113], ["oxygen", "CHEMICAL", 107, 113], ["patient", "ORGANISM", 9, 16], ["oxygen", "SIMPLE_CHEMICAL", 107, 113], ["patient", "SPECIES", 9, 16], ["persisting dyspnea", "PROBLEM", 45, 63], ["low-flow oxygen therapy", "TREATMENT", 98, 121], ["persisting", "OBSERVATION_MODIFIER", 45, 55], ["dyspnea", "OBSERVATION", 56, 63], ["flow oxygen therapy", "OBSERVATION", 102, 121]]], ["Colchicine was in general well tolerated.", [["Colchicine", "CHEMICAL", 0, 10], ["Colchicine", "CHEMICAL", 0, 10], ["Colchicine", "SIMPLE_CHEMICAL", 0, 10], ["Colchicine", "TREATMENT", 0, 10]]], ["Two patients reported a mild diarrhea that did not interfere with the completion of the treatment.Journal Pre-proofColchicine is an alkaloid extracted from the autumn colchicum, an herbaceous plant belonging to the Liliaceae family.", [["diarrhea", "DISEASE", 29, 37], ["Pre-proofColchicine", "CHEMICAL", 106, 125], ["patients", "ORGANISM", 4, 12], ["autumn colchicum", "ORGANISM", 160, 176], ["Liliaceae", "GENE_OR_GENE_PRODUCT", 215, 224], ["patients", "SPECIES", 4, 12], ["autumn colchicum", "SPECIES", 160, 176], ["a mild diarrhea", "PROBLEM", 22, 37], ["the treatment", "TREATMENT", 84, 97], ["an alkaloid", "PROBLEM", 129, 140], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["diarrhea", "OBSERVATION", 29, 37], ["alkaloid", "OBSERVATION", 132, 140]]], ["Its analgesic and anti-inflammatory properties has been known since ancient times, and colchicine is now approved to treat autoinflammatory conditions such as gout, familiar Mediterranean fever, and pericarditis [5] .", [["colchicine", "CHEMICAL", 87, 97], ["autoinflammatory conditions", "DISEASE", 123, 150], ["gout", "DISEASE", 159, 163], ["familiar Mediterranean fever", "DISEASE", 165, 193], ["pericarditis", "DISEASE", 199, 211], ["colchicine", "CHEMICAL", 87, 97], ["colchicine", "SIMPLE_CHEMICAL", 87, 97], ["Its analgesic", "TREATMENT", 0, 13], ["anti-inflammatory properties", "TREATMENT", 18, 46], ["colchicine", "TREATMENT", 87, 97], ["autoinflammatory conditions", "PROBLEM", 123, 150], ["gout", "PROBLEM", 159, 163], ["familiar Mediterranean fever", "PROBLEM", 165, 193], ["pericarditis", "PROBLEM", 199, 211], ["gout", "OBSERVATION", 159, 163], ["pericarditis", "OBSERVATION", 199, 211]]], ["In the present study, colchicine was used offlabel based on its capability to interfere with pathogenic mechanisms implicated in COVID-19 related hyper-inflammation, including inflammasome activation and cytokines release [2] [3] 5 ].", [["colchicine", "CHEMICAL", 22, 32], ["inflammation", "DISEASE", 152, 164], ["colchicine", "CHEMICAL", 22, 32], ["colchicine", "SIMPLE_CHEMICAL", 22, 32], ["COVID-19", "GENE_OR_GENE_PRODUCT", 129, 137], ["cytokines", "PROTEIN", 204, 213], ["colchicine", "TREATMENT", 22, 32], ["pathogenic mechanisms", "PROBLEM", 93, 114], ["COVID", "TEST", 129, 134], ["hyper-inflammation", "PROBLEM", 146, 164], ["inflammasome activation", "PROBLEM", 176, 199], ["cytokines release", "TEST", 204, 221], ["inflammation", "OBSERVATION", 152, 164]]], ["In addition, by interfering with the polymerization of microtubules, colchicine inhibits the chemotaxis of monocytes and neutrophils, cells that have been abundantly found in the lungs of COVID-19 patients [1] [2] [3] 6] .", [["microtubules", "ANATOMY", 55, 67], ["monocytes", "ANATOMY", 107, 116], ["neutrophils", "ANATOMY", 121, 132], ["cells", "ANATOMY", 134, 139], ["lungs", "ANATOMY", 179, 184], ["colchicine", "CHEMICAL", 69, 79], ["colchicine", "CHEMICAL", 69, 79], ["microtubules", "CELLULAR_COMPONENT", 55, 67], ["colchicine", "SIMPLE_CHEMICAL", 69, 79], ["monocytes", "CELL", 107, 116], ["neutrophils", "CELL", 121, 132], ["cells", "CELL", 134, 139], ["lungs", "ORGAN", 179, 184], ["patients", "ORGANISM", 197, 205], ["monocytes", "CELL_TYPE", 107, 116], ["neutrophils", "CELL_TYPE", 121, 132], ["patients", "SPECIES", 197, 205], ["the polymerization of microtubules", "TREATMENT", 33, 67], ["colchicine", "TREATMENT", 69, 79], ["the chemotaxis of monocytes", "TEST", 89, 116], ["neutrophils", "TEST", 121, 132], ["cells", "TEST", 134, 139], ["COVID", "TEST", 188, 193], ["lungs", "ANATOMY", 179, 184]]], ["Our hypothesis-driven experience supports the use of colchicine in outpatient settings to intercept rampant \"cytokine storm\" in a subset of patients with hyperinflammatory phenotype clinically characterized by persistent high fever.Journal Pre-proofNotably, this population of patients is considered at high risk of progression to respiratory failure, and typically shows increased serum levels of the pro-inflammatory cytokines interleukin (IL)-1 and IL-6 [1] [2] [3] .", [["respiratory", "ANATOMY", 331, 342], ["serum", "ANATOMY", 382, 387], ["colchicine", "CHEMICAL", 53, 63], ["fever", "DISEASE", 226, 231], ["respiratory failure", "DISEASE", 331, 350], ["colchicine", "CHEMICAL", 53, 63], ["colchicine", "SIMPLE_CHEMICAL", 53, 63], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 277, 285], ["serum", "ORGANISM_SUBSTANCE", 382, 387], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 429, 447], ["IL-6 [1] [2] [3]", "SIMPLE_CHEMICAL", 452, 468], ["cytokine", "PROTEIN", 109, 117], ["pro-inflammatory cytokines", "PROTEIN", 402, 428], ["interleukin (IL)-1", "PROTEIN", 429, 447], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 277, 285], ["colchicine", "TREATMENT", 53, 63], ["hyperinflammatory phenotype", "PROBLEM", 154, 181], ["persistent high fever", "PROBLEM", 210, 231], ["respiratory failure", "PROBLEM", 331, 350], ["increased serum levels", "PROBLEM", 372, 394], ["the pro-inflammatory cytokines", "TEST", 398, 428], ["interleukin", "TEST", 429, 440], ["IL", "TEST", 442, 444], ["IL", "TEST", 452, 454], ["persistent", "OBSERVATION_MODIFIER", 210, 220], ["high", "OBSERVATION_MODIFIER", 221, 225], ["fever", "OBSERVATION", 226, 231], ["respiratory failure", "OBSERVATION", 331, 350]]], ["Based on this evidence, patients hospitalized with severe COVID-19 are J o u r n a l P r e -p r o o f Journal Pre-proof currently being treated with anti-cytokine biologic drugs including the IL-1 receptor antagonist anakinra and the IL-6 receptor blockers tocilizumab and sarilumab [7] [8] [9] ].", [["COVID", "DISEASE", 58, 63], ["anakinra", "CHEMICAL", 217, 225], ["tocilizumab", "CHEMICAL", 257, 268], ["sarilumab", "CHEMICAL", 273, 282], ["COVID-19", "CHEMICAL", 58, 66], ["sarilumab", "CHEMICAL", 273, 282], ["patients", "ORGANISM", 24, 32], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 192, 205], ["anakinra", "SIMPLE_CHEMICAL", 217, 225], ["IL-6 receptor blockers", "SIMPLE_CHEMICAL", 234, 256], ["tocilizumab", "SIMPLE_CHEMICAL", 257, 268], ["sarilumab [7] [8] [9] ].", "SIMPLE_CHEMICAL", 273, 297], ["patients", "SPECIES", 24, 32], ["severe COVID", "PROBLEM", 51, 63], ["anti-cytokine biologic drugs", "TREATMENT", 149, 177], ["the IL", "TREATMENT", 188, 194], ["receptor antagonist anakinra", "TREATMENT", 197, 225], ["the IL-6 receptor blockers tocilizumab", "TREATMENT", 230, 268], ["sarilumab", "TEST", 273, 282]]], ["Yet, although these targeted approaches have provided encouraging results in preliminary retrospective cohorts, they do not seem to induce a prompt recovery as optimistically expected, likely because administered at a later stage of the disease when irreversible organ damage is already established [7] [8] [9] .Journal Pre-proofTreating COVID-19 patients early in the rampant phase of systemic inflammation becomes, therefore, essential in order to prevent tissue damage caused by an uncontrolled \"cytokine storm\".", [["organ", "ANATOMY", 263, 268], ["tissue", "ANATOMY", 458, 464], ["organ damage", "DISEASE", 263, 275], ["inflammation", "DISEASE", 395, 407], ["tissue damage", "DISEASE", 458, 471], ["organ", "ORGAN", 263, 268], ["patients", "ORGANISM", 347, 355], ["tissue", "TISSUE", 458, 464], ["cytokine", "PROTEIN", 499, 507], ["patients", "SPECIES", 347, 355], ["the disease", "PROBLEM", 233, 244], ["irreversible organ damage", "PROBLEM", 250, 275], ["systemic inflammation", "PROBLEM", 386, 407], ["tissue damage", "PROBLEM", 458, 471], ["an uncontrolled \"cytokine storm\"", "PROBLEM", 482, 514], ["systemic", "OBSERVATION_MODIFIER", 386, 394], ["inflammation", "OBSERVATION", 395, 407], ["tissue", "ANATOMY", 458, 464], ["damage", "OBSERVATION", 465, 471], ["uncontrolled", "OBSERVATION_MODIFIER", 485, 497], ["cytokine storm", "OBSERVATION", 499, 513]]], ["In this regard, identifying the right therapeutic window where anti-inflammatory treatment might perform better is not a trivial concern since early colchicine administration could impair physiological immune response to Sars-CoV-2 while late administration might not be as effective on established ARDS.Journal Pre-proofKeeping into consideration the limitations of an uncontrolled case series, our study cohort represents the first describing the use of colchicine in COVID-19 on the territory.", [["colchicine", "CHEMICAL", 149, 159], ["ARDS", "DISEASE", 299, 303], ["colchicine", "CHEMICAL", 456, 466], ["colchicine", "CHEMICAL", 149, 159], ["colchicine", "CHEMICAL", 456, 466], ["colchicine", "SIMPLE_CHEMICAL", 149, 159], ["CoV-2", "GENE_OR_GENE_PRODUCT", 226, 231], ["colchicine", "SIMPLE_CHEMICAL", 456, 466], ["Sars-CoV", "SPECIES", 221, 229], ["the right therapeutic window", "TREATMENT", 28, 56], ["anti-inflammatory treatment", "TREATMENT", 63, 90], ["early colchicine administration", "TREATMENT", 143, 174], ["Sars-CoV", "TEST", 221, 229], ["established ARDS", "PROBLEM", 287, 303], ["our study", "TEST", 396, 405], ["colchicine in COVID", "TREATMENT", 456, 475], ["right", "ANATOMY_MODIFIER", 32, 37], ["ARDS", "OBSERVATION", 299, 303], ["territory", "ANATOMY_MODIFIER", 486, 495]]], ["In a setting overwhelmed by COVID-19 and in shortage of ICU resources -as Lombardy was when hit by the pandemic -colchicine may allow relieving pressure on emergency departments and reducing hospitalizations.", [["colchicine", "CHEMICAL", 113, 123], ["colchicine", "CHEMICAL", 113, 123], ["colchicine", "SIMPLE_CHEMICAL", 113, 123], ["colchicine", "TREATMENT", 113, 123]]], ["Large randomized controlled trials in both inpatient and outpatient settings will definitively confirm the utility of colchicine in the current and future COVID-19 outbreaks.", [["colchicine", "CHEMICAL", 118, 128], ["colchicine", "CHEMICAL", 118, 128], ["colchicine", "SIMPLE_CHEMICAL", 118, 128], ["Large randomized controlled trials", "TREATMENT", 0, 34], ["colchicine", "TREATMENT", 118, 128]]]], "d5b581e94d9b60e535436e234870a3ecf0b8135c": [["The COVID-19 pandemic has led to a variety of behaviors as people try to cope with the very real personal and societal threats and the associated anxieties.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["The COVID", "TEST", 0, 9], ["the associated anxieties", "PROBLEM", 131, 155]]], ["Some behaviors, like toilet paper hoarding, would border on the comical if the situation were not so tragic.", [["Some behaviors", "PROBLEM", 0, 14]]], ["Others, like hand washing, social distancing and staying at home have real impact on viral spread and are crucial.", [["hand", "ANATOMY", 13, 17], ["viral spread", "PROBLEM", 85, 97], ["hand", "ANATOMY", 13, 17], ["washing", "OBSERVATION", 18, 25]]], ["As expected, many people from ordinary citizens to biomedical researchers are seeking remedies.", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24]]], ["However, the urgency of the search for new treatments during the current crisis has a dark side.", [["new treatments", "TREATMENT", 39, 53]]], ["That desperate people are at risk for fraudulent exploitation is well-recognized and, sadly, has been reported.", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["fraudulent exploitation", "PROBLEM", 38, 61]]], ["In this context, chicken soup may offer some insights.", [["chicken", "ORGANISM", 17, 24], ["chicken", "SPECIES", 17, 24], ["chicken", "SPECIES", 17, 24]]]], "91a27c0a3a3ae3d932c2e154ec9a672a0e97631d": [["IntroductionThe Eukaryotic EndoU ribonuclease family is a novel protein class which includes several enzymes that share significant sequence homology with the founding member XendoU (Snijder et al., 2003; Renzi et al., 2006) .", [["EndoU ribonuclease", "GENE_OR_GENE_PRODUCT", 27, 45], ["Eukaryotic EndoU ribonuclease family", "PROTEIN", 16, 52], ["protein class", "PROTEIN", 64, 77], ["enzymes", "PROTEIN", 101, 108], ["several enzymes", "TEST", 93, 108]]], ["This family includes several proteins from a variety of organisms that range from viruses to humans.", [["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["several proteins", "PROBLEM", 21, 37]]], ["For example, Xenopus XendoU is a uridylate-specific, divalent cation-dependent enzyme that produces molecules with 2 0 ,3 0 -cyclic phosphate ends, a unique characteristic of this particular class of RNases involved in generating U16 and U86 small nucleolar RNAs (snoRNAs) through the cleavage of pre-mRNAs encoded within introns (Laneve et al., 2003; Gioia et al., 2005; Renzi et al., 2006) .", [["XendoU", "CHEMICAL", 21, 27], ["uridylate", "CHEMICAL", 33, 42], ["2 0 ,3 0 -cyclic phosphate", "CHEMICAL", 115, 141], ["uridylate", "CHEMICAL", 33, 42], ["2 0 ,3 0 -cyclic phosphate", "CHEMICAL", 115, 141], ["Xenopus", "ORGANISM", 13, 20], ["XendoU", "GENE_OR_GENE_PRODUCT", 21, 27], ["uridylate", "SIMPLE_CHEMICAL", 33, 42], ["cation", "SIMPLE_CHEMICAL", 62, 68], ["2 0 ,3 0 -cyclic phosphate ends", "SIMPLE_CHEMICAL", 115, 146], ["U16", "GENE_OR_GENE_PRODUCT", 230, 233], ["U86 small nucleolar RNAs", "GENE_OR_GENE_PRODUCT", 238, 262], ["Xenopus XendoU", "PROTEIN", 13, 27], ["divalent cation-dependent enzyme", "PROTEIN", 53, 85], ["RNases", "PROTEIN", 200, 206], ["U16 and U86 small nucleolar RNAs", "RNA", 230, 262], ["snoRNAs", "RNA", 264, 271], ["pre-mRNAs", "RNA", 297, 306], ["introns", "DNA", 322, 329], ["divalent cation-dependent enzyme", "TEST", 53, 85], ["cyclic phosphate ends", "TREATMENT", 125, 146], ["small nucleolar RNAs (snoRNAs)", "PROBLEM", 242, 272], ["the cleavage of pre-mRNAs", "PROBLEM", 281, 306], ["small", "OBSERVATION_MODIFIER", 242, 247], ["nucleolar RNAs", "OBSERVATION", 248, 262]]], ["The human Endou, known as PP11, has been recently characterized as a member of the XendoU family.", [["PP11", "CHEMICAL", 26, 30], ["human", "ORGANISM", 4, 9], ["Endou", "GENE_OR_GENE_PRODUCT", 10, 15], ["PP11", "GENE_OR_GENE_PRODUCT", 26, 30], ["XendoU", "GENE_OR_GENE_PRODUCT", 83, 89], ["human Endou", "PROTEIN", 4, 15], ["PP11", "PROTEIN", 26, 30], ["XendoU family", "PROTEIN", 83, 96], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9]]], ["Despite its annotated function as a putative serine protease, human Endou has endoribonuclease activity with placental tissue specificity.", [["placental tissue", "ANATOMY", 109, 125], ["serine", "CHEMICAL", 45, 51], ["human", "ORGANISM", 62, 67], ["Endou", "GENE_OR_GENE_PRODUCT", 68, 73], ["endoribonuclease", "GENE_OR_GENE_PRODUCT", 78, 94], ["placental tissue", "TISSUE", 109, 125], ["serine protease", "PROTEIN", 45, 60], ["human Endou", "PROTEIN", 62, 73], ["endoribonuclease", "PROTEIN", 78, 94], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["a putative serine protease", "TREATMENT", 34, 60], ["placental tissue specificity", "TEST", 109, 137]]], ["The dysregulated expression of PP11 in tumor tissues suggests that it may be associated with carcinogenesis (Inaba et al., 1980) .", [["tumor tissues", "ANATOMY", 39, 52], ["tumor", "DISEASE", 39, 44], ["carcinogenesis", "DISEASE", 93, 107], ["PP11", "GENE_OR_GENE_PRODUCT", 31, 35], ["tumor tissues", "TISSUE", 39, 52], ["PP11", "PROTEIN", 31, 35], ["The dysregulated expression of PP11 in tumor tissues", "PROBLEM", 0, 52], ["carcinogenesis", "PROBLEM", 93, 107], ["dysregulated", "OBSERVATION_MODIFIER", 4, 16], ["expression", "OBSERVATION_MODIFIER", 17, 27], ["tumor tissues", "OBSERVATION", 39, 52], ["may be associated with", "UNCERTAINTY", 70, 92], ["carcinogenesis", "OBSERVATION", 93, 107]]], ["Recent studies also demonstrate that both Xenopus XendoU and human Endou play important roles in cellular processes, including the regulation of ER structure, RNA degradation and cell survival (Schwarz and Blower, 2014; Poe et al., 2014) .", [["cellular", "ANATOMY", 97, 105], ["cell", "ANATOMY", 179, 183], ["Endou", "CHEMICAL", 67, 72], ["Xenopus XendoU", "ORGANISM", 42, 56], ["human", "ORGANISM", 61, 66], ["Endou", "GENE_OR_GENE_PRODUCT", 67, 72], ["cellular", "CELL", 97, 105], ["ER", "GENE_OR_GENE_PRODUCT", 145, 147], ["cell", "CELL", 179, 183], ["Xenopus XendoU", "PROTEIN", 42, 56], ["human Endou", "PROTEIN", 61, 72], ["ER", "PROTEIN", 145, 147], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Recent studies", "TEST", 0, 14], ["cellular processes", "OBSERVATION", 97, 115]]], ["Nsp15 (NendoU), a viral ortholog of XendoU, is unique to the nidovirus family of ssRNA viruses, which includes severe acute respiratory syndrome (SARS) coronavirus (Laneve et al., 2003; Bhardwaj et al., 2004; Gioia et al., 2005) .", [["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 118, 163], ["Nsp15", "GENE_OR_GENE_PRODUCT", 0, 5], ["NendoU", "GENE_OR_GENE_PRODUCT", 7, 13], ["XendoU", "GENE_OR_GENE_PRODUCT", 36, 42], ["nidovirus", "GENE_OR_GENE_PRODUCT", 61, 70], ["Nsp15", "PROTEIN", 0, 5], ["NendoU", "PROTEIN", 7, 13], ["XendoU", "PROTEIN", 36, 42], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 111, 163], ["ssRNA viruses", "PROBLEM", 81, 94], ["severe acute respiratory syndrome", "PROBLEM", 111, 144], ["ssRNA viruses", "OBSERVATION", 81, 94], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144]]], ["Nsp15 is a component of the replicaseetranscriptase complex that plays important roles in virus replication and transcription (Ivanov et al., 2004) .", [["Nsp15", "GENE_OR_GENE_PRODUCT", 0, 5], ["replicaseetranscriptase", "GENE_OR_GENE_PRODUCT", 28, 51], ["Nsp15", "PROTEIN", 0, 5], ["replicaseetranscriptase complex", "PROTEIN", 28, 59], ["the replicaseetranscriptase complex", "PROBLEM", 24, 59]]], ["Like XendoU, Nsp15 has endoribonuclease activity which can cleave RNA, either upstream or downstream of uridylates, at GUU or GU to produce molecules with 2 0 ,3 0 -cyclic phosphate ends (Ivanov et al., 2004) .", [["Nsp15", "CHEMICAL", 13, 18], ["GUU", "CHEMICAL", 119, 122], ["2 0 ,3 0 -cyclic phosphate", "CHEMICAL", 155, 181], ["2 0 ,3 0 -cyclic phosphate", "CHEMICAL", 155, 181], ["XendoU", "GENE_OR_GENE_PRODUCT", 5, 11], ["Nsp15", "GENE_OR_GENE_PRODUCT", 13, 18], ["uridylates", "SIMPLE_CHEMICAL", 104, 114], ["GUU", "SIMPLE_CHEMICAL", 119, 122], ["2 0 ,3 0 -cyclic phosphate ends", "SIMPLE_CHEMICAL", 155, 186], ["XendoU", "PROTEIN", 5, 11], ["Nsp15", "PROTEIN", 13, 18], ["endoribonuclease", "PROTEIN", 23, 39], ["endoribonuclease activity", "PROBLEM", 23, 48], ["cyclic phosphate ends", "TREATMENT", 165, 186]]], ["NendoU has also been postulated to suppress host immune responses (Ricagno et al., 2006) and facilitate apoptosis in cells expressing the mitochondrial antiviral signaling adapter protein that induces host antiviral responses (Lei et al., 2009) .IntroductionRecent studies have focused on XendoU enzymatic activity and its three-dimensional structure (Laneve et al., 2003 (Laneve et al., , 2008 Gioia et al., 2005; Renzi et al., 2006) .", [["cells", "ANATOMY", 117, 122], ["mitochondrial", "ANATOMY", 138, 151], ["NendoU", "CHEMICAL", 0, 6], ["NendoU", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 117, 122], ["mitochondrial", "CELLULAR_COMPONENT", 138, 151], ["XendoU", "SIMPLE_CHEMICAL", 289, 295], ["NendoU", "PROTEIN", 0, 6], ["mitochondrial antiviral signaling adapter protein", "PROTEIN", 138, 187], ["apoptosis in cells", "PROBLEM", 104, 122], ["the mitochondrial antiviral signaling adapter protein", "TREATMENT", 134, 187], ["Recent studies", "TEST", 258, 272], ["mitochondrial antiviral", "OBSERVATION", 138, 161]]], ["Zebrafish (Danio rerio) has become a powerful vertebrate model system for the in vivo study of gene expression.", [["Zebrafish", "ORGANISM", 0, 9], ["Danio rerio", "ORGANISM", 11, 22], ["Zebrafish", "SPECIES", 0, 9], ["Danio rerio", "SPECIES", 11, 22], ["Zebrafish", "SPECIES", 0, 9], ["Danio rerio", "SPECIES", 11, 22], ["Zebrafish (Danio rerio", "TREATMENT", 0, 22]]], ["However, the molecular implications of endonuclease, polyU-specific C (endouC) are not well known.", [["polyU-specific C", "GENE_OR_GENE_PRODUCT", 53, 69], ["endouC", "GENE_OR_GENE_PRODUCT", 71, 77], ["endonuclease", "PROTEIN", 39, 51], ["polyU-specific C (endouC)", "PROTEIN", 53, 78], ["endonuclease", "PROBLEM", 39, 51]]], ["Nor has the spatiotemporal pattern of the endouC gene been reported.", [["endouC", "GENE_OR_GENE_PRODUCT", 42, 48], ["endouC gene", "DNA", 42, 53], ["spatiotemporal", "OBSERVATION_MODIFIER", 12, 26], ["pattern", "OBSERVATION_MODIFIER", 27, 34]]], ["Therefore, in the present work, a phylogenic tree of EndouC among known vertebrate species was elucidated.", [["EndouC", "GENE_OR_GENE_PRODUCT", 53, 59], ["EndouC", "DNA", 53, 59], ["known vertebrate species", "PROBLEM", 66, 90], ["tree", "OBSERVATION_MODIFIER", 45, 49], ["vertebrate species", "OBSERVATION", 72, 90]]], ["The spatiotemporal expression pattern of endouC in zebrafish embryos at different developmental stages was also analyzed.Zebrafish husbandry and microscopyBoth zebrafish AB strain and transgenic line huORFZ (Lee et al., 2011) were cultured as previously described (Westerfield, 2000) .", [["embryos", "ANATOMY", 61, 68], ["endouC", "GENE_OR_GENE_PRODUCT", 41, 47], ["zebrafish", "ORGANISM", 51, 60], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 68], ["Zebrafish", "ORGANISM", 121, 130], ["zebrafish", "ORGANISM", 160, 169], ["transgenic line huORFZ", "CELL", 184, 206], ["endouC", "PROTEIN", 41, 47], ["zebrafish", "SPECIES", 51, 60], ["Zebrafish", "SPECIES", 121, 130], ["zebrafish", "SPECIES", 160, 169], ["Zebrafish", "SPECIES", 121, 130], ["endouC in zebrafish embryos", "PROBLEM", 41, 68], ["Zebrafish husbandry", "TREATMENT", 121, 140], ["microscopyBoth zebrafish AB strain", "TREATMENT", 145, 179], ["transgenic line huORFZ", "TREATMENT", 184, 206], ["spatiotemporal", "OBSERVATION_MODIFIER", 4, 18], ["expression", "OBSERVATION_MODIFIER", 19, 29], ["pattern", "OBSERVATION_MODIFIER", 30, 37], ["zebrafish embryos", "OBSERVATION", 51, 68]]], ["Embryos were grown at 28.5 C in embryo media (EM) and staged according to standardized morphological criteria (Westerfield, 2000) .", [["Embryos", "ANATOMY", 0, 7], ["embryo", "ANATOMY", 32, 38], ["Embryos", "CELL", 0, 7], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 32, 38], ["Embryos", "PROBLEM", 0, 7]]], ["EM was supplemented with 0.003e0.006% of 1-phenyl 2thiourea (PTU) (Sigma) to prevent pigment formation in embryos at 24 h post-fertilizationn (hpf).", [["pigment", "ANATOMY", 85, 92], ["embryos", "ANATOMY", 106, 113], ["1-phenyl 2thiourea", "CHEMICAL", 41, 59], ["PTU", "CHEMICAL", 61, 64], ["1-phenyl 2thiourea", "CHEMICAL", 41, 59], ["PTU", "CHEMICAL", 61, 64], ["1-phenyl 2thiourea", "SIMPLE_CHEMICAL", 41, 59], ["PTU", "SIMPLE_CHEMICAL", 61, 64], ["Sigma", "SIMPLE_CHEMICAL", 67, 72], ["pigment", "TISSUE", 85, 92], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 106, 113], ["phenyl 2thiourea (PTU", "TREATMENT", 43, 64], ["pigment formation in embryos", "PROBLEM", 85, 113], ["pigment formation", "OBSERVATION", 85, 102]]], ["Fluorescence was visualized with a fluorescent stereomicroscope (MZ FLIII, Leica) and a confocal spectral microscope (TCS SP5, Leica).", [["Fluorescence", "TEST", 0, 12], ["a fluorescent stereomicroscope", "TEST", 33, 63], ["a confocal spectral microscope", "TEST", 86, 116]]], ["The experiments and treatments of this animal have been reviewed and approved by the Institute of Biomedical Science, Mackay Medical College Institutional Animal Care and Use Committee with ethics approval number A1040009.Whole-mount in situ hybridization (WISH)The full-length coding sequence of zebrafish endouC was isolated by RT-PCR, inserted into plasmid pGEMTeasy (Promega), and confirmed by sequencing.", [["zebrafish", "ORGANISM", 297, 306], ["endouC", "GENE_OR_GENE_PRODUCT", 307, 313], ["zebrafish endouC", "DNA", 297, 313], ["plasmid pGEMTeasy", "DNA", 352, 369], ["zebrafish", "SPECIES", 297, 306], ["zebrafish", "SPECIES", 297, 306], ["treatments", "TREATMENT", 20, 30], ["zebrafish endouC", "TREATMENT", 297, 313], ["plasmid pGEMTeasy (Promega)", "TREATMENT", 352, 379]]], ["After cloning the partial DNA fragments of the desired gene, the probe was labeled by Digoxigenin (DIG).", [["Digoxigenin", "CHEMICAL", 86, 97], ["Digoxigenin", "CHEMICAL", 86, 97], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["Digoxigenin", "SIMPLE_CHEMICAL", 86, 97], ["DIG", "SIMPLE_CHEMICAL", 99, 102], ["partial DNA fragments", "DNA", 18, 39], ["cloning the partial DNA fragments", "TREATMENT", 6, 39], ["Digoxigenin (DIG)", "TREATMENT", 86, 103]]], ["After permeabilization, embryos were hybridized overnight.", [["embryos", "ANATOMY", 24, 31], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 24, 31], ["permeabilization", "TREATMENT", 6, 22], ["embryos", "PROBLEM", 24, 31]]], ["Then, embryos were incubated with anti-DIG antibody (Roche; 1:8000), stained, and observed under a fluorescent stereomicroscope (MZ FLIII, Leica).RNA extraction and RT-PCRTotal RNA isolation, cDNA synthesis and reverse transcriptase polymerase chain reaction (RT-PCR) were performed as previously described (Lee et al., 2011) .", [["embryos", "ANATOMY", 6, 13], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 6, 13], ["anti-DIG antibody", "PROTEIN", 34, 51], ["reverse transcriptase", "PROTEIN", 211, 232], ["anti-DIG antibody", "TEST", 34, 51], ["a fluorescent stereomicroscope", "TEST", 97, 127], ["RNA extraction", "TREATMENT", 146, 160], ["RT-PCRTotal RNA isolation", "TREATMENT", 165, 190], ["cDNA synthesis", "TREATMENT", 192, 206], ["reverse transcriptase polymerase chain reaction", "TREATMENT", 211, 258], ["RT-PCR", "TEST", 260, 266]]], ["For RT-PCR and molecular cloning, the primers used were as follows: forward primer: 5 0 -ATGGCCAGTG-GATATGATTTTGGA-3'; reverse primer:RNA extraction and RT-PCREndouB) and D. rerio EndouC (EndouC).", [["D. rerio", "ORGANISM", 171, 179], ["EndouC", "ORGANISM", 180, 186], ["reverse primer", "DNA", 119, 133], ["D. rerio EndouC", "DNA", 171, 186], ["EndouC", "DNA", 188, 194], ["D. rerio", "SPECIES", 171, 179], ["D. rerio", "SPECIES", 171, 179], ["RT-PCR", "TEST", 4, 10], ["RNA extraction", "TREATMENT", 134, 148], ["RT-PCREndouB)", "TREATMENT", 153, 166]]], ["Using Signal-blast software, the predicted signal peptide is labeled with blue color.", [["blue color", "TEST", 74, 84], ["blue color", "OBSERVATION", 74, 84]]], ["The conserved regions are boxed with red, Xendou-domain.", [["red, Xendou-domain", "PROTEIN", 37, 55], ["boxed", "OBSERVATION_MODIFIER", 26, 31]]], ["Asterisks, two dot and one dot were indicated that amino acid residues were 100%, 75%, 50% conserved among all species, respectively.Comparison of deduced amino acids and functional domains of EndouC among known vertebrate speciesZebrafish endouC is located on chromosome 18 at 15,490,813e15,498,934, and is composed of eight exons separated by seven introns.", [["amino acid", "CHEMICAL", 51, 61], ["amino acids", "CHEMICAL", 155, 166], ["amino acid", "CHEMICAL", 51, 61], ["amino acids", "CHEMICAL", 155, 166], ["amino acid", "AMINO_ACID", 51, 61], ["amino acids", "AMINO_ACID", 155, 166], ["EndouC", "GENE_OR_GENE_PRODUCT", 193, 199], ["Zebrafish", "ORGANISM", 230, 239], ["endouC", "GENE_OR_GENE_PRODUCT", 240, 246], ["chromosome 18", "CELLULAR_COMPONENT", 261, 274], ["EndouC", "PROTEIN", 193, 199], ["endouC", "DNA", 240, 246], ["chromosome 18", "DNA", 261, 274], ["15,490,813e15,498,934", "DNA", 278, 299], ["exons", "DNA", 326, 331], ["introns", "DNA", 351, 358], ["amino acid residues", "TEST", 51, 70], ["deduced amino acids", "TEST", 147, 166], ["functional domains of EndouC", "PROBLEM", 171, 199], ["known vertebrate species", "PROBLEM", 206, 230], ["amino acids", "OBSERVATION", 155, 166], ["vertebrate species", "OBSERVATION", 212, 230], ["seven introns", "OBSERVATION", 345, 358]]], ["The full-length cDNA of zebrafish endouC contains 930 nucleotide base pairs encoding 309 amino acid residues.Comparison of deduced amino acids and functional domains of EndouC among known vertebrate speciesThree XendoU homologs in zebrafish were reported: EndouA, EndouB and EndouC (Strausberg et al., 2002) .", [["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 89, 99], ["amino acids", "CHEMICAL", 131, 142], ["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 89, 99], ["amino acids", "CHEMICAL", 131, 142], ["zebrafish", "ORGANISM", 24, 33], ["endouC", "GENE_OR_GENE_PRODUCT", 34, 40], ["amino acid", "AMINO_ACID", 89, 99], ["amino acids", "AMINO_ACID", 131, 142], ["EndouC", "GENE_OR_GENE_PRODUCT", 169, 175], ["XendoU", "GENE_OR_GENE_PRODUCT", 212, 218], ["zebrafish", "ORGANISM", 231, 240], ["EndouA", "GENE_OR_GENE_PRODUCT", 256, 262], ["EndouB", "GENE_OR_GENE_PRODUCT", 264, 270], ["full-length cDNA", "DNA", 4, 20], ["zebrafish endouC", "DNA", 24, 40], ["930 nucleotide base pairs", "DNA", 50, 75], ["functional domains", "PROTEIN", 147, 165], ["EndouC", "PROTEIN", 169, 175], ["XendoU homologs", "PROTEIN", 212, 227], ["zebrafish", "SPECIES", 24, 33], ["zebrafish", "SPECIES", 231, 240], ["nucleotide base pairs", "TREATMENT", 54, 75], ["amino acid residues", "TREATMENT", 89, 108], ["deduced amino acids", "TEST", 123, 142], ["functional domains of EndouC", "PROBLEM", 147, 175], ["known vertebrate species", "PROBLEM", 182, 206], ["amino acids", "OBSERVATION", 131, 142], ["vertebrate species", "OBSERVATION", 188, 206]]], ["Their corresponding deduced amino acid sequences were shown on NCBI Reference Sequence NM_001080698, NM_001020562, and NM_001044974, respectively.", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["Their corresponding deduced amino acid sequences", "TEST", 0, 48]]], ["When the deduced amino acid residues of EndouA/-B/-C were aligned with the counterpart of other vertebrates, a highly conserved XendoU domain was identified at residues 28e290 (Fig. 1) .", [["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "AMINO_ACID", 17, 27], ["EndouA", "PROTEIN", 40, 46], ["B", "PROTEIN", 48, 49], ["C", "PROTEIN", 51, 52], ["XendoU domain", "PROTEIN", 128, 141], ["the deduced amino acid residues", "TEST", 5, 36], ["EndouA", "TEST", 40, 46]]], ["This result supported the conclusion proposed by Laneve et al. (2003) and Renzi et al. (2006) who demonstrated that Endou family proteins have a highly conserved XendoU domain (residues 131e285) with homologs from eukaryotes.", [["Endou", "GENE_OR_GENE_PRODUCT", 116, 121], ["Endou family proteins", "PROTEIN", 116, 137], ["XendoU domain", "PROTEIN", 162, 175], ["residues 131e285", "PROTEIN", 177, 193]]], ["Moreover, this XendoU domain was speculated to have endoribonucleolytic activity (Renzi et al., 2006) .", [["XendoU domain", "PROTEIN", 15, 28], ["this XendoU domain", "PROBLEM", 10, 28], ["endoribonucleolytic activity", "PROBLEM", 52, 80]]], ["Using Singal-blast software, we found that all human three Endou isoforms, mouse two Endou isoforms, and zebrafish EndouA and EndouC contain a signal peptide at N-terminus, while Xenopus Xendou, chicken Endou and zebrafish EndouB did not (Fig. 1) .", [["human", "ORGANISM", 47, 52], ["Endou", "GENE_OR_GENE_PRODUCT", 59, 64], ["mouse", "ORGANISM", 75, 80], ["Endou", "GENE_OR_GENE_PRODUCT", 85, 90], ["zebrafish", "ORGANISM", 105, 114], ["EndouA", "GENE_OR_GENE_PRODUCT", 115, 121], ["EndouC", "GENE_OR_GENE_PRODUCT", 126, 132], ["Xenopus Xendou", "ORGANISM", 179, 193], ["chicken Endou", "ORGANISM", 195, 208], ["zebrafish", "ORGANISM", 213, 222], ["EndouB", "GENE_OR_GENE_PRODUCT", 223, 229], ["Singal", "PROTEIN", 6, 12], ["human three Endou isoforms", "PROTEIN", 47, 73], ["mouse two Endou isoforms", "PROTEIN", 75, 99], ["zebrafish EndouA", "PROTEIN", 105, 121], ["EndouC", "PROTEIN", 126, 132], ["N-terminus", "PROTEIN", 161, 171], ["Xenopus Xendou", "PROTEIN", 179, 193], ["chicken Endou", "PROTEIN", 195, 208], ["zebrafish EndouB", "PROTEIN", 213, 229], ["human", "SPECIES", 47, 52], ["mouse", "SPECIES", 75, 80], ["zebrafish", "SPECIES", 105, 114], ["chicken", "SPECIES", 195, 202], ["zebrafish", "SPECIES", 213, 222], ["human", "SPECIES", 47, 52], ["mouse", "SPECIES", 75, 80], ["chicken", "SPECIES", 195, 202], ["a signal peptide", "TREATMENT", 141, 157], ["Xenopus Xendou", "TREATMENT", 179, 193]]], ["Interestingly, three zebrafish Endou proteins lacked the Somatomedin B (SMB) and SMB-like domain otherwise conserved among vertebrate Endou proteins (Fig. 1) .Comparison of deduced amino acid residues of three zebrafish Endou proteins with those of higher vertebratesBased on a comparison of the three zebrafish Endou proteins, the deduced amino acid sequence of zebrafish EndouC shared 26% and 42% similarity with EndouA and EndouB, respectively.", [["amino acid", "CHEMICAL", 181, 191], ["amino acid", "CHEMICAL", 340, 350], ["amino acid", "CHEMICAL", 181, 191], ["amino acid", "CHEMICAL", 340, 350], ["zebrafish", "ORGANISM", 21, 30], ["Endou", "GENE_OR_GENE_PRODUCT", 31, 36], ["Somatomedin B", "GENE_OR_GENE_PRODUCT", 57, 70], ["SMB", "GENE_OR_GENE_PRODUCT", 72, 75], ["Endou proteins", "GENE_OR_GENE_PRODUCT", 134, 148], ["amino acid", "AMINO_ACID", 181, 191], ["zebrafish", "ORGANISM", 210, 219], ["Endou", "GENE_OR_GENE_PRODUCT", 220, 225], ["zebrafish", "ORGANISM", 302, 311], ["Endou", "GENE_OR_GENE_PRODUCT", 312, 317], ["amino acid", "AMINO_ACID", 340, 350], ["zebrafish", "ORGANISM", 363, 372], ["EndouC", "GENE_OR_GENE_PRODUCT", 373, 379], ["EndouA", "GENE_OR_GENE_PRODUCT", 415, 421], ["zebrafish Endou proteins", "PROTEIN", 21, 45], ["Somatomedin B", "PROTEIN", 57, 70], ["SMB", "PROTEIN", 72, 75], ["SMB", "PROTEIN", 81, 84], ["like domain", "PROTEIN", 85, 96], ["vertebrate Endou proteins", "PROTEIN", 123, 148], ["zebrafish Endou proteins", "PROTEIN", 210, 234], ["zebrafish Endou proteins", "PROTEIN", 302, 326], ["deduced amino acid sequence", "PROTEIN", 332, 359], ["zebrafish EndouC", "DNA", 363, 379], ["EndouA", "PROTEIN", 415, 421], ["EndouB", "PROTEIN", 426, 432], ["zebrafish", "SPECIES", 363, 372], ["the Somatomedin B (SMB", "TEST", 53, 75], ["deduced amino acid residues", "PROBLEM", 173, 200], ["the deduced amino acid sequence", "TEST", 328, 359]]], ["The deduced amino acid sequence of zebrafish EndouA shared 49e50%, 50%, 54% and 49% identity with human (Homo sapiens), mouse (Mus musculus), chicken (Gallus gallus), and frog (Xenopus tropicalis), respectively.", [["amino acid", "CHEMICAL", 12, 22], ["amino acid", "CHEMICAL", 12, 22], ["amino acid", "AMINO_ACID", 12, 22], ["zebrafish", "ORGANISM", 35, 44], ["EndouA", "GENE_OR_GENE_PRODUCT", 45, 51], ["human", "ORGANISM", 98, 103], ["Homo sapiens", "ORGANISM", 105, 117], ["mouse", "ORGANISM", 120, 125], ["Mus musculus", "ORGANISM", 127, 139], ["chicken", "ORGANISM", 142, 149], ["Gallus gallus", "ORGANISM", 151, 164], ["frog", "ORGANISM_SUBDIVISION", 171, 175], ["Xenopus tropicalis", "ORGANISM", 177, 195], ["deduced amino acid sequence", "PROTEIN", 4, 31], ["zebrafish EndouA", "DNA", 35, 51], ["zebrafish", "SPECIES", 35, 44], ["human", "SPECIES", 98, 103], ["Homo sapiens", "SPECIES", 105, 117], ["mouse", "SPECIES", 120, 125], ["Mus musculus", "SPECIES", 127, 139], ["chicken", "SPECIES", 142, 149], ["Gallus gallus", "SPECIES", 151, 164], ["Xenopus tropicalis", "SPECIES", 177, 195], ["human", "SPECIES", 98, 103], ["Homo sapiens", "SPECIES", 105, 117], ["mouse", "SPECIES", 120, 125], ["Mus musculus", "SPECIES", 127, 139], ["chicken", "SPECIES", 142, 149], ["Gallus gallus", "SPECIES", 151, 164], ["Xenopus tropicalis", "SPECIES", 177, 195], ["The deduced amino acid sequence", "TEST", 0, 31], ["human (Homo sapiens", "TEST", 98, 117], ["chicken (Gallus gallus", "TEST", 142, 164], ["frog (Xenopus tropicalis", "TREATMENT", 171, 195], ["Gallus gallus", "ANATOMY", 151, 164]]], ["Meanwhile, zebrafish EndouB and EndouC respectively shared 28%, 30%, 31% and 30% and 27%, 27%, 27% and 25% identity with human, mouse, chicken and frog.", [["zebrafish", "ORGANISM", 11, 20], ["EndouB", "GENE_OR_GENE_PRODUCT", 21, 27], ["EndouC", "GENE_OR_GENE_PRODUCT", 32, 38], ["human", "ORGANISM", 121, 126], ["mouse", "ORGANISM", 128, 133], ["chicken", "ORGANISM", 135, 142], ["frog", "ORGANISM_SUBDIVISION", 147, 151], ["zebrafish EndouB", "DNA", 11, 27], ["EndouC", "PROTEIN", 32, 38], ["human", "SPECIES", 121, 126], ["mouse", "SPECIES", 128, 133], ["chicken", "SPECIES", 135, 142], ["zebrafish", "SPECIES", 11, 20], ["human", "SPECIES", 121, 126], ["mouse", "SPECIES", 128, 133], ["chicken", "SPECIES", 135, 142], ["human, mouse", "TREATMENT", 121, 133]]], ["Interestingly, similarity of the XendoU domain among the three zebrafish Endou proteins was low, and zebrafish EndouA was more closely related to vertebrate Endou proteins.Phylogenetic analysis of three zebrafish Endou proteinsTo examine the evolutionary relationship between Endou of teleost and that of other species, we generated a phylogenetic tree based on the deduced amino acid residues of the three zebrafish Endou proteins in comparison with Endous of other vertebrates (Fig. 2) .", [["amino acid", "CHEMICAL", 374, 384], ["amino acid", "CHEMICAL", 374, 384], ["zebrafish", "ORGANISM", 63, 72], ["Endou", "GENE_OR_GENE_PRODUCT", 73, 78], ["zebrafish", "ORGANISM", 101, 110], ["EndouA", "GENE_OR_GENE_PRODUCT", 111, 117], ["Endou proteins", "GENE_OR_GENE_PRODUCT", 157, 171], ["zebrafish", "ORGANISM", 203, 212], ["Endou", "GENE_OR_GENE_PRODUCT", 213, 218], ["amino acid", "AMINO_ACID", 374, 384], ["zebrafish", "ORGANISM", 407, 416], ["Endou", "GENE_OR_GENE_PRODUCT", 417, 422], ["XendoU domain", "PROTEIN", 33, 46], ["zebrafish Endou proteins", "PROTEIN", 63, 87], ["zebrafish EndouA", "PROTEIN", 101, 117], ["vertebrate Endou proteins", "PROTEIN", 146, 171], ["zebrafish Endou proteins", "PROTEIN", 203, 227], ["zebrafish Endou proteins", "PROTEIN", 407, 431], ["zebrafish", "SPECIES", 101, 110], ["zebrafish", "SPECIES", 203, 212], ["zebrafish", "SPECIES", 101, 110], ["the XendoU domain", "TEST", 29, 46], ["the three zebrafish Endou proteins", "TEST", 53, 87], ["Phylogenetic analysis", "TEST", 172, 193], ["the deduced amino acid residues", "PROBLEM", 362, 393], ["low", "OBSERVATION_MODIFIER", 92, 95]]], ["Results showed that zebrafish EndouA was clustered with vertebrate Endou groups.", [["zebrafish", "ORGANISM", 20, 29], ["EndouA", "GENE_OR_GENE_PRODUCT", 30, 36], ["zebrafish EndouA", "DNA", 20, 36], ["zebrafish", "SPECIES", 20, 29], ["zebrafish EndouA", "OBSERVATION", 20, 36]]], ["Interestingly, zebrafish EndouB and EndouC were found to belong to a unique monophyletic group.", [["zebrafish", "ORGANISM", 15, 24], ["EndouB", "GENE_OR_GENE_PRODUCT", 25, 31], ["EndouC", "GENE_OR_GENE_PRODUCT", 36, 42], ["zebrafish EndouB", "DNA", 15, 31], ["EndouC", "PROTEIN", 36, 42], ["zebrafish", "SPECIES", 15, 24], ["zebrafish", "SPECIES", 15, 24]]], ["Further study of this unusual characteristic should provide additional insight into the molecular structure of endou genes.Expression pattern of endouC in zebrafish embryosTo analyze the spatiotemporal expression pattern of endouC during zebrafish embryogenesis, we performed RT-PCR and WISH.", [["embryos", "ANATOMY", 165, 172], ["endou", "GENE_OR_GENE_PRODUCT", 111, 116], ["endouC", "GENE_OR_GENE_PRODUCT", 145, 151], ["zebrafish", "ORGANISM", 155, 164], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 165, 172], ["endouC", "GENE_OR_GENE_PRODUCT", 224, 230], ["zebrafish", "ORGANISM", 238, 247], ["endou genes", "DNA", 111, 122], ["endouC", "PROTEIN", 145, 151], ["endouC", "PROTEIN", 224, 230], ["zebrafish", "SPECIES", 155, 164], ["zebrafish", "SPECIES", 238, 247], ["zebrafish", "SPECIES", 238, 247], ["Further study", "TEST", 0, 13], ["endouC in zebrafish embryos", "PROBLEM", 145, 172], ["RT-PCR", "TEST", 276, 282], ["endou genes", "OBSERVATION", 111, 122]]], ["We found that the endouC was a maternal gene because its transcript was present in one-cell embryos (Fig. 3) .", [["cell embryos", "ANATOMY", 87, 99], ["endouC", "GENE_OR_GENE_PRODUCT", 18, 24], ["cell", "TISSUE", 87, 91], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 92, 99], ["endouC", "DNA", 18, 24], ["maternal gene", "DNA", 31, 44], ["cell embryos", "OBSERVATION", 87, 99]]], ["Expression of endouC was low at early developmental stages (Fig. 3) .", [["endouC", "GENE_OR_GENE_PRODUCT", 14, 20], ["endouC", "DNA", 14, 20]]], ["It gradually increased from 18 to 48 hpf and then decreased after 72 hpf (Fig. 3) .Expression pattern of endouC in zebrafish embryosWISH analysis to detect the spatiotemporal expression of zebrafish endouC demonstrated that the endouC transcript was ubiquitously expressed throughout the whole embryo after 12 hpf (Fig. 4A) .", [["embryo", "ANATOMY", 294, 300], ["endouC", "GENE_OR_GENE_PRODUCT", 105, 111], ["zebrafish", "ORGANISM", 115, 124], ["zebrafish", "ORGANISM", 189, 198], ["endouC", "GENE_OR_GENE_PRODUCT", 199, 205], ["endouC", "GENE_OR_GENE_PRODUCT", 228, 234], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 294, 300], ["endouC", "DNA", 105, 111], ["zebrafish endouC", "DNA", 189, 205], ["endouC transcript", "RNA", 228, 245], ["zebrafish", "SPECIES", 115, 124], ["zebrafish", "SPECIES", 115, 124], ["the endouC transcript", "PROBLEM", 224, 245], ["gradually", "OBSERVATION_MODIFIER", 3, 12], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["At 24 hpf, endouC was still strongly expressed at the head and ventral body regions above the yolk sack (Fig. 4B ), but it was weakly expressed in somite and spinal cord (Fig. 4C) .", [["head", "ANATOMY", 54, 58], ["ventral body", "ANATOMY", 63, 75], ["yolk sack", "ANATOMY", 94, 103], ["somite", "ANATOMY", 147, 153], ["spinal cord", "ANATOMY", 158, 169], ["endouC", "GENE_OR_GENE_PRODUCT", 11, 17], ["head", "ORGANISM_SUBDIVISION", 54, 58], ["ventral body", "TISSUE", 63, 75], ["yolk sack", "ORGANISM_SUBSTANCE", 94, 103], ["somite", "TISSUE", 147, 153], ["spinal cord", "ORGAN", 158, 169], ["endouC", "PROTEIN", 11, 17], ["head", "ANATOMY", 54, 58], ["ventral", "ANATOMY_MODIFIER", 63, 70], ["body", "ANATOMY_MODIFIER", 71, 75], ["regions", "ANATOMY_MODIFIER", 76, 83], ["yolk sack", "ANATOMY", 94, 103], ["spinal cord", "ANATOMY", 158, 169]]], ["During 36 to 48 hpf, the expression of endouC became more limited, appearing in brain, eyes and fin buds (Fig. 4DeG) .", [["brain", "ANATOMY", 80, 85], ["eyes", "ANATOMY", 87, 91], ["fin buds", "ANATOMY", 96, 104], ["endouC", "GENE_OR_GENE_PRODUCT", 39, 45], ["brain", "ORGAN", 80, 85], ["eyes", "ORGAN", 87, 91], ["fin buds", "TISSUE", 96, 104], ["endouC", "PROTEIN", 39, 45], ["brain", "ANATOMY", 80, 85], ["eyes", "ANATOMY", 87, 91]]], ["In brain, endouC was observed at forebrain, midbrain, midbrain hindbrain boundary (MHB), and hindbrain ( Fig. 4E and G) , while in eyes, endouC was expressed in lens and retinae (Fig. 4G) .", [["brain", "ANATOMY", 3, 8], ["forebrain", "ANATOMY", 33, 42], ["midbrain", "ANATOMY", 44, 52], ["midbrain hindbrain", "ANATOMY", 54, 72], ["MHB", "ANATOMY", 83, 86], ["hindbrain", "ANATOMY", 93, 102], ["eyes", "ANATOMY", 131, 135], ["lens", "ANATOMY", 161, 165], ["retinae", "ANATOMY", 170, 177], ["brain", "ORGAN", 3, 8], ["endouC", "GENE_OR_GENE_PRODUCT", 10, 16], ["forebrain", "ORGAN", 33, 42], ["midbrain", "MULTI-TISSUE_STRUCTURE", 44, 52], ["midbrain hindbrain boundary", "TISSUE", 54, 81], ["hindbrain", "ORGAN", 93, 102], ["Fig. 4E", "GENE_OR_GENE_PRODUCT", 105, 112], ["G", "GENE_OR_GENE_PRODUCT", 117, 118], ["eyes", "ORGAN", 131, 135], ["endouC", "GENE_OR_GENE_PRODUCT", 137, 143], ["lens", "TISSUE", 161, 165], ["retinae", "MULTI-TISSUE_STRUCTURE", 170, 177], ["endouC", "DNA", 137, 143], ["brain", "ANATOMY", 3, 8], ["forebrain", "ANATOMY", 33, 42], ["midbrain", "ANATOMY", 44, 52], ["midbrain", "ANATOMY", 54, 62], ["hindbrain", "ANATOMY_MODIFIER", 63, 72], ["hindbrain", "ANATOMY", 93, 102], ["eyes", "ANATOMY", 131, 135], ["retinae", "ANATOMY", 170, 177]]], ["The endouC transcript was first detected at the fin bud at 48 hpf (Fig. 4G) .Expression pattern of endouC in zebrafish embryosLater at 72 hpf, endouC was expressed in the midline of the midbrain and hindbrain, but it was weakly detected in the spinal cord and somite (Fig. 4H ).", [["fin bud", "ANATOMY", 48, 55], ["midline", "ANATOMY", 171, 178], ["midbrain", "ANATOMY", 186, 194], ["hindbrain", "ANATOMY", 199, 208], ["spinal cord", "ANATOMY", 244, 255], ["somite", "ANATOMY", 260, 266], ["endouC", "GENE_OR_GENE_PRODUCT", 4, 10], ["fin bud", "MULTI-TISSUE_STRUCTURE", 48, 55], ["endouC", "GENE_OR_GENE_PRODUCT", 99, 105], ["zebrafish", "ORGANISM", 109, 118], ["endouC", "GENE_OR_GENE_PRODUCT", 143, 149], ["midbrain", "MULTI-TISSUE_STRUCTURE", 186, 194], ["hindbrain", "ORGAN", 199, 208], ["spinal cord", "ORGAN", 244, 255], ["somite", "ORGAN", 260, 266], ["endouC transcript", "RNA", 4, 21], ["endouC", "PROTEIN", 99, 105], ["zebrafish", "SPECIES", 109, 118], ["The endouC transcript", "TREATMENT", 0, 21], ["midline", "ANATOMY_MODIFIER", 171, 178], ["midbrain", "ANATOMY", 186, 194], ["hindbrain", "ANATOMY", 199, 208], ["spinal cord", "ANATOMY", 244, 255]]], ["In hindbrain, the endouC transcript was visible as a triangular shape emerging from the anterior part of hindbrain midline (Fig. 4I) .", [["hindbrain", "ANATOMY", 3, 12], ["anterior part", "ANATOMY", 88, 101], ["hindbrain midline", "ANATOMY", 105, 122], ["hindbrain", "MULTI-TISSUE_STRUCTURE", 3, 12], ["endouC", "GENE_OR_GENE_PRODUCT", 18, 24], ["anterior part", "MULTI-TISSUE_STRUCTURE", 88, 101], ["hindbrain midline", "MULTI-TISSUE_STRUCTURE", 105, 122], ["endouC transcript", "RNA", 18, 35], ["the endouC transcript", "TREATMENT", 14, 35], ["a triangular shape", "PROBLEM", 51, 69], ["hindbrain", "ANATOMY", 3, 12], ["triangular", "OBSERVATION_MODIFIER", 53, 63], ["shape", "OBSERVATION_MODIFIER", 64, 69], ["anterior", "ANATOMY_MODIFIER", 88, 96], ["hindbrain", "ANATOMY", 105, 114], ["midline", "ANATOMY_MODIFIER", 115, 122]]], ["At 96 hpf, the expression pattern of endouC in brain was similar to that of embryos at 72 hpf; however, in head, the signal appeared to be more restricted to pharynx, MHB and hindbrain, and the signal in eye was reduced greatly (Fig. 4J and K) .", [["brain", "ANATOMY", 47, 52], ["embryos", "ANATOMY", 76, 83], ["head", "ANATOMY", 107, 111], ["pharynx", "ANATOMY", 158, 165], ["MHB", "ANATOMY", 167, 170], ["hindbrain", "ANATOMY", 175, 184], ["eye", "ANATOMY", 204, 207], ["endouC", "GENE_OR_GENE_PRODUCT", 37, 43], ["brain", "ORGAN", 47, 52], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 76, 83], ["head", "ORGANISM_SUBDIVISION", 107, 111], ["pharynx", "ORGAN", 158, 165], ["hindbrain", "ORGAN", 175, 184], ["eye", "ORGAN", 204, 207], ["endouC", "PROTEIN", 37, 43], ["endouC in brain", "PROBLEM", 37, 52], ["embryos", "PROBLEM", 76, 83], ["brain", "ANATOMY", 47, 52], ["head", "ANATOMY", 107, 111], ["pharynx", "ANATOMY", 158, 165], ["hindbrain", "ANATOMY", 175, 184], ["eye", "ANATOMY", 204, 207]]], ["The marker length of 0.1 corresponds to 10% sequence difference.", [["The marker length", "TEST", 0, 17], ["marker", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["Human (H. sapiens), mouse (M. musculus), chicken (G. gallus), frog (X. tropicalis) and zebrafish (D. rerio) were marked in green, blue, red, brown and black, respectively.", [["Human", "ORGANISM", 0, 5], ["H. sapiens", "ORGANISM", 7, 17], ["mouse", "ORGANISM", 20, 25], ["M. musculus", "ORGANISM", 27, 38], ["chicken", "ORGANISM", 41, 48], ["G. gallus", "ORGANISM", 50, 59], ["frog (X. tropicalis", "ORGANISM", 62, 81], ["zebrafish", "ORGANISM", 87, 96], ["D. rerio", "ORGANISM", 98, 106], ["Human", "SPECIES", 0, 5], ["H. sapiens", "SPECIES", 7, 17], ["mouse", "SPECIES", 20, 25], ["M. musculus", "SPECIES", 27, 38], ["chicken", "SPECIES", 41, 48], ["G. gallus", "SPECIES", 50, 59], ["X. tropicalis", "SPECIES", 68, 81], ["zebrafish", "SPECIES", 87, 96], ["D. rerio", "SPECIES", 98, 106], ["Human", "SPECIES", 0, 5], ["H. sapiens", "SPECIES", 7, 17], ["mouse", "SPECIES", 20, 25], ["M. musculus", "SPECIES", 27, 38], ["chicken", "SPECIES", 41, 48], ["G. gallus", "SPECIES", 50, 59], ["X. tropicalis", "SPECIES", 68, 81], ["zebrafish", "SPECIES", 87, 96], ["D. rerio", "SPECIES", 98, 106], ["Human (H. sapiens)", "TREATMENT", 0, 18], ["marked", "OBSERVATION_MODIFIER", 113, 119]]], ["Embryos at different stages as indicated were collected and hybridized with endouC probe using whole-mount in situ hybridization.", [["Embryos", "ANATOMY", 0, 7], ["Embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 0, 7], ["endouC probe", "DNA", 76, 88], ["Embryos at different stages", "PROBLEM", 0, 27], ["endouC probe", "TREATMENT", 76, 88], ["whole-mount in situ hybridization", "TREATMENT", 95, 128]]], ["Panels A, B, D, F, H, and J were lateral views with anterior of embryo on the left; panel C was dorsal view with anterior of embryo on the left; panel E, G, I and K were dorsal views with anterior of embryos on the top.", [["embryo", "ANATOMY", 64, 70], ["left", "ANATOMY", 78, 82], ["embryo", "ANATOMY", 125, 131], ["embryos", "ANATOMY", 200, 207], ["B", "CELL", 10, 11], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 64, 70], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 125, 131], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 200, 207], ["Panels", "TEST", 0, 6], ["lateral views", "TEST", 33, 46], ["panel C", "TEST", 84, 91], ["dorsal view", "TEST", 96, 107], ["panel E", "TEST", 145, 152], ["dorsal views", "TEST", 170, 182], ["anterior of embryos on the top", "TREATMENT", 188, 218], ["anterior", "ANATOMY_MODIFIER", 52, 60], ["embryo", "OBSERVATION", 64, 70], ["left", "ANATOMY_MODIFIER", 78, 82], ["anterior", "ANATOMY_MODIFIER", 113, 121], ["left", "ANATOMY_MODIFIER", 139, 143], ["anterior", "ANATOMY_MODIFIER", 188, 196], ["embryos", "OBSERVATION", 200, 207]]], ["At 12 hpf, endouC was expressed in whole embryo.", [["embryo", "ANATOMY", 41, 47], ["endouC", "GENE_OR_GENE_PRODUCT", 11, 17], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 41, 47], ["endouC", "PROTEIN", 11, 17]]], ["At 24 hpf, endouC was highly expressed in head, including forebrain (fb), midbrain (mb), midbrain hibrain boundary (mhb), and hindbrain (hb).", [["head", "ANATOMY", 42, 46], ["forebrain", "ANATOMY", 58, 67], ["fb", "ANATOMY", 69, 71], ["midbrain", "ANATOMY", 74, 82], ["midbrain hibrain boundary", "ANATOMY", 89, 114], ["mhb", "ANATOMY", 116, 119], ["hindbrain", "ANATOMY", 126, 135], ["endouC", "GENE_OR_GENE_PRODUCT", 11, 17], ["head", "ORGANISM_SUBDIVISION", 42, 46], ["forebrain", "ORGAN", 58, 67], ["fb", "GENE_OR_GENE_PRODUCT", 69, 71], ["midbrain (mb)", "GENE_OR_GENE_PRODUCT", 74, 87], ["midbrain hibrain boundary", "TISSUE", 89, 114], ["hindbrain", "ORGAN", 126, 135], ["hb", "GENE_OR_GENE_PRODUCT", 137, 139], ["endouC", "PROTEIN", 11, 17], ["forebrain (fb), midbrain (mb), midbrain hibrain boundary (mhb), and hindbrain (hb)", "PROBLEM", 58, 140], ["head", "ANATOMY", 42, 46], ["forebrain", "ANATOMY", 58, 67], ["midbrain", "ANATOMY", 74, 82], ["mb", "ANATOMY", 84, 86], ["midbrain", "ANATOMY", 89, 97], ["hindbrain", "ANATOMY", 126, 135]]], ["The endouC transcript was also detected in somite (s) during 24e96 hpf. f, fin bud; sc, spinal cord; r, retina; e: eyes; l, lens; ph, pharynx.", [["somite", "ANATOMY", 43, 49], ["fin bud", "ANATOMY", 75, 82], ["spinal cord", "ANATOMY", 88, 99], ["retina", "ANATOMY", 104, 110], ["eyes", "ANATOMY", 115, 119], ["lens", "ANATOMY", 124, 128], ["pharynx", "ANATOMY", 134, 141], ["endouC", "GENE_OR_GENE_PRODUCT", 4, 10], ["somite", "TISSUE", 43, 49], ["fin bud", "MULTI-TISSUE_STRUCTURE", 75, 82], ["spinal cord", "ORGAN", 88, 99], ["retina", "MULTI-TISSUE_STRUCTURE", 104, 110], ["eyes", "ORGAN", 115, 119], ["pharynx", "ORGAN", 134, 141], ["endouC transcript", "RNA", 4, 21], ["The endouC transcript", "TREATMENT", 0, 21], ["hpf", "TEST", 67, 70], ["sc", "ANATOMY", 84, 86], ["spinal cord", "ANATOMY", 88, 99], ["retina", "ANATOMY", 104, 110], ["eyes", "ANATOMY", 115, 119], ["lens", "ANATOMY", 124, 128], ["pharynx", "ANATOMY", 134, 141]]], ["Scale bar: 100 mm.", [["100 mm", "OBSERVATION_MODIFIER", 11, 17]]]], "78b7ffc8f886ba7559cdf198b2f0f4f93a9d5265": [["IntroductionThere exist many sophisticated models trying to forecast the evolution of the Covid-19 pandemic.", [["the Covid", "TEST", 86, 95], ["pandemic", "PROBLEM", 99, 107]]], ["These require, for example, fitting of the epidemics data to data sets obtained by evolving differential equations with many parameters.", [["data sets", "TEST", 61, 70]]], ["Obtaining well motivated estimates for all these parameters is a difficult task, so guesses are unavoidable, leading to severe uncertainties concerning the predictive power of the models.IntroductionThe question therefore arises, whether the epidemics data can be satisfactorily described by some explicit curves with a small number of parameters which are easily obtainable from the available data and, if so, whether such curves can be used to make predictions of the further evolution of the epidemics.", [["severe uncertainties", "PROBLEM", 120, 140], ["the epidemics data", "PROBLEM", 238, 256], ["the epidemics", "PROBLEM", 491, 504], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["uncertainties", "OBSERVATION", 127, 140]]], ["The object of this work is to analyse the suitability towards this of a few empirical curves, to present an algorithm based on the logistic curve for short-term predictions of the epidemics, and to present the results of a study of the quality of this algorithm.IntroductionWe note that most countries have infection curves with very similar shapes.", [["infection", "DISEASE", 307, 316], ["an algorithm", "TEST", 105, 117], ["the logistic curve", "TEST", 127, 145], ["a study", "TEST", 221, 228], ["this algorithm", "TEST", 247, 261], ["infection curves", "PROBLEM", 307, 323], ["infection", "OBSERVATION", 307, 316]]], ["A few other data curves (e.g. the Hubei province in China, France, Spain) have unusual jumps.", [["A few other data curves", "TEST", 0, 23], ["unusual jumps", "PROBLEM", 79, 92]]], ["Our predictability analysis only concerns typical curves, which are in vast majority.Introduction2 Phenomenological curves 2.1 Logistic curve Some authors have been using the logistic curve for describing the number I(t) of infected individuals.", [["Our predictability analysis", "TEST", 0, 27], ["Phenomenological curves", "TEST", 99, 122], ["Logistic curve", "TEST", 127, 141], ["infected individuals", "PROBLEM", 224, 244], ["infected", "OBSERVATION", 224, 232]]], ["The function I is given by the equation as of the day of writing of this work, an optically satisfactory description for several countries, with decent confidence intervals for the parameters of the fits.IntroductionWe present some such fits in Figure 2 .2.", [["fits", "DISEASE", 237, 241]]], ["However, the fit parameters change in time so that fitting the logistic curve to the data has no value for long-range predictions of the epidemics.", [["the logistic curve", "TEST", 59, 77], ["the epidemics", "PROBLEM", 133, 146]]], ["One can nevertheless try to test whether one can use the logistic curve for short-term predictions.", [["the logistic curve", "TEST", 53, 71], ["short-term predictions", "TREATMENT", 76, 98]]], ["This is made precise by the histograms in Figure 2 .3.IntroductionThis behaviour is typical for several countries.", [["the histograms", "TEST", 24, 38]]], ["This is clearly not satisfactory, and we will present a way of exploiting the systematic trends of these fits to propose an improved predictability algorithm shortly.The Gauss-error curveOther authors suggested to use the Gaussian-error curve, where I(t) is taken to beThe Gauss-error curvefor some constants k G , a G and t G .", [["clearly not", "UNCERTAINTY", 8, 19], ["satisfactory", "OBSERVATION", 20, 32]]], ["Here the subscript G is a shorthand for \"Gaussian\", the number k G is the predicted total number of infected individuals, the number a G governs the steepness of the curve, and t G is the inflection time of the curve.", [["subscript G", "DNA", 9, 20], ["infected individuals", "PROBLEM", 100, 120], ["infected", "OBSERVATION", 100, 108]]], ["See Figure 2 .1 for a typical plot.", [["a typical plot", "PROBLEM", 20, 34]]], ["Fitting the Gauss-error curve to the Covid-19 data at any moment of time gives again an optically satisfactory description for several countries, with decent confidence intervals for the parameters.", [["error curve", "TEST", 18, 29], ["the Covid", "TEST", 33, 42]]], ["In fact the fits look somewhat better than the logistic ones for many countries, whether by optical inspection of the curve (see Figure 2 .2 for some examples), or by residuals, or by intervals of confidence of the parameters.", [["the curve", "TEST", 114, 123], ["the parameters", "TEST", 211, 225]]], ["But, similarly to the logistic curve, the parameters of the fit do not stabilise.", [["the logistic curve", "TEST", 18, 36]]], ["Finally, at any day of the epidemics, the fitted numbers k l and k G , which provide a prediction for the total number of infected in their respective models, differ substantially for many countries.The Gauss-error curveSimilarly to the logistic curve, this makes it clear that fitting the Gaussianerror curve to the data has no value for long-range predictions of the epidemics.", [["k G", "GENE_OR_GENE_PRODUCT", 65, 68], ["k G", "TEST", 65, 68], ["the logistic curve", "TEST", 233, 251], ["the epidemics", "PROBLEM", 365, 378], ["infected", "OBSERVATION", 122, 130]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 2 .3: Histograms showing the number of predictions within 1% error bins, for Austria using the logistic fit (first row) and the double-logistic fit (second row), generated in the period April 5 -May 4, for 1 day, one week, and two weeks.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Histograms", "TEST", 216, 226], ["the double-logistic fit (second row)", "TREATMENT", 334, 370], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The double-logistic fits are more scattered, but centred around 0%.", [["double", "OBSERVATION_MODIFIER", 4, 10], ["more", "OBSERVATION_MODIFIER", 29, 33], ["scattered", "OBSERVATION_MODIFIER", 34, 43]]], ["The fact that the total number of fits on each histogram (here equal to the sum of the areas of the bins) decreases with the number of prediction days is due to the fact that we are testing predictions within a data set of prescribed total length.", [["fits", "DISEASE", 34, 38], ["each histogram", "TEST", 42, 56], ["total", "OBSERVATION_MODIFIER", 18, 23], ["number", "OBSERVATION_MODIFIER", 24, 30]]], ["The short-term predictability properties of the logistic and the Gauss-error curves are very similar, with systematic undershooting of the number of new infections.The Gauss-error curveWe use the built-in function NonlinearModelFit of Wolfram's Mathematica to find our fits.", [["infections", "DISEASE", 153, 163], ["the Gauss-error curves", "TEST", 61, 83], ["new infections", "PROBLEM", 149, 163], ["Wolfram's Mathematica", "TREATMENT", 235, 256], ["short-term predictability", "OBSERVATION_MODIFIER", 4, 29], ["number", "OBSERVATION_MODIFIER", 139, 145], ["new", "OBSERVATION_MODIFIER", 149, 152], ["infections", "OBSERVATION", 153, 163]]], ["It turns out that this function finds a fit to the logistic fit without difficulties, though with poor confidence intervals for the fitting parameters at the beginning of the epidemics.", [["difficulties", "PROBLEM", 72, 84], ["the fitting parameters", "TEST", 128, 150]]], ["On the other hand, no fits at all are found for the Gauss-error function in early stages of the epidemics.", [["the epidemics", "PROBLEM", 92, 105]]], ["This makes this curve much less useful in applications, if at all.The Gauss-error curveAs a curiosity, we note that one can write down an ad-hoc system of SI equations for which I(t) is the Gauss-error curve:The double-logistic curveIn view of the above the question arises, whether some different families of explicit curves with a small number of parameters would fit better the problem at hand.The double-logistic curveAs such, by inspection of the majority of curves of total confirmed cases of Covid-19 the following picture emerges.", [["hand", "ORGANISM_SUBDIVISION", 392, 396], ["The double-logistic curveIn view", "TREATMENT", 208, 240], ["explicit curves", "PROBLEM", 310, 325], ["Covid", "TEST", 499, 504]]], ["The epidemics starts with the usual exponential growth, evolving into a forward-leaning-S-shaped curve without symmetry about the inflection point, and finishing in a very slow, optically linear dying-out phase.The double-logistic curveWe have made no attempt to include this last phase in our analysis, because for the period of data under consideration most countries have not reached a stable form of this last dying-out phase.", [["The epidemics", "PROBLEM", 0, 13], ["our analysis", "TEST", 290, 302], ["epidemics", "OBSERVATION", 4, 13], ["growth", "OBSERVATION_MODIFIER", 48, 54], ["stable", "OBSERVATION", 389, 395]]], ["In other words, we will be interested in a model where a good approximation of the end of the curve is a standard exponential dying-out of the epidemics.", [["the epidemics", "PROBLEM", 139, 152]]], ["Now, it is clear from the data that the initial exponential growth rate of the epidemics is different from the rate at which the epidemics dies out.", [["the epidemics", "PROBLEM", 75, 88], ["clear", "OBSERVATION", 11, 16], ["exponential", "OBSERVATION_MODIFIER", 48, 59], ["growth", "OBSERVATION_MODIFIER", 60, 66], ["different", "OBSERVATION_MODIFIER", 92, 101]]], ["On the other hand, both the logistic curve and the Gauss-error curve are symmetric in that respect.", [["the logistic curve", "TEST", 24, 42], ["the Gauss-error curve", "TEST", 47, 68], ["symmetric", "OBSERVATION_MODIFIER", 73, 82]]], ["This leads us to consider the functionThe double-logistic curve(2.4) with five free positive parameters k, b 1 , b 2 , c 1 and c 2 .", [["c 1", "GENE_OR_GENE_PRODUCT", 119, 122], ["c 2", "GENE_OR_GENE_PRODUCT", 127, 130], ["the function", "TEST", 26, 38], ["The double-logistic curve", "TEST", 38, 63], ["k", "TEST", 104, 105], ["b", "TEST", 107, 108]]], ["For definiteness and without loss of generality we will assume thatThe double-logistic curveA simple analysis of (2.4) shows that:The double-logistic curve1.", [["definiteness", "PROBLEM", 4, 16], ["loss of generality", "PROBLEM", 29, 47], ["The double-logistic curveA simple analysis", "TEST", 67, 109], ["The double-logistic curve1", "TREATMENT", 130, 156], ["without", "UNCERTAINTY", 21, 28]]], ["The function I(t) tends to k as t tends to infinity, so that k describes the predicted total number of infected.The double-logistic curve2.", [["I(t)", "PROTEIN", 13, 17], ["The double-logistic curve2", "TREATMENT", 112, 138], ["infected", "OBSERVATION", 103, 111]]], ["For large negative t the function behaves approximatively asThe double-logistic curveso that the initial rate of growth of the epidemics is b 1 + b 2 , with growth coefficient k/(c 1 c 2 ).The double-logistic curve3.", [["growth coefficient k", "TEST", 157, 177], ["The double-logistic curve3", "TREATMENT", 189, 215], ["large", "OBSERVATION_MODIFIER", 4, 9], ["negative", "OBSERVATION", 10, 18]]], ["For large positive t we haveThe double-logistic curveso that b 1 describes the dying-out rate of the epidemics, with amplitude kc 1 .The double-logistic curveIt is convenient to make trivial renaming of the parameters occurring in (2.4) to obtain, without loss of generality, the following form of the double-logistic function:The double-logistic curveso that the parameter a has the interpretation of the dying-out rate of the epidemics, and b of the initial growth rate.", [["amplitude kc", "TREATMENT", 117, 129], ["The double-logistic curveIt", "TREATMENT", 133, 160], ["loss of generality", "PROBLEM", 256, 274], ["the initial growth rate", "TEST", 448, 471], ["large", "OBSERVATION_MODIFIER", 4, 9], ["positive", "OBSERVATION", 10, 18]]], ["Examples of plots of the curve (2.8) can be found in Figure 2 .4.6.", [["plots of the curve", "TEST", 12, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)6The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 203, 223], ["med", "ANATOMY", 105, 108]]], ["It is seen in Figure 2 .2 that rather good daily fits to the Covid-19 data can be obtained using the function (2.4), although the fits are somewhat worse in the middle region for the wobbly time series of Denmark and Singapore.", [["the Covid", "TEST", 57, 66], ["somewhat", "OBSERVATION_MODIFIER", 139, 147], ["worse", "OBSERVATION_MODIFIER", 148, 153], ["middle", "ANATOMY_MODIFIER", 161, 167]]], ["Compared to the fits previously discussed, the fits look much better optically; the residuals are smaller; the systematic undershooting at the end of the curve, inherent to the logistic and Gauss-error curves, disappears or is visibly reduced.6One finds, however, that the confidence intervals for the parameters are not as good as for the previous fits.", [["residuals", "OBSERVATION", 84, 93], ["smaller", "OBSERVATION_MODIFIER", 98, 105], ["visibly", "OBSERVATION_MODIFIER", 227, 234], ["reduced", "OBSERVATION_MODIFIER", 235, 242]]], ["Moreover, with more free parameters Mathematica's fitting procedure is very unstable and sometimes requires a trial-and-error procedure to find a fit, if at all.6On one hand, the fitting parameters do not stabilise in time either so that this curve is again unsuitable for global predictions.", [["Mathematica's fitting procedure", "TREATMENT", 36, 67], ["very unstable", "PROBLEM", 71, 84], ["error procedure", "TREATMENT", 120, 135]]], ["On the other, the shortterm predictions are typically better than for the previous curves, if stable fits are available.", [["the previous curves", "TEST", 70, 89]]], ["This can be seen in Figure 2 .3.6While this is better than the short-time predictions based on the logistic curve, we will see in Section 3 how to obtain much better such predictions.6Ignoring its relatively poor predictability properties, the double-logistic curve seems to provide a good description of the overall features of the confirmed-cases curves and deceased curves for many countries.", [["the logistic curve", "TEST", 95, 113], ["relatively", "OBSERVATION_MODIFIER", 197, 207], ["poor predictability", "OBSERVATION_MODIFIER", 208, 227]]], ["This could make this curve useful for further comparative studies of the Covid-19 epidemics.6We finish this section by noting that the Richards curve [2] , which has been used in various models of population dynamics, is somewhat related to our double-logistic curve.", [["this curve", "TEST", 16, 26], ["further comparative studies", "TEST", 38, 65], ["the Covid", "TEST", 69, 78], ["epidemics", "PROBLEM", 82, 91]]], ["We comment on this in Appendix B. discussed above, for many countries, when used in the period April 5 -May, 5, 2020.", [["Appendix", "ANATOMY", 22, 30]]], ["In what follows we will often simply say \"infected individuals\", meaning the number of confirmed infected cases as available on the John Hopkins University (JHU) server.6Let us write the logistic curve (2.2) as6We denote by k i , a i , \u03c4 i , the values of the parameters k, a, and \u03c4 of the curve (3.1), determined by fitting the data for the epidemics curve from the start of the epidemics to day i.", [["the logistic curve", "TEST", 183, 201], ["the parameters k", "TEST", 256, 272], ["the curve", "TEST", 286, 295], ["the epidemics curve", "PROBLEM", 338, 357]]], ["For conciseness of notation we write6Thus, for \u2264 i the number I i ( ) is the number of infected at day , as approximated using the best fit, calculated at day i, to the infection data known up to day i.", [["infection", "DISEASE", 169, 178], ["the infection data", "PROBLEM", 165, 183], ["infected", "OBSERVATION", 87, 95], ["infection", "OBSERVATION", 169, 178]]], ["It turns out that this is not the case: in the period covered by this analysis, for several countries the parameters so obtained change approximately linearly with i.", [["this analysis", "TEST", 65, 78]]], ["For j > 0 this provides us an extrapolation to the future of the values of (k, a, \u03c4 ), which we denote by k i,j , a i,j , and \u03c4 i,j .6Thus the values k i , a i , and \u03c4 i are known from the data at day i, while for j > 0 the values k i,j , a i,j , and \u03c4 i,j are calculated by linear regression from data known up to day i.2.We calculate the shift, say s i , so that I i (i) + s i coincides with the observed data on day i:2.This compensates for the systematic undershooting of the logistic curve.2.3.", [["the values", "TEST", 61, 71]]], ["Finally, for j > 0 the number I ki,j ,ai,j ,\u03c4i,j (i + j) + s i is the prediction, on day i, of the number of confirmed infections on day i + j.2.We have applied this procedure to several countries using the data available from the JHU server.", [["infections", "DISEASE", 119, 129], ["infections", "PROBLEM", 119, 129], ["this procedure", "TREATMENT", 161, 175], ["infections", "OBSERVATION", 119, 129]]], ["The results of the algorithm, as applied to Austria, 8 .", [["the algorithm", "TEST", 15, 28]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)2.The copyright holder for this preprint this version posted May 26, 2020. . are presented in Section 4.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["A sample of countries is similarly analysed in Appendix A. A systematic simultaneous study for several countries is presented in Section 6.2.We refer to the above method of making predictions as the logistic fit with running constants.2.The algorithm is quite successful when tested on the epidemic curve of Italy.", [["A sample of countries", "TEST", 0, 21], ["A systematic simultaneous study", "TEST", 59, 90], ["Appendix", "ANATOMY", 47, 55], ["successful", "OBSERVATION", 260, 270]]], ["The point is that in order to gain any confidence in the usefulness of the procedure one has to have a sufficient collection of reasonable logistic fits.", [["the procedure", "TREATMENT", 71, 84]]], ["This is not the case at the beginning of the epidemics, where a simple exponential provides instead a good description of the dynamics.2.Our attempt to apply an analogous procedure based instead on the doublelogistic curve failed to produce successful results.", [["an analogous procedure", "TREATMENT", 158, 180], ["the doublelogistic curve", "TREATMENT", 198, 222]]], ["We believe that this is due to the numerical instability of the fits obtained, as was clear in some of our attempts to do so.", [["fits", "DISEASE", 64, 68], ["the numerical instability of the fits", "PROBLEM", 31, 68]]], ["It is conceivable that the double-logistic curve together with a more sophisticated fitting algorithm could provide better predictability results than our algorithm based on the straightforward logistic curve, but this remains to be seen.2.Alternatively, since the Gauss-error function also produces better fits than the logistic curve, it would be natural to use our algorithm using the Gausserror function.", [["the double-logistic curve", "TREATMENT", 23, 48], ["a more sophisticated fitting algorithm", "PROBLEM", 63, 101], ["our algorithm", "TEST", 151, 164], ["the straightforward logistic curve", "TEST", 174, 208], ["the Gauss-error function", "TEST", 261, 285], ["the logistic curve", "TEST", 317, 335], ["our algorithm", "TEST", 364, 377]]], ["We did not do this because the fits to that last function seem to be less stable, when using Mathematica, compared the logistic ones.", [["less", "OBSERVATION_MODIFIER", 69, 73], ["stable", "OBSERVATION_MODIFIER", 74, 80]]], ["In particular Mathematica finds no fit at all to the Gauss-error function in the early stages of the epidemics, while fits to the logistic curve are found.The fitsWe present here some more details of the analysis discussed above.The fitsAll data are retrieved from the John Hopkins University (JHU) server, URL http://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/c sse_covid_19_data/csse_covid_19_time_series/time_series_covid19_c onfirmed_global.csvThe fitsThe analysis presented here is based on the cumulative data set downloaded from the JHU server on May 6.", [["the epidemics", "PROBLEM", 97, 110], ["the logistic curve", "TEST", 126, 144], ["the analysis", "TEST", 200, 212], ["The analysis", "TEST", 470, 482], ["early stages", "OBSERVATION_MODIFIER", 81, 93]]], ["This data set contains data up-to-and-including May 5, 2020.", [["This data", "TEST", 0, 9]]], ["Now, many data sets at JHU start with a long string of zeros.", [["JHU start", "DNA", 23, 32], ["a long string of zeros", "TREATMENT", 38, 60]]], ["We disregard those zeros and, unless explicitly indicated otherwise, day one of the epidemics on all our plots is the first day at which there are at least two cases of confirmed infected individuals.The fitsSome time series in the JHU data set contain repeated entries, which are unlikely in the middle of a fast spreading epidemics.", [["infected individuals", "PROBLEM", 179, 199], ["the JHU data", "TEST", 228, 240], ["a fast spreading epidemics", "PROBLEM", 307, 333], ["infected", "OBSERVATION", 179, 187], ["middle", "ANATOMY_MODIFIER", 297, 303]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The fitsThe copyright holder for this preprint this version posted May 26, 2020. . effect, or an accidental omission by the reporting authorities, who made up for this on the next day by inputting the same cumulated number of new infections twice.", [["CC", "CHEMICAL", 0, 2], ["infections", "DISEASE", 432, 442], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 210, 230], ["new infections", "PROBLEM", 428, 442], ["med", "ANATOMY", 105, 108], ["new", "OBSERVATION_MODIFIER", 428, 431], ["infections", "OBSERVATION", 432, 442]]], ["In order to smooth-out the resulting jumps in the curve we replace systematically the first point of such a pair by the average of neighbouring points.", [["smooth", "OBSERVATION_MODIFIER", 12, 18]]], ["No other alterations to the time series have been performed.", [["the time series", "TEST", 24, 39]]], ["We have not attempted to study whether further smoothing of the data would result in better predictability properties of our algorithm.The fitsAll fits are done using the NonlinearModelFit procedure in Mathematica.", [["further smoothing of the data", "TEST", 39, 68], ["our algorithm", "TEST", 121, 134], ["the NonlinearModelFit procedure", "TREATMENT", 167, 198]]], ["In order to find a good fit, or a fit at all, the procedure sometimes requires providing by hand the values of the parameters near which the fit should be performed.", [["the procedure", "TREATMENT", 46, 59]]], ["Most fits have been found automatically, by using the number of infected on the day of the fit as the initial value of the parameter k for the fitting procedure, with the starting points of the remaining parameters set to average values observed (roughly) in our analysis so far, independently of the country.", [["the fitting procedure", "TREATMENT", 139, 160], ["infected", "OBSERVATION", 64, 72]]], ["For the logistic fit, the starting value of a for the fitting procedure was 0.08 and that for \u03c4 was 22, unless indicated otherwise by hand for unstable fits.", [["fits", "DISEASE", 152, 156], ["the fitting procedure", "TREATMENT", 50, 71], ["unstable fits", "PROBLEM", 143, 156]]], ["In order to steer the system away from poor fits we imposed that the search for a fit should be done with the constraints that 0 < a < 2 and that k be smaller than 100 times the number of infected cases at the last day of the fit; these values being compatible, by a huge margin, with all good fits we have inspected.The fitsIt is appropriate to provide more details concerning the logistic fit with running parameters.The fitsFirst, as already pointed out, we decided randomly that the epidemics starts when there are at least two infected individuals.", [["infected cases", "PROBLEM", 188, 202], ["running parameters", "TREATMENT", 400, 418], ["the epidemics", "PROBLEM", 483, 496], ["infected", "OBSERVATION", 188, 196], ["huge", "OBSERVATION_MODIFIER", 267, 271], ["margin", "OBSERVATION_MODIFIER", 272, 278], ["infected", "OBSERVATION", 532, 540]]], ["This is counted as day one of the epidemics, all previous zeros and ones in the time series are ignored.The fitsNext, we decided randomly that no time series which, after the above adjustment, are shorter than 18 days will be considered.", [["the epidemics", "PROBLEM", 30, 43], ["the above adjustment", "TREATMENT", 171, 191]]], ["The procedure is then somewhat different according to whether the series is shorter or longer than 25 days.The fitsSuppose that the time series is between 18 and 24 days.", [["The procedure", "TREATMENT", 0, 13]]], ["We then calculate the best fit parameters to the logistic curve ending at the last eight days of the series.", [["the logistic curve", "TEST", 45, 63]]], ["Hence, every fit to a logistic curve is based on at least eleven data points.", [["a logistic curve", "TEST", 20, 36]]], ["Using these eight logistic curves, we make four linear fits to the values of each of the parameters k, a and \u03c4 of (3.1), one for each of the four intervals containing 8, 7, 6 or 5 successive days which are anchored at the last day of the time series.", [["these eight logistic curves", "TEST", 6, 33]]], ["This is done using standard linear regression.", [["standard linear regression", "TREATMENT", 19, 45]]], ["The method is illustrated in Figure 4 .1.The fitsIf the time series is longer than 24 days, the procedure is identical except that we seek the best linear fit for the 11 intervals ending at the last day of the time series, with the length of the intervals varying from 14 to 4.The fitsAll the numbers above have been chosen randomly, and we have not attempted to study whether some other choice would lead to an algorithm with better predictability properties.10.", [["the procedure", "TREATMENT", 92, 105], ["an algorithm", "TEST", 409, 421]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .AustriaWe continue with the details of our analysis on the example of Austria.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["our analysis", "TEST", 314, 326], ["med", "ANATOMY", 105, 108]]], ["The results of a similar analysis for some selected time series from JHU can be found in Appendix A.AustriaIn Figure 5 .1 we show the latest fits to the double logistic, Gauss-error, and logistic curve, including the residuals (defined as the difference between the data and the fitting function) and the fit parameters.", [["a similar analysis", "TEST", 15, 33], ["logistic curve", "TEST", 187, 201], ["the residuals", "TEST", 213, 226], ["Appendix", "ANATOMY", 89, 97]]], ["We note that a good fit should lead to residuals without any obvious structure.", [["any obvious structure", "PROBLEM", 57, 78]]], ["So, from this point of view, none of the fits is satisfactory, with the double-logistic fit providing the optically-best residuals in any case.AustriaIn Figure 5 .2 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curve.AustriaIn order to test the predictability value of our algorithm we proceed as follows.", [["logistic curve", "TEST", 295, 309]]], ["For each day in the period April 5 -May 4 we calculate the number of confirmed infected individuals, as predicted by our algorithm, for the remaining days of the period.", [["infected individuals", "PROBLEM", 79, 99], ["infected", "OBSERVATION", 79, 87]]], ["1 1 Note that this sign is opposite to that of the conventional definition of residuals.11.", [["residuals", "OBSERVATION", 78, 87]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .(which was not certified by peer review)We will refer to these sequences of predictions as \"predictability strings\".", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In Figure 5 .4 we show the histograms of the errors of the predictions so obtained using one-percent bins.", [["one-percent bins", "TREATMENT", 89, 105]]], ["We see that one-day predictions in the period April 5-May 5, 2020, were within 1.5% of the data, with more than 4/5 of them within 1%; four day predictions within 5% of the data with more than half within 1%; and one week predictions in an interval of 7% around the observed value, with more than one third within 1%.(which was not certified by peer review)Not unexpectedly, the later in the epidemic, the better the predictability of the algorithm.", [["the algorithm", "TEST", 435, 448]]], ["The third row of Figure 5 .3 should be compared to the second one, where the predictability strings starting on April 5 are truncated to the two-weeks period ending on April 20.(which was not certified by peer review)Inspection of the predictability plots shows that some fits fare significantly worse than most.", [["the predictability plots", "TEST", 231, 255]]], ["The result of the fit comes with a warning from the system, in which case an ad-hoc subjective intervention by hand can sometimes solve the problem.", [["hand", "ORGANISM_SUBDIVISION", 111, 115], ["an ad-hoc subjective intervention", "TREATMENT", 74, 107]]], ["But this is not practical for an automatic procedure for the statistical analysis of many thousands of predictability data carried out in Section 6.", [["an automatic procedure", "TREATMENT", 30, 52], ["the statistical analysis", "TEST", 57, 81], ["predictability data", "TEST", 103, 122]]], ["So we ignore the warnings and let the system calculate the associated predictability strings, but we need a method to exclude such results from the predictions.(which was not certified by peer review)For this we implemented the following procedure.", [["procedure", "TREATMENT", 238, 247]]], ["The first badness number is calculated as the size of the absolute values of the largest residual in the fit divided by the value of the fit at the end of the fitting period, multiplied by 100.", [["size", "OBSERVATION_MODIFIER", 46, 50], ["largest", "OBSERVATION_MODIFIER", 81, 88], ["residual", "OBSERVATION_MODIFIER", 89, 97]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.", [["these predictability strings", "PROBLEM", 25, 53], ["predictability strings", "OBSERVATION", 31, 53]]], ["It can be seen that fits with larger second badness parameter have worse predictability properties.15.", [["larger second badness parameter", "TREATMENT", 30, 61]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In all our calculations a fit had first badness number 100 if and only if Mathematica returned the zero function as a fit, which happened sometimes when the fitting procedure did not succeed.(which was not certified by peer review)3.", [["the fitting procedure", "TREATMENT", 153, 174]]], ["This feature is not a problem from our perspective, since we are interested in extrapolating the epidemics curve to the future, hence in the region where the numbers are large.", [["region", "ANATOMY_MODIFIER", 141, 147], ["large", "OBSERVATION", 170, 175]]], ["So a fit can have a low badness number when it fits well the data towards the end of the epidemics even though the fit is very poor at the beginning.(which was not certified by peer review)Next, in order to calculate our predictions, we need reliable values of the parameters (k, a, \u03c4 ) of the fit.", [["the parameters", "TEST", 261, 275], ["k", "TEST", 277, 278]]], ["We note that there is a lot of freedom of optimising this, and we made no attempts to do this.(which was not certified by peer review)We emphasise that the badness parameters are known at the date of the fit, and that it is clear from the predictability tables in Appendix A that they can be used a priori to filter-out the blatantly wrong predictions by setting up thresholds.", [["the badness parameters", "TEST", 152, 174], ["a priori to filter", "TREATMENT", 297, 315], ["Appendix", "ANATOMY", 264, 272]]], ["These thresholds need to be fine-tuned individually for each country.(which was not certified by peer review)The badness parameters of the logistic fit with running parameters are set to be the maximum value of the badness parameters of those logistic fits which have been used to determine the best linear interpolation of the parameters.", [["running parameters", "TREATMENT", 157, 175]]], ["For example, if four logistic fits have been used to provide the linear interpolation of the parameter k, and three for the parameter a, then the maximal values of the badness parameters of the four relevant fits are deemed to be the badness parameters of the fit.(which was not certified by peer review)Plots of the first badness parameter can be found in Figure 5 .5, and plots of errors of k, a and \u03c4 in Figure 5 .6.17.", [["the maximal values", "TEST", 142, 160], ["k", "TEST", 393, 394], ["Figure", "TEST", 407, 413]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .18.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Recall, first, that the US time series, other than the collective one, are kept on the JHU server as a separate data set.", [["JHU server", "DNA", 87, 97]]], ["We decided arbitrarily not to consider the US data set.(which was not certified by peer review)Next, from the remaining time series, we chose to consider only those where at least 2000 confirmed cases have been observed on May 5, 2020.", [["the US data", "TEST", 39, 50]]], ["We decided, again arbitrarily, to exclude these time series from the analysis.", [["the analysis", "TEST", 65, 77]]], ["Excluding China does not lead to any loss of information for the purposes of the analysis here in any case, since there the number of confirmed cases was essentially constant during the period under consideration.(which was not certified by peer review)We calculated all predictions for these time series.", [["the analysis", "TEST", 77, 89], ["these time series", "TEST", 287, 304]]], ["From these predictions we arbitrarily decided to consider only these 16307 predictions with all badness parameters less than 10%.", [["all badness parameters", "TEST", 92, 114]]], ["For these predictions we calculated, for each country, both the average and the maximal error for 1-day predictions (1197 predictions), 7-days predictions (802 predictions), and 14-days predictions (563 predictions).(which was not certified by peer review)Histograms showing the number of all predictions as above, within 1%-error bins, for all one-day, seven-days, and two-weeks predictions can be found in Figure 6 .1.(which was not certified by peer review)We ordered our one-day, seven-days, and two-weeks predictions according to the average error of the prediction.", [["Histograms", "TEST", 256, 266]]], ["We emphasise that the ordering is only done to illustrate the effectiveness of our method, no other interpretations are implied.(which was not certified by peer review)It is legitimate to raise the question, how otherwise reasonable fits can lead to very poor predictions, be it for one or more days.", [["fits", "DISEASE", 233, 237]]], ["Such cases arise when the rates of increase of the k parameter exhibit significant variations.", [["the k parameter", "TEST", 47, 62], ["significant variations", "PROBLEM", 71, 93], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["variations", "OBSERVATION", 83, 93]]], ["This can be due to a wobbly epidemic curve which results from a lack of systematic or consistent reporting of new cases, or a change in testing practices.", [["a wobbly epidemic curve", "PROBLEM", 19, 42], ["a change in testing practices", "PROBLEM", 124, 153], ["new", "OBSERVATION_MODIFIER", 110, 113], ["cases", "OBSERVATION", 114, 119]]], ["Barring that, this can also result from a real decrease of the dynamics the epidemics, e.g. from the introduction of stricter confinement measures.", [["stricter confinement measures", "TREATMENT", 117, 146]]], ["In any case, our algorithm is only tailored to periods where the rates of change of the fitting parameters do not vary much in time.(which was not certified by peer review)For comparison we also present in Table 6 .4 the analysis of the 20888 predictions with all badness parameters less than 20% (where Qatar dropped out from the list of 69 countries considered), and the 7840 predictions with badness parameters less than 5% in Table 6 .5.(which was not certified by peer review)The results of the above analysis restricted to EU countries can be found in Figure 6 .3 and in Tables 6.6-6.10.19.", [["the fitting parameters", "TEST", 84, 106], ["the analysis", "TEST", 217, 229], ["all badness parameters", "TEST", 260, 282], ["badness parameters", "TEST", 395, 413], ["the above analysis", "TEST", 496, 514], ["Figure", "TEST", 558, 564], ["Tables", "TEST", 577, 583]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.20.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Table 6 .1: The average and maximal errors of one-day predictions, in percents, in the period April 5 -May 4 for selected countries.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Only predictions with badness parameters smaller than 10% are kept.", [["badness parameters", "TEST", 22, 40]]], ["The bad predictions for Russia correlate with fits with high badness parameters (around 8.8%) which we believe to be related to the fact that Russia is still in a relatively early phase of the epidemics.21.", [["fits", "DISEASE", 46, 50], ["Russia", "OBSERVATION", 142, 148]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Table 6 .2: One-week predictions; the remaining details as in Table 6 .1.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Table 6 .4: The average error of one-day predictions, in percents, with all badness parameters smaller than 20%.", [["all badness parameters", "TEST", 72, 94]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Table 6 .5: The average error of one-day predictions, in percents, with all badness parameters smaller than 5%.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["all badness parameters", "TEST", 414, 436], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["smaller", "OBSERVATION_MODIFIER", 437, 444]]], ["All badness parameters smaller than 10%.", [["All badness parameters", "TEST", 0, 22], ["smaller", "OBSERVATION_MODIFIER", 23, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Table 6 .8: Two-weeks predictions; the remaining details as in Table 6 .6.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Table 6 .9: One-day fits with badness parameters smaller than 20%.", [["badness parameters", "TEST", 30, 48]]], ["Table 6 .10: One-day fits with badness parameters smaller than 5%.", [["badness parameters", "TEST", 31, 49]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .ConclusionsWe have shown that a phenomenological curve, the \"double-logistic\" five-parameter curve, can be used to describe the Covid-19 epidemics with reasonable accuracy at any given moment of time.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["a phenomenological curve", "TEST", 305, 329], ["the Covid", "TEST", 399, 408], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We have analysed how the logistic, double-logistic, and Gauss-error models can be used for short-term predictions for the evolution of the current phase of the epidemics.", [["Gauss-error models", "TREATMENT", 56, 74], ["short-term predictions", "TREATMENT", 91, 113], ["the epidemics", "PROBLEM", 156, 169]]], ["We have presented an algorithm, based on the logistic curve, which is moderately successful in short-term predictions for a range of countries.ConclusionsIt is clear that neither the curves analysed, nor the algorithm, are suitable for long-term predictions of the epidemics.ConclusionsWe will be glad to provide the results of a similar analysis for other countries, or other fitting periods, upon request.A.1 ItalyIn this section we present the results of our analysis for Italy, in parallel to the presentation of Austria in Section 5.A.1 ItalyThe plots of the first badness parameter are found in Figure A. 1, while the relative errors of the fits can be found in Figure A. 2.A.1 ItalyThe fits with their standard errors and residuals are found in Figure A. 3.", [["fits", "DISEASE", 647, 651], ["the logistic curve", "TEST", 41, 59], ["the curves", "TEST", 179, 189], ["the algorithm", "TEST", 204, 217], ["the epidemics", "PROBLEM", 261, 274], ["a similar analysis", "TEST", 328, 346], ["our analysis", "TEST", 458, 470], ["the first badness parameter", "TREATMENT", 560, 587], ["moderately", "OBSERVATION_MODIFIER", 70, 80], ["successful", "OBSERVATION_MODIFIER", 81, 91], ["clear", "OBSERVATION", 160, 165]]], ["In Figure A .4 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curves.A.1 ItalyThe predictability strings for Italy are plotted in Figure A .5.27.", [["logistic curves", "TEST", 145, 160], ["predictability", "OBSERVATION_MODIFIER", 174, 188]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.29.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.31.", [["predictability strings", "OBSERVATION", 31, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .6: Histograms showing the numbers predictions with 1% error bins for the logistic fits with running parameters, for Italy, generated in the period April 5 -May 4, for 1 days, 4 days, one week and two weeks.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Histograms", "TEST", 355, 365], ["running parameters", "TREATMENT", 444, 462], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The last row shows a 3D histogram for all 30 fits.", [["a 3D histogram", "TEST", 19, 33]]], ["The individual histograms in the first two rows are slices, at the given number of days, of the 3D histogram.32.", [["slices", "ANATOMY", 52, 58], ["The individual histograms", "TEST", 0, 25], ["slices", "TEST", 52, 58], ["the 3D histogram", "TEST", 92, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .A.2 New YorkIn this section we present the results of our analysis for New York, in parallel to the presentation of Austria in Section 5.A.2 New YorkOne would have avoided the worst predictions by deciding, after the first week of fitting, to reject those predictions where the second badness parameter is larger than 7%.A.2 New YorkThe plots of the first badness parameter are found in Figure A .7, while the relative errors of the fits can be found in Figure A. 8.A.2 New YorkThe fits with their standard errors and residuals are found in Figure A .9.", [["CC", "CHEMICAL", 0, 2], ["fits", "DISEASE", 708, 712], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["our analysis", "TEST", 329, 341], ["the second badness parameter", "TEST", 549, 577], ["residuals", "TEST", 793, 802], ["med", "ANATOMY", 105, 108], ["larger", "OBSERVATION_MODIFIER", 581, 587]]], ["In Figure A .10 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curves.A.2 New YorkThe predictability strings for New York are plotted in Figure A .11.", [["logistic curves", "TEST", 146, 161]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.34.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.36.", [["predictability strings", "OBSERVATION", 31, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .12: Histograms showing the numbers predictions with 1% error bins for the logistic fits with running parameters, for New York, generated in the period April 5 -May 4, for 1 days, 4 days, one week and two weeks.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Histograms", "TEST", 356, 366], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The last row shows a 3D histogram for all 30 fits.", [["a 3D histogram", "TEST", 19, 33]]], ["The individual histograms in the first two rows are slices, at the given number of days, of the 3D histogram.37.", [["slices", "ANATOMY", 52, 58], ["The individual histograms", "TEST", 0, 25], ["slices", "TEST", 52, 58], ["the 3D histogram", "TEST", 92, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.A.3 PolandIn this section we present the results of our analysis for Poland, in parallel to the presentation of Austria in Section 5.A.3 PolandSimilarly to New York, one would have avoided the worst predictions by deciding, after the first week of fitting, to reject those predictions where the second badness parameter is larger than 7%.A.3 PolandThe plots of the first badness parameter are found in Figure A .13, while the relative errors of the fits can be found in Figure A. 14.A.3 PolandThe fits with their standard errors and residuals are found in Figure A .15.", [["CC", "CHEMICAL", 0, 2], ["fits", "DISEASE", 610, 614], ["ND", "PROBLEM", 9, 11], ["our analysis", "TEST", 213, 225], ["the second badness parameter", "TEST", 452, 480], ["residuals", "TEST", 694, 703], ["med", "ANATOMY", 105, 108], ["larger", "OBSERVATION_MODIFIER", 484, 490]]], ["In Figure A .16 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curves.A.3 PolandThe predictability strings for Poland are plotted in Figure A .17.", [["logistic curves", "TEST", 146, 161]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.39.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .16: Evolution of the fit parameters in time, together with their confidence intervals, for Poland; day 1 is April 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.41.", [["predictability strings", "OBSERVATION", 31, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.A.4 SloveniaWe included Slovenia in our analysis as it is one of the first countries to suspend all confinement measures, on May 15, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["All residuals are smaller than about 2% of the total number of cases; and smaller than about 1.6% when two worse residuals are excluded.", [["All residuals", "TEST", 0, 13], ["two worse residuals", "PROBLEM", 103, 122], ["residuals", "OBSERVATION", 4, 13], ["smaller", "OBSERVATION_MODIFIER", 18, 25], ["smaller", "OBSERVATION_MODIFIER", 74, 81]]], ["The number of cases is about 1/10th of that of Austria, but the double-logistic curve has distinctively different parameters.", [["the double-logistic curve", "TREATMENT", 60, 85]]], ["On the other had, its residuals are again of the order of 1/10th of those of Austria.", [["residuals", "OBSERVATION", 22, 31]]], ["The predictability algorithm which excludes predictions with badness parameters larger than 7% would have produced rather good predictions for the whole month of the epidemics under consideration.A.4 SloveniaThe plots of the first badness parameter are found in Figure A. 19, while the relative errors of the fits can be found in Figure A .20.A.4 SloveniaThe fits with their standard errors and residuals are found in Figure A .21.43.", [["A.4 Slovenia", "CHEMICAL", 196, 208], ["A.4 Slovenia", "CHEMICAL", 343, 355], ["Slovenia", "SPECIES", 200, 208], ["Slovenia", "SPECIES", 347, 355], ["The predictability algorithm", "TEST", 0, 28], ["badness parameters", "TEST", 61, 79], ["residuals", "TEST", 395, 404], ["Slovenia", "OBSERVATION", 200, 208], ["Slovenia", "OBSERVATION", 347, 355]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.44.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In Figure A .22 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curves.(which was not certified by peer review)The predictability strings for Slovenia are plotted in Figure A .23.", [["logistic curves", "TEST", 146, 161]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .22: Evolution of the fit parameters in time, together with their confidence intervals, for Slovenia; day 1 is April 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.47.", [["predictability strings", "OBSERVATION", 31, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .24: Histograms showing the numbers predictions with 1% error bins for the logistic fits with running parameters, for Slovenia, generated in the period April 5 -May 4, for 1 days, 4 days, one week and two weeks.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Histograms", "TEST", 356, 366], ["running parameters", "TREATMENT", 445, 463], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The last row shows a 3D histogram for all 30 fits.", [["a 3D histogram", "TEST", 19, 33]]], ["The individual histograms in the first two rows are slices, at the given number of days, of the 3D histogram.48.", [["slices", "ANATOMY", 52, 58], ["The individual histograms", "TEST", 0, 25], ["slices", "TEST", 52, 58], ["the 3D histogram", "TEST", 92, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .A.5 USIn this section we present the results of our analysis for the US, in parallel to the presentation of Austria in Section 5.A.5 USTo avoid the worst predictions one should have decided, after the first week of fitting, to reject those predictions where the second badness parameter is larger than 5%.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["our analysis", "TEST", 323, 335], ["the US", "TEST", 340, 346], ["the second badness parameter", "TEST", 533, 561], ["med", "ANATOMY", 105, 108], ["larger", "OBSERVATION_MODIFIER", 565, 571]]], ["Note that the 7% threshold, seen in other countries, would not have worked here.A.5 USThe plots of the first badness parameter are found in Figure A .25, while the relative errors of the fits can be found in Figure49.", [["fits", "DISEASE", 187, 191]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)49The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["med", "ANATOMY", 105, 108]]], ["Same for the Gauss-error curve in the second row, and the logistic curves in the third row.", [["the Gauss-error curve", "TEST", 9, 30], ["the logistic curves", "TEST", 54, 73]]], ["Note distinct scales for the residual plots as compared to the fitted curve, as well as a distinct scale for the residuals of the double-logistic curve compared to the other residuals.50.", [["the residual plots", "PROBLEM", 25, 43], ["the fitted curve", "TEST", 59, 75], ["the double-logistic curve", "TREATMENT", 126, 151], ["residual plots", "OBSERVATION", 29, 43]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)50The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint50In Figure A .28 we show how the parameters of the fits, and their confidence intervals, change in time, for the double logistic, Gauss-error, and logistic curves.50The predictability strings for US are plotted in Figure A .29.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["logistic curves", "TEST", 492, 507], ["US", "TEST", 541, 543], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)51The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .28: Evolution of the fit parameters in time, together with their confidence intervals, for US; day 1 is April 5.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["med", "ANATOMY", 105, 108]]], ["First row: parameter k for the double-logistic curve (left), and for all three curves (right).", [["the double-logistic curve", "TEST", 27, 52], ["left", "ANATOMY_MODIFIER", 54, 58], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Second row: the \u03c4 -parameter for the double-logistic curve (left) and for both the logistic and Gauss-error curves (right).", [["\u03c4", "PROTEIN", 16, 17], ["the double-logistic curve", "TREATMENT", 33, 58], ["Gauss-error curves", "TEST", 96, 114], ["left", "ANATOMY_MODIFIER", 60, 64], ["right", "ANATOMY_MODIFIER", 116, 121]]], ["Third row: plots of the parameters b (left) and \u03c3 (right) for the double-logistic curve.", [["\u03c3", "PROTEIN", 48, 49], ["the double-logistic curve", "TREATMENT", 62, 87], ["left", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 51, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)52The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["med", "ANATOMY", 105, 108]]], ["Figure A .29: Predictability plots for US generated in the period April 5 -May 4.", [["Predictability plots", "TEST", 14, 34], ["US", "TEST", 39, 41]]], ["The first row shows all predictability strings with last prediction on May 5, which is the last day on the first and third rows.", [["all", "OBSERVATION_MODIFIER", 20, 23], ["predictability strings", "OBSERVATION", 24, 46]]], ["The shadings correspond to a 1.5%, 3%, and 6% error zones.", [["The shadings", "TEST", 0, 12], ["zones", "ANATOMY_MODIFIER", 52, 57]]], ["The second row shows the predictability strings cut-off at April 20, with badness parameters indicated.", [["badness parameters", "TEST", 74, 92], ["predictability", "OBSERVATION_MODIFIER", 25, 39], ["strings", "OBSERVATION_MODIFIER", 40, 47], ["cut", "OBSERVATION_MODIFIER", 48, 51]]], ["The third row shows only these predictability strings which start within a two-weeks period ending on May 5.53.", [["predictability strings", "OBSERVATION", 31, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)53The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprint Figure A .30: Histograms showing the numbers predictions with 1% error bins for the logistic fits with running parameters, for US, generated in the period April 5 -May 4, for 1 days, 4 days, one week and two weeks.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["running parameters", "TEST", 448, 466], ["US", "TEST", 472, 474], ["med", "ANATOMY", 105, 108]]], ["The last row shows a 3D histogram for all 30 fits.", [["a 3D histogram", "TEST", 19, 33]]], ["The individual histograms in the first two rows are slices, at the given number of days, of the 3D histogram.54.", [["slices", "ANATOMY", 52, 58], ["The individual histograms", "TEST", 0, 25], ["slices", "TEST", 52, 58], ["the 3D histogram", "TEST", 92, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)54The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20098350 doi: medRxiv preprintB The Richards curveA family of curves modeling growth phenomena has been proposed by Richards [2] , and has been used by several authors.", [["CC", "CHEMICAL", 0, 2], ["Richards curveA family", "PROTEIN", 350, 372], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["medRxiv preprintB", "TREATMENT", 328, 345], ["curves modeling growth phenomena", "PROBLEM", 376, 408], ["med", "ANATOMY", 105, 108]]], ["The Richards curve can be written asB The Richards curvefor some constants k R > 0, a R > 0, t R \u2208 R and p > 0.", [["The Richards", "TEST", 38, 50]]], ["The function I R tends to k R as t tends to infinity, so that k R describes the total number of infected.B The Richards curve2.", [["I R", "GENE_OR_GENE_PRODUCT", 13, 16], ["k R", "GENE_OR_GENE_PRODUCT", 26, 29], ["k R", "GENE_OR_GENE_PRODUCT", 62, 65], ["I R", "PROTEIN", 13, 16], ["infected", "PROBLEM", 96, 104], ["total", "OBSERVATION_MODIFIER", 80, 85], ["number", "OBSERVATION_MODIFIER", 86, 92], ["infected", "OBSERVATION", 96, 104]]], ["For large negative t the Richards functions behave asB The Richards curveso that the initial rate of growth of the epidemics is pa R , with growth coefficient k R e \u2212pa R t R .B The Richards curve3.", [["pa R", "GENE_OR_GENE_PRODUCT", 128, 132], ["growth", "TEST", 140, 146], ["large", "OBSERVATION_MODIFIER", 4, 9], ["negative", "OBSERVATION", 10, 18]]], ["For large positive t we haveB The Richards curveso that a R describes the dying-out rate of the epidemics, with decay amplitude pk R e a R t R .", [["R t R", "GENE_OR_GENE_PRODUCT", 137, 142], ["the epidemics", "PROBLEM", 92, 105], ["large", "OBSERVATION_MODIFIER", 4, 9], ["positive", "OBSERVATION", 10, 18]]]], "1ecf7930fc9eca85bc703ea81f842846f845b38e": [["IntroductionSevere Hand, Foot, and Mouth Disease induced by enterovirus 71 (EV71) infection is a known health risk for infants.", [["Foot, and Mouth Disease", "DISEASE", 25, 48], ["enterovirus 71 (EV71) infection", "DISEASE", 60, 91], ["enterovirus 71", "ORGANISM", 60, 74], ["EV71", "ORGANISM", 76, 80], ["infants", "ORGANISM", 119, 126], ["infants", "SPECIES", 119, 126], ["enterovirus 71", "SPECIES", 60, 74], ["EV71", "SPECIES", 76, 80], ["Hand, Foot, and Mouth Disease", "PROBLEM", 19, 48], ["enterovirus", "PROBLEM", 60, 71], ["infection", "PROBLEM", 82, 91], ["Foot", "ANATOMY", 25, 29], ["Mouth", "ANATOMY", 35, 40]]], ["More than 80 % of critically infected infants have pulmonary edema (PE) or hemorrhage [1] .", [["pulmonary", "ANATOMY", 51, 60], ["critically infected", "DISEASE", 18, 37], ["pulmonary edema", "DISEASE", 51, 66], ["PE", "DISEASE", 68, 70], ["hemorrhage", "DISEASE", 75, 85], ["infants", "ORGANISM", 38, 45], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 51, 66], ["infants", "SPECIES", 38, 45], ["pulmonary edema", "PROBLEM", 51, 66], ["PE", "PROBLEM", 68, 70], ["hemorrhage", "PROBLEM", 75, 85], ["infected", "OBSERVATION", 29, 37], ["pulmonary", "ANATOMY", 51, 60], ["edema", "OBSERVATION", 61, 66], ["PE", "OBSERVATION", 68, 70], ["hemorrhage", "OBSERVATION", 75, 85]]], ["PE is fatal, and most affected infants die within 24 h of developing PE [2] .IntroductionThe pathogenesis of EV71-induced PE is uncertain and has been studied only rarely.", [["PE", "DISEASE", 0, 2], ["PE", "DISEASE", 69, 71], ["EV71", "DISEASE", 109, 113], ["PE", "DISEASE", 122, 124], ["infants", "ORGANISM", 31, 38], ["EV71", "ORGANISM", 109, 113], ["infants", "SPECIES", 31, 38], ["PE", "PROBLEM", 0, 2], ["developing PE", "PROBLEM", 58, 71], ["EV71", "PROBLEM", 109, 113], ["PE", "PROBLEM", 122, 124], ["fatal", "OBSERVATION_MODIFIER", 6, 11], ["PE", "OBSERVATION", 69, 71], ["PE", "OBSERVATION", 122, 124]]], ["Wu et al. used pulmonary artery catheterization to monitor pulmonary circulation hemodynamics in 5 infants with EV71-induced PE and found that pulmonary artery wedge pressure (PAWP) was normal or slightly elevated [3] .", [["pulmonary artery", "ANATOMY", 15, 31], ["pulmonary", "ANATOMY", 59, 68], ["pulmonary artery", "ANATOMY", 143, 159], ["EV71", "DISEASE", 112, 116], ["PE", "DISEASE", 125, 127], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 15, 31], ["pulmonary circulation", "MULTI-TISSUE_STRUCTURE", 59, 80], ["infants", "ORGANISM", 99, 106], ["EV71", "ORGANISM", 112, 116], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 143, 159], ["infants", "SPECIES", 99, 106], ["pulmonary artery catheterization", "TREATMENT", 15, 47], ["pulmonary circulation hemodynamics", "TEST", 59, 93], ["EV71", "PROBLEM", 112, 116], ["PE", "PROBLEM", 125, 127], ["pulmonary artery wedge pressure", "TEST", 143, 174], ["PAWP", "TEST", 176, 180], ["slightly elevated", "PROBLEM", 196, 213], ["pulmonary artery", "ANATOMY", 15, 31], ["catheterization", "OBSERVATION", 32, 47], ["pulmonary", "ANATOMY", 59, 68], ["PE", "OBSERVATION", 125, 127], ["pulmonary artery", "ANATOMY", 143, 159], ["wedge pressure", "OBSERVATION", 160, 174], ["slightly", "OBSERVATION_MODIFIER", 196, 204], ["elevated", "OBSERVATION_MODIFIER", 205, 213]]], ["Therefore, pulmonary capillary leakage may be a key factor in PE development.IntroductionAngiopoietin-2 (Ang-2) is reportedly related to increased vascular permeability.", [["pulmonary capillary", "ANATOMY", 11, 30], ["vascular", "ANATOMY", 147, 155], ["PE", "DISEASE", 62, 64], ["pulmonary capillary", "TISSUE", 11, 30], ["PE", "PATHOLOGICAL_FORMATION", 62, 64], ["IntroductionAngiopoietin-2", "GENE_OR_GENE_PRODUCT", 77, 103], ["Ang-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["vascular", "MULTI-TISSUE_STRUCTURE", 147, 155], ["pulmonary capillary leakage", "PROBLEM", 11, 38], ["IntroductionAngiopoietin", "TREATMENT", 77, 101], ["increased vascular permeability", "PROBLEM", 137, 168], ["pulmonary", "ANATOMY", 11, 20], ["capillary leakage", "OBSERVATION", 21, 38], ["PE", "OBSERVATION", 62, 64], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["vascular", "ANATOMY", 147, 155], ["permeability", "OBSERVATION", 156, 168]]], ["Ang-1 is its natural antagonist.", [["Ang", "CHEMICAL", 0, 3], ["Ang-1", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Ang-1 and Ang-2 are ligands for the endothelial cell-specific receptor tyrosine kinase Tie-2.", [["endothelial cell", "ANATOMY", 36, 52], ["Ang", "CHEMICAL", 0, 3], ["Ang", "CHEMICAL", 10, 13], ["tyrosine", "CHEMICAL", 71, 79], ["tyrosine", "CHEMICAL", 71, 79], ["Ang-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ang-2", "GENE_OR_GENE_PRODUCT", 10, 15], ["endothelial cell", "CELL", 36, 52], ["receptor tyrosine kinase Tie-2", "GENE_OR_GENE_PRODUCT", 62, 92], ["endothelial cell-specific receptor tyrosine kinase", "PROTEIN", 36, 86], ["Tie-2", "PROTEIN", 87, 92], ["Ang", "TEST", 0, 3], ["Ang", "TEST", 10, 13], ["the endothelial cell", "TEST", 32, 52], ["endothelial cell", "ANATOMY", 36, 52]]], ["Tie-2 is expressed throughout the surface of endothelial cells and has low activity [4] .", [["surface", "ANATOMY", 34, 41], ["endothelial cells", "ANATOMY", 45, 62], ["Tie-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["surface", "CELLULAR_COMPONENT", 34, 41], ["endothelial cells", "CELL", 45, 62], ["Tie-2", "PROTEIN", 0, 5], ["endothelial cells", "CELL_TYPE", 45, 62], ["endothelial cells", "OBSERVATION", 45, 62], ["low activity", "OBSERVATION_MODIFIER", 71, 83]]], ["Ang-2 antagonizes Tie-2, and Ang-1 activates Tie-2.", [["Ang", "CHEMICAL", 0, 3], ["Ang", "CHEMICAL", 29, 32], ["Ang-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Tie-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["Ang-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["Tie-2", "GENE_OR_GENE_PRODUCT", 45, 50], ["Tie-2", "PROTEIN", 18, 23], ["Ang-1", "PROTEIN", 29, 34], ["Tie-2", "PROTEIN", 45, 50], ["Ang", "TEST", 0, 3]]], ["Tie-2 activation helps decrease vascular permeability and prevents endothelial cell death [5, 6] .", [["vascular", "ANATOMY", 32, 40], ["endothelial cell", "ANATOMY", 67, 83], ["death", "DISEASE", 84, 89], ["Tie-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["vascular", "MULTI-TISSUE_STRUCTURE", 32, 40], ["endothelial cell", "CELL", 67, 83], ["decrease vascular permeability", "PROBLEM", 23, 53], ["endothelial cell death", "PROBLEM", 67, 89], ["vascular", "ANATOMY", 32, 40], ["prevents", "UNCERTAINTY", 58, 66], ["endothelial cell death", "OBSERVATION", 67, 89]]], ["Ang-2 is normally stored in Weibel-Palade bodies and is rapidly released upon stimulation to mediate endothelium activation and sensitize endothelial response to inflammatory cytokines [7, 8] .", [["Weibel-Palade bodies", "ANATOMY", 28, 48], ["endothelium", "ANATOMY", 101, 112], ["endothelial", "ANATOMY", 138, 149], ["Ang", "CHEMICAL", 0, 3], ["Ang-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelium", "TISSUE", 101, 112], ["endothelial", "CELL", 138, 149], ["inflammatory cytokines", "PROTEIN", 162, 184], ["inflammatory cytokines", "TEST", 162, 184], ["Palade", "ANATOMY", 35, 41], ["bodies", "ANATOMY_MODIFIER", 42, 48], ["inflammatory", "OBSERVATION_MODIFIER", 162, 174]]], ["Ang-2 levels increase in septic shock and are associated with vascular leakage and the development of acute respiratory distress syndrome (ARDS) [9] .", [["vascular", "ANATOMY", 62, 70], ["respiratory", "ANATOMY", 108, 119], ["Ang", "CHEMICAL", 0, 3], ["septic shock", "DISEASE", 25, 37], ["acute respiratory distress syndrome", "DISEASE", 102, 137], ["ARDS", "DISEASE", 139, 143], ["Ang-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["vascular", "MULTI-TISSUE_STRUCTURE", 62, 70], ["Ang", "TEST", 0, 3], ["septic shock", "PROBLEM", 25, 37], ["vascular leakage", "PROBLEM", 62, 78], ["acute respiratory distress syndrome", "PROBLEM", 102, 137], ["ARDS)", "PROBLEM", 139, 144], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["septic shock", "OBSERVATION", 25, 37], ["vascular", "ANATOMY", 62, 70], ["leakage", "OBSERVATION", 71, 78], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["respiratory distress syndrome", "OBSERVATION", 108, 137]]], ["Whether Ang-2 is also associated with EV71-induced PE remains unknown.IntroductionIn the present study, the authors measured Ang-2 levels in the serum and PE fluid of infants with EV71 infection, and observed the effects of human recombinant Ang-2 and infected infant serum on the intercellular junctions of human pulmonary microvascular endothelial cells (HPMECs).", [["serum", "ANATOMY", 145, 150], ["PE fluid", "ANATOMY", 155, 163], ["serum", "ANATOMY", 268, 273], ["intercellular junctions", "ANATOMY", 281, 304], ["pulmonary microvascular endothelial cells", "ANATOMY", 314, 355], ["HPMECs", "ANATOMY", 357, 363], ["Ang", "CHEMICAL", 8, 11], ["EV71", "DISEASE", 38, 42], ["PE", "DISEASE", 51, 53], ["Ang", "CHEMICAL", 125, 128], ["EV71 infection", "DISEASE", 180, 194], ["Ang", "CHEMICAL", 242, 245], ["Ang-2", "GENE_OR_GENE_PRODUCT", 8, 13], ["EV71", "ORGANISM", 38, 42], ["Ang-2", "GENE_OR_GENE_PRODUCT", 125, 130], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["PE fluid", "ORGANISM_SUBSTANCE", 155, 163], ["infants", "ORGANISM", 167, 174], ["EV71", "ORGANISM", 180, 184], ["human", "ORGANISM", 224, 229], ["Ang-2", "GENE_OR_GENE_PRODUCT", 242, 247], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["intercellular junctions", "CELLULAR_COMPONENT", 281, 304], ["human", "ORGANISM", 308, 313], ["pulmonary microvascular endothelial cells", "CELL", 314, 355], ["HPMECs", "CELL", 357, 363], ["human recombinant Ang-2", "PROTEIN", 224, 247], ["human pulmonary microvascular endothelial cells", "CELL_TYPE", 308, 355], ["HPMECs", "CELL_TYPE", 357, 363], ["infants", "SPECIES", 167, 174], ["human", "SPECIES", 224, 229], ["infant", "SPECIES", 261, 267], ["human", "SPECIES", 308, 313], ["EV71", "SPECIES", 180, 184], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 308, 313], ["EV71", "PROBLEM", 38, 42], ["induced PE", "PROBLEM", 43, 53], ["the present study", "TEST", 85, 102], ["Ang", "TEST", 125, 128], ["the serum", "TEST", 141, 150], ["PE fluid of infants", "PROBLEM", 155, 174], ["EV71 infection", "PROBLEM", 180, 194], ["human recombinant Ang", "TREATMENT", 224, 245], ["infected infant serum", "TEST", 252, 273], ["PE", "OBSERVATION", 51, 53], ["PE", "OBSERVATION", 155, 157], ["fluid", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 185, 194], ["intercellular junctions", "ANATOMY", 281, 304], ["human", "ANATOMY_MODIFIER", 308, 313], ["pulmonary microvascular", "ANATOMY", 314, 337], ["endothelial cells", "OBSERVATION", 338, 355]]], ["The aim was to explore the relationship between Ang-2 and PE to further clarify the pathogenesis of PE.Material and MethodsAll of the infants included in this study were admitted to the intensive care unit of the Binzhou Medical University Affiliated Hospital (Binzhou, China) between April 2013 and June 2014.", [["Ang", "CHEMICAL", 48, 51], ["PE", "DISEASE", 100, 102], ["Ang-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["PE", "SIMPLE_CHEMICAL", 58, 60], ["infants", "ORGANISM", 134, 141], ["infants", "SPECIES", 134, 141], ["Ang", "TEST", 48, 51], ["PE", "PROBLEM", 58, 60], ["PE", "PROBLEM", 100, 102], ["this study", "TEST", 154, 164], ["PE", "OBSERVATION", 58, 60], ["PE", "OBSERVATION", 100, 102]]], ["The study was approved by the hospital's Medical Ethics Committee, and the parents of the infants provided informed consent.Material and MethodsThe included infants met the following criteria: (1) EV71 infection diagnostic criteria [10] including presenting symptoms of fever and maculopapular rash on the hand, foot, and buttock, mouth papules, or herpangina, with positive nucleic acid detection via throat or rectal swab or herpes fluid sampling; (2) Other criteria [11] including (a) sustained high fever (axillary temperature higher than 39\u00b0C with poor response to conventional antipyretics), (b) neurological manifestations (the emergence of depression, vomiting, frightfulness, limb shaking), (c) respiratory abnormalities [irregular breath or breath frequency exceeding 30-40/min (by age) in a resting state], (d) circulatory dysfunction [increased heart rate (>140-150/min, by age), cold limbs, piebald skin, elevated blood pressure], (e) elevated peripheral white blood cell (WBC) count (peripheral blood WBC exceeding 15\u00d710 9 /L), and (f) elevated blood sugar (emergent stress hyperglycemia exceeding 8.3 mmol/L).Material and MethodsThe EV71-infected infants were divided into PE and non-PE groups according to the presence or absence of PE, respectively.", [["maculopapular", "ANATOMY", 280, 293], ["hand", "ANATOMY", 306, 310], ["foot", "ANATOMY", 312, 316], ["buttock", "ANATOMY", 322, 329], ["mouth papules", "ANATOMY", 331, 344], ["herpangina", "ANATOMY", 349, 359], ["throat", "ANATOMY", 402, 408], ["rectal swab", "ANATOMY", 412, 423], ["axillary", "ANATOMY", 510, 518], ["neurological", "ANATOMY", 602, 614], ["limb", "ANATOMY", 685, 689], ["respiratory", "ANATOMY", 704, 715], ["circulatory", "ANATOMY", 822, 833], ["heart", "ANATOMY", 857, 862], ["limbs", "ANATOMY", 897, 902], ["skin", "ANATOMY", 912, 916], ["blood", "ANATOMY", 927, 932], ["peripheral white blood cell", "ANATOMY", 957, 984], ["WBC", "ANATOMY", 986, 989], ["peripheral blood WBC", "ANATOMY", 998, 1018], ["blood", "ANATOMY", 1059, 1064], ["infection", "DISEASE", 202, 211], ["fever", "DISEASE", 270, 275], ["rash", "DISEASE", 294, 298], ["mouth papules", "DISEASE", 331, 344], ["herpangina", "DISEASE", 349, 359], ["nucleic acid", "CHEMICAL", 375, 387], ["fever", "DISEASE", 503, 508], ["depression", "DISEASE", 648, 658], ["vomiting", "DISEASE", 660, 668], ["frightfulness", "DISEASE", 670, 683], ["respiratory abnormalities", "DISEASE", 704, 729], ["circulatory dysfunction", "DISEASE", 822, 845], ["hyperglycemia", "DISEASE", 1088, 1101], ["EV71-infected", "DISEASE", 1148, 1161], ["PE", "DISEASE", 1249, 1251], ["sugar", "CHEMICAL", 1065, 1070], ["infants", "ORGANISM", 90, 97], ["infants", "ORGANISM", 157, 164], ["EV71", "ORGANISM", 197, 201], ["hand", "ORGANISM_SUBDIVISION", 306, 310], ["foot", "ORGANISM_SUBDIVISION", 312, 316], ["buttock", "ORGANISM_SUBDIVISION", 322, 329], ["mouth", "ORGANISM_SUBDIVISION", 331, 336], ["papules", "PATHOLOGICAL_FORMATION", 337, 344], ["throat", "ORGANISM_SUBDIVISION", 402, 408], ["herpes", "ORGANISM", 427, 433], ["limb", "ORGANISM_SUBDIVISION", 685, 689], ["heart", "ORGAN", 857, 862], ["limbs", "ORGANISM_SUBDIVISION", 897, 902], ["skin", "ORGAN", 912, 916], ["blood", "ORGANISM_SUBSTANCE", 927, 932], ["peripheral white blood cell", "CELL", 957, 984], ["WBC", "CELL", 986, 989], ["peripheral", "ORGANISM_SUBSTANCE", 998, 1008], ["blood", "ORGANISM_SUBSTANCE", 1009, 1014], ["blood", "ORGANISM_SUBSTANCE", 1059, 1064], ["sugar", "SIMPLE_CHEMICAL", 1065, 1070], ["EV71", "ORGANISM", 1148, 1152], ["infants", "ORGANISM", 1162, 1169], ["peripheral white blood cell", "CELL_TYPE", 957, 984], ["peripheral blood WBC", "CELL_TYPE", 998, 1018], ["infants", "SPECIES", 90, 97], ["infants", "SPECIES", 157, 164], ["infants", "SPECIES", 1162, 1169], ["The study", "TEST", 0, 9], ["presenting symptoms", "PROBLEM", 247, 266], ["fever", "PROBLEM", 270, 275], ["maculopapular rash on the hand, foot, and buttock", "PROBLEM", 280, 329], ["mouth papules", "PROBLEM", 331, 344], ["herpangina", "PROBLEM", 349, 359], ["positive nucleic acid detection", "PROBLEM", 366, 397], ["throat", "PROBLEM", 402, 408], ["rectal swab", "TEST", 412, 423], ["herpes fluid sampling", "TEST", 427, 448], ["sustained high fever (axillary temperature", "PROBLEM", 488, 530], ["conventional antipyretics", "TREATMENT", 570, 595], ["(b) neurological manifestations", "PROBLEM", 598, 629], ["depression", "PROBLEM", 648, 658], ["vomiting", "PROBLEM", 660, 668], ["frightfulness", "PROBLEM", 670, 683], ["limb shaking)", "PROBLEM", 685, 698], ["(c) respiratory abnormalities", "PROBLEM", 700, 729], ["irregular breath", "PROBLEM", 731, 747], ["breath frequency", "PROBLEM", 751, 767], ["(d) circulatory dysfunction", "PROBLEM", 818, 845], ["increased heart rate", "PROBLEM", 847, 867], ["cold limbs, piebald skin", "PROBLEM", 892, 916], ["elevated blood pressure", "PROBLEM", 918, 941], ["elevated peripheral white blood cell", "PROBLEM", 948, 984], ["WBC", "TEST", 986, 989], ["count", "TEST", 991, 996], ["peripheral blood WBC", "TEST", 998, 1018], ["elevated blood sugar", "PROBLEM", 1050, 1070], ["emergent stress hyperglycemia", "PROBLEM", 1072, 1101], ["The EV71", "TEST", 1144, 1152], ["PE", "PROBLEM", 1188, 1190], ["PE", "PROBLEM", 1249, 1251], ["fever", "OBSERVATION", 270, 275], ["maculopapular", "OBSERVATION_MODIFIER", 280, 293], ["rash", "OBSERVATION", 294, 298], ["hand", "ANATOMY", 306, 310], ["foot", "ANATOMY", 312, 316], ["buttock", "ANATOMY", 322, 329], ["mouth", "ANATOMY", 331, 336], ["papules", "OBSERVATION", 337, 344], ["throat", "ANATOMY", 402, 408], ["rectal", "ANATOMY", 412, 418], ["high", "OBSERVATION_MODIFIER", 498, 502], ["fever", "OBSERVATION", 503, 508], ["axillary", "ANATOMY", 510, 518], ["limb", "ANATOMY", 685, 689], ["respiratory", "ANATOMY", 704, 715], ["abnormalities", "OBSERVATION", 716, 729], ["heart", "ANATOMY", 857, 862], ["limbs", "ANATOMY", 897, 902], ["skin", "ANATOMY", 912, 916], ["elevated", "OBSERVATION", 918, 926], ["peripheral", "ANATOMY_MODIFIER", 957, 967], ["PE", "OBSERVATION", 1188, 1190], ["PE", "OBSERVATION", 1249, 1251]]], ["PE was defined as the appearance of pulmonary crackles, alveolar congestion on chest radiography, or fresh red/pink blood in the endotracheal tube.", [["pulmonary", "ANATOMY", 36, 45], ["alveolar", "ANATOMY", 56, 64], ["chest", "ANATOMY", 79, 84], ["blood", "ANATOMY", 116, 121], ["endotracheal tube", "ANATOMY", 129, 146], ["PE", "DISEASE", 0, 2], ["pulmonary", "ORGAN", 36, 45], ["alveolar", "MULTI-TISSUE_STRUCTURE", 56, 64], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 129, 146], ["PE", "PROBLEM", 0, 2], ["pulmonary crackles", "PROBLEM", 36, 54], ["alveolar congestion", "PROBLEM", 56, 75], ["chest radiography", "TEST", 79, 96], ["fresh red/pink blood in the endotracheal tube", "PROBLEM", 101, 146], ["pulmonary", "ANATOMY", 36, 45], ["crackles", "OBSERVATION", 46, 54], ["alveolar", "ANATOMY_MODIFIER", 56, 64], ["congestion", "OBSERVATION", 65, 75], ["chest", "ANATOMY", 79, 84], ["pink blood", "OBSERVATION", 111, 121], ["endotracheal tube", "OBSERVATION", 129, 146]]], ["Infants in the preoperative period of elective inguinal hernia surgery were enrolled in the control group.Material and MethodsInformation about vital signs, pulmonary symptoms, and chest radiography were collected for EV71-infected infants after admission.", [["inguinal hernia", "ANATOMY", 47, 62], ["pulmonary", "ANATOMY", 157, 166], ["chest", "ANATOMY", 181, 186], ["EV71-infected", "DISEASE", 218, 231], ["Infants", "ORGANISM", 0, 7], ["hernia", "ORGAN", 56, 62], ["pulmonary", "ORGAN", 157, 166], ["EV71", "ORGANISM", 218, 222], ["infants", "ORGANISM", 232, 239], ["Infants", "SPECIES", 0, 7], ["infants", "SPECIES", 232, 239], ["EV71", "SPECIES", 218, 222], ["elective inguinal hernia surgery", "TREATMENT", 38, 70], ["vital signs", "TEST", 144, 155], ["pulmonary symptoms", "PROBLEM", 157, 175], ["chest radiography", "TEST", 181, 198], ["EV71", "PROBLEM", 218, 222], ["inguinal", "ANATOMY", 47, 55], ["hernia", "OBSERVATION", 56, 62], ["pulmonary", "ANATOMY", 157, 166], ["chest", "ANATOMY", 181, 186]]], ["Cerebrospinal fluid (CSF) pressure was measured, and the CSF was analyzed.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["CSF", "ORGANISM_SUBSTANCE", 21, 24], ["CSF", "GENE_OR_GENE_PRODUCT", 57, 60], ["CSF", "PROTEIN", 57, 60], ["Cerebrospinal fluid (CSF) pressure", "TEST", 0, 34], ["the CSF", "TEST", 53, 60], ["fluid", "OBSERVATION", 14, 19]]], ["Infants with PE were immediately treated with orotracheal intubation and positive pressure ventilation.", [["orotracheal", "ANATOMY", 46, 57], ["PE", "DISEASE", 13, 15], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["PE", "PROBLEM", 13, 15], ["orotracheal intubation", "TREATMENT", 46, 68], ["positive pressure ventilation", "TREATMENT", 73, 102], ["PE", "OBSERVATION", 13, 15], ["pressure ventilation", "OBSERVATION", 82, 102]]], ["Alveolar edema fluid was collected via suction catheters when abundant blood-tinged secretion overflowed the intubation.", [["Alveolar edema fluid", "ANATOMY", 0, 20], ["blood", "ANATOMY", 71, 76], ["edema", "DISEASE", 9, 14], ["Alveolar edema fluid", "ORGANISM_SUBSTANCE", 0, 20], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["Alveolar edema fluid", "PROBLEM", 0, 20], ["suction catheters", "TREATMENT", 39, 56], ["abundant blood-tinged secretion", "PROBLEM", 62, 93], ["the intubation", "TREATMENT", 105, 119], ["edema", "OBSERVATION", 9, 14], ["fluid", "OBSERVATION", 15, 20], ["tinged secretion", "OBSERVATION", 77, 93]]], ["The secretion was centrifuged, and the supernatant was used for analysis.", [["supernatant", "ANATOMY", 39, 50], ["analysis", "TEST", 64, 72]]], ["Routine blood tests were performed to measure the levels of serum total protein, albumin, blood glucose, and creatine kinase isoenzymes (CK-MB) and the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ).", [["blood", "ANATOMY", 8, 13], ["serum", "ANATOMY", 60, 65], ["blood", "ANATOMY", 90, 95], ["arterial", "ANATOMY", 185, 193], ["creatine", "CHEMICAL", 109, 117], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "CHEMICAL", 229, 235], ["glucose", "CHEMICAL", 96, 103], ["creatine", "CHEMICAL", 109, 117], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "CHEMICAL", 229, 235], ["PaO 2 /FiO 2", "CHEMICAL", 237, 249], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["albumin", "GENE_OR_GENE_PRODUCT", 81, 88], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["glucose", "SIMPLE_CHEMICAL", 96, 103], ["creatine kinase isoenzymes", "GENE_OR_GENE_PRODUCT", 109, 135], ["CK-MB", "GENE_OR_GENE_PRODUCT", 137, 142], ["arterial", "MULTI-TISSUE_STRUCTURE", 185, 193], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["oxygen", "SIMPLE_CHEMICAL", 229, 235], ["serum total protein", "PROTEIN", 60, 79], ["albumin", "PROTEIN", 81, 88], ["creatine kinase isoenzymes", "PROTEIN", 109, 135], ["CK", "PROTEIN", 137, 139], ["Routine blood tests", "TEST", 0, 19], ["serum total protein", "TEST", 60, 79], ["albumin", "TEST", 81, 88], ["blood glucose", "TEST", 90, 103], ["creatine kinase isoenzymes", "TEST", 109, 135], ["CK-MB", "TEST", 137, 142], ["the ratio", "TEST", 148, 157], ["arterial oxygen", "TREATMENT", 185, 200], ["inspired oxygen", "TREATMENT", 220, 235], ["PaO", "TEST", 237, 240], ["FiO", "TEST", 244, 247], ["partial pressure", "OBSERVATION", 165, 181], ["arterial oxygen", "OBSERVATION", 185, 200], ["inspired oxygen", "OBSERVATION", 220, 235]]], ["All serum and alveolar edema fluid samples were stored in a refrigerator at -80\u00b0C until analysis.Material and MethodsEV71-infected infants were administered antiviral therapy, human immunoglobulin and methylprednisolone to suppress inflammatory reactions, mannitol to reduce intracranial pressure, and symptomatic treatment.", [["serum", "ANATOMY", 4, 9], ["alveolar edema fluid samples", "ANATOMY", 14, 42], ["intracranial", "ANATOMY", 275, 287], ["edema", "DISEASE", 23, 28], ["methylprednisolone", "CHEMICAL", 201, 219], ["mannitol", "CHEMICAL", 256, 264], ["methylprednisolone", "CHEMICAL", 201, 219], ["mannitol", "CHEMICAL", 256, 264], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["alveolar edema fluid samples", "ORGANISM_SUBSTANCE", 14, 42], ["MethodsEV71", "GENE_OR_GENE_PRODUCT", 110, 121], ["infants", "ORGANISM", 131, 138], ["human", "ORGANISM", 176, 181], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 182, 196], ["methylprednisolone", "SIMPLE_CHEMICAL", 201, 219], ["mannitol", "SIMPLE_CHEMICAL", 256, 264], ["intracranial", "MULTI-TISSUE_STRUCTURE", 275, 287], ["human immunoglobulin", "PROTEIN", 176, 196], ["infants", "SPECIES", 131, 138], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["All serum and alveolar edema fluid samples", "TEST", 0, 42], ["analysis", "TEST", 88, 96], ["Material", "TEST", 97, 105], ["MethodsEV71", "TEST", 110, 121], ["antiviral therapy", "TREATMENT", 157, 174], ["human immunoglobulin", "TREATMENT", 176, 196], ["methylprednisolone", "TREATMENT", 201, 219], ["inflammatory reactions", "PROBLEM", 232, 254], ["mannitol", "TREATMENT", 256, 264], ["intracranial pressure", "TREATMENT", 275, 296], ["symptomatic treatment", "TREATMENT", 302, 323], ["alveolar", "ANATOMY", 14, 22], ["edema", "OBSERVATION", 23, 28], ["symptomatic", "OBSERVATION_MODIFIER", 302, 313]]], ["Infants with PE were provided heart strengthening and diuresis treatments.Material and MethodsSimilar methods were used to record preoperative vital signs and perform routine blood tests in infants in the control group.", [["heart", "ANATOMY", 30, 35], ["blood", "ANATOMY", 175, 180], ["PE", "DISEASE", 13, 15], ["Infants", "ORGANISM", 0, 7], ["heart", "ORGAN", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["infants", "ORGANISM", 190, 197], ["Infants", "SPECIES", 0, 7], ["infants", "SPECIES", 190, 197], ["PE", "PROBLEM", 13, 15], ["heart strengthening", "TREATMENT", 30, 49], ["diuresis treatments", "TREATMENT", 54, 73], ["MethodsSimilar methods", "TREATMENT", 87, 109], ["preoperative vital signs", "TEST", 130, 154], ["routine blood tests", "TEST", 167, 186], ["PE", "OBSERVATION", 13, 15], ["heart", "ANATOMY", 30, 35]]], ["After routine preoperative tests, the discarded serum samples were kept in a refrigerator at -80\u00b0C for analysis.Material and MethodsAng-2 levels in serum and PE fluid were measured with enzyme-linked immunosorbent assay (R&D Systems, USA) according to the manufacturer's instructions.Material and MethodsHPMECs (Sciencell, USA) were cultured in endothelial basal medium 2 supplemented with 5 % fetal bovine plasma and growth factors according to the manufacturer's instructions.", [["serum samples", "ANATOMY", 48, 61], ["serum", "ANATOMY", 148, 153], ["PE fluid", "ANATOMY", 158, 166], ["endothelial", "ANATOMY", 345, 356], ["fetal bovine plasma", "ANATOMY", 394, 413], ["serum samples", "ORGANISM_SUBSTANCE", 48, 61], ["MethodsAng-2", "GENE_OR_GENE_PRODUCT", 125, 137], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["PE fluid", "ORGANISM_SUBSTANCE", 158, 166], ["endothelial basal medium 2", "CELL", 345, 371], ["bovine", "ORGANISM", 400, 406], ["plasma", "ORGANISM_SUBSTANCE", 407, 413], ["growth factors", "PROTEIN", 418, 432], ["bovine", "SPECIES", 400, 406], ["bovine", "SPECIES", 400, 406], ["routine preoperative tests", "TEST", 6, 32], ["the discarded serum samples", "TEST", 34, 61], ["analysis", "TEST", 103, 111], ["Material and MethodsAng-2 levels in serum and PE fluid", "TEST", 112, 166], ["enzyme", "TEST", 186, 192], ["immunosorbent assay", "TEST", 200, 219], ["MethodsHPMECs", "TEST", 297, 310], ["5 % fetal bovine plasma and growth factors", "TREATMENT", 390, 432], ["PE", "OBSERVATION", 158, 160], ["fluid", "OBSERVATION", 161, 166]]], ["HPMECs were grown to confluence on glass coverslips and then divided into four groups.", [["HPMECs", "ANATOMY", 0, 6], ["HPMECs", "CELL", 0, 6], ["HPMECs", "CELL_TYPE", 0, 6], ["HPMECs", "TEST", 0, 6], ["glass coverslips", "TREATMENT", 35, 51], ["confluence", "OBSERVATION_MODIFIER", 21, 31], ["glass coverslips", "OBSERVATION", 35, 51]]], ["In group 1, 0.2 ml serum from the control group was added; in group 2, 0.2 ml of human recombinant Ang-2 (R&D Systems) was added; in group 3, 0.2 ml of serum from the PE group was added; and in group 4, 0.2 ml of serum from the PE group and 0.1 ml 10 ng/ml human recombinant Ang-1 (R&D Systems) was added.", [["serum", "ANATOMY", 19, 24], ["serum", "ANATOMY", 152, 157], ["serum", "ANATOMY", 213, 218], ["Ang-2", "CHEMICAL", 99, 104], ["PE", "CHEMICAL", 167, 169], ["PE", "CHEMICAL", 228, 230], ["Ang", "CHEMICAL", 275, 278], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["human", "ORGANISM", 81, 86], ["Ang-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["R&D", "SIMPLE_CHEMICAL", 106, 109], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["PE", "SIMPLE_CHEMICAL", 167, 169], ["serum", "ORGANISM_SUBSTANCE", 213, 218], ["human", "ORGANISM", 257, 262], ["Ang-1", "GENE_OR_GENE_PRODUCT", 275, 280], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 257, 262], ["human recombinant Ang-2 (R&D Systems", "TREATMENT", 81, 117], ["serum from the PE group", "TREATMENT", 213, 236], ["human recombinant Ang-1 (R&D Systems", "TREATMENT", 257, 293], ["PE", "OBSERVATION", 167, 169], ["PE", "OBSERVATION", 228, 230]]], ["All coverslips were incubated for 24 h, and the cells were fixed for 30 min in 4 % paraformaldehyde.", [["coverslips", "ANATOMY", 4, 14], ["cells", "ANATOMY", 48, 53], ["paraformaldehyde", "CHEMICAL", 83, 99], ["cells", "CELL", 48, 53], ["paraformaldehyde", "SIMPLE_CHEMICAL", 83, 99], ["All coverslips", "TREATMENT", 0, 14], ["the cells", "TREATMENT", 44, 53]]], ["The monolayers were incubated overnight with anti-F-actin monoclonal antibody (R&D Systems) and anti-vascular endothelial (VE)-cadherin monoclonal antibody (R&D Systems) at 4\u00b0C. The cells were stained with AlexaFluor 488 goat anti-mouse IgG (Abcam, USA) for F-actin, AlexaFluor 647 goat anti-rabbit IgG (Abcam) for VE-cadherin, and 4\u2032,6-diamidino-2-phenylindole for nuclear staining, and the coverslips were mounted with 95 % glycerol.", [["monolayers", "ANATOMY", 4, 14], ["cells", "ANATOMY", 182, 187], ["nuclear", "ANATOMY", 366, 373], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 332, 361], ["glycerol", "CHEMICAL", 426, 434], ["AlexaFluor 488", "CHEMICAL", 206, 220], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 332, 361], ["glycerol", "CHEMICAL", 426, 434], ["monolayers", "CELL", 4, 14], ["anti-vascular endothelial (VE)-cadherin", "GENE_OR_GENE_PRODUCT", 96, 135], ["cells", "CELL", 182, 187], ["Abcam", "GENE_OR_GENE_PRODUCT", 242, 247], ["F-actin", "GENE_OR_GENE_PRODUCT", 258, 265], ["AlexaFluor 647", "SIMPLE_CHEMICAL", 267, 281], ["Abcam", "GENE_OR_GENE_PRODUCT", 304, 309], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 315, 326], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 332, 361], ["nuclear", "CELLULAR_COMPONENT", 366, 373], ["glycerol", "SIMPLE_CHEMICAL", 426, 434], ["anti-F-actin monoclonal antibody", "PROTEIN", 45, 77], ["R&D Systems", "PROTEIN", 79, 90], ["anti-vascular endothelial (VE)-cadherin monoclonal antibody", "PROTEIN", 96, 155], ["R&D", "PROTEIN", 157, 160], ["AlexaFluor 488 goat anti-mouse IgG", "PROTEIN", 206, 240], ["Abcam, USA", "PROTEIN", 242, 252], ["F-actin", "PROTEIN", 258, 265], ["AlexaFluor 647 goat anti-rabbit IgG", "PROTEIN", 267, 302], ["Abcam", "PROTEIN", 304, 309], ["cadherin", "PROTEIN", 318, 326], ["goat", "SPECIES", 221, 225], ["anti-mouse", "SPECIES", 226, 236], ["goat", "SPECIES", 282, 286], ["anti-rabbit", "SPECIES", 287, 298], ["goat", "SPECIES", 221, 225], ["goat", "SPECIES", 282, 286], ["anti-F-actin monoclonal antibody", "TEST", 45, 77], ["anti-vascular endothelial (VE", "TEST", 96, 125], ["cadherin monoclonal antibody", "TEST", 127, 155], ["AlexaFluor", "TEST", 206, 216], ["anti-mouse IgG", "TEST", 226, 240], ["F-actin", "TEST", 258, 265], ["AlexaFluor", "TEST", 267, 277], ["anti-rabbit IgG", "TEST", 287, 302], ["Abcam", "TEST", 304, 309], ["VE", "TEST", 315, 317], ["cadherin", "TEST", 318, 326], ["diamidino", "TREATMENT", 337, 346], ["phenylindole", "TREATMENT", 349, 361], ["nuclear staining", "PROBLEM", 366, 382], ["the coverslips", "TREATMENT", 388, 402], ["95 % glycerol", "TREATMENT", 421, 434], ["anti-vascular endothelial", "ANATOMY", 96, 121]]], ["The stained cells were observed under a confocal fluorescence microscope to examine any gap formation between the endothelial cells.Material and MethodsThe data are presented as means\u00b1 standard deviation.", [["cells", "ANATOMY", 12, 17], ["endothelial cells", "ANATOMY", 114, 131], ["cells", "CELL", 12, 17], ["endothelial cells", "CELL", 114, 131], ["stained cells", "CELL_TYPE", 4, 17], ["endothelial cells", "CELL_TYPE", 114, 131], ["The stained cells", "PROBLEM", 0, 17], ["a confocal fluorescence microscope", "TEST", 38, 72], ["any gap formation between the endothelial cells", "PROBLEM", 84, 131], ["stained cells", "OBSERVATION", 4, 17], ["endothelial cells", "ANATOMY", 114, 131]]], ["Comparisons among three groups were performed with oneway analysis of variance followed by the Student-Newman-Keuls multiple-range test or Tamhane's T2 test.", [["Tamhane's T2 test", "TEST", 139, 156]]], ["Comparisons between two groups were made with the t-test.", [["the t-test", "TEST", 46, 56]]], ["A P value of <0.05 was considered statistically significant.ResultsA total of 161 infants with critical EV71 infection were admitted to the hospital during the study period.", [["EV71 infection", "DISEASE", 104, 118], ["infants", "ORGANISM", 82, 89], ["EV71", "ORGANISM", 104, 108], ["infants", "SPECIES", 82, 89], ["EV71", "SPECIES", 104, 108], ["A P value", "TEST", 0, 9], ["critical EV71 infection", "PROBLEM", 95, 118], ["the study", "TEST", 156, 165], ["EV71", "OBSERVATION_MODIFIER", 104, 108], ["infection", "OBSERVATION", 109, 118]]], ["Of these, 39 infants had PE.", [["PE", "DISEASE", 25, 27], ["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20], ["PE", "PROBLEM", 25, 27], ["PE", "OBSERVATION", 25, 27]]], ["Among the infants with PE, 19 died and 18 had large amounts of blood-tinged secretions overflowing the tracheal intubation (collected for the analysis).", [["blood", "ANATOMY", 63, 68], ["secretions", "ANATOMY", 76, 86], ["tracheal", "ANATOMY", 103, 111], ["PE", "DISEASE", 23, 25], ["infants", "ORGANISM", 10, 17], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["secretions", "ORGANISM_SUBSTANCE", 76, 86], ["tracheal", "ORGAN", 103, 111], ["infants", "SPECIES", 10, 17], ["PE", "PROBLEM", 23, 25], ["large amounts of blood-tinged secretions", "PROBLEM", 46, 86], ["the tracheal intubation", "TREATMENT", 99, 122], ["the analysis", "TEST", 138, 150], ["PE", "OBSERVATION", 23, 25], ["tracheal", "ANATOMY", 103, 111], ["intubation", "OBSERVATION", 112, 122]]], ["A total of 122 infants in the non-PE group survived.", [["infants", "ORGANISM", 15, 22], ["non-PE", "CANCER", 30, 36], ["infants", "SPECIES", 15, 22]]], ["Compared with infants in the non-PE group, those in the PE group had a higher respiratory rate (37.3 \u00b1 4.2 vs. 52.7 \u00b1 4.4 breaths/min; P<0.001) and a higher heart rate (144.2\u00b117.7 vs. 181.3\u00b1 30.1 beats/min; P<0.001; Table 1 ).", [["respiratory", "ANATOMY", 78, 89], ["heart", "ANATOMY", 157, 162], ["infants", "ORGANISM", 14, 21], ["non-PE", "CANCER", 29, 35], ["heart", "ORGAN", 157, 162], ["infants", "SPECIES", 14, 21], ["a higher respiratory rate", "PROBLEM", 69, 94], ["breaths/min", "TEST", 122, 133], ["P", "TEST", 135, 136], ["a higher heart rate", "TEST", 148, 167], ["beats/min", "TEST", 196, 205], ["P", "TEST", 207, 208], ["PE", "OBSERVATION", 56, 58], ["heart", "ANATOMY", 157, 162]]], ["At admission, the blood pressures of 9 PE infants dropped distinctly or were unobtainable, whereas 30 PE infants showed elevated blood pressure.", [["blood", "ANATOMY", 18, 23], ["blood", "ANATOMY", 129, 134], ["elevated blood pressure", "DISEASE", 120, 143], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["infants", "ORGANISM", 42, 49], ["infants", "ORGANISM", 105, 112], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["infants", "SPECIES", 42, 49], ["infants", "SPECIES", 105, 112], ["the blood pressures", "TEST", 14, 33], ["elevated blood pressure", "PROBLEM", 120, 143], ["PE", "OBSERVATION", 39, 41], ["PE", "OBSERVATION", 102, 104], ["elevated", "OBSERVATION", 120, 128], ["pressure", "OBSERVATION_MODIFIER", 135, 143]]], ["Oxygen saturation (PaO 2 /FiO 2 ) in the PE group was significantly lower than that in the non-PE group (148.4\u00b179.9 vs. 383.1\u00b147.1; P<0.001).", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["non-PE", "CANCER", 91, 97], ["Oxygen saturation", "TEST", 0, 17], ["PaO", "TEST", 19, 22], ["FiO", "TEST", 26, 29], ["P", "TEST", 132, 133], ["PE", "OBSERVATION", 41, 43]]], ["The severity of PE depends on oxygenation failure and was graded as severe, moderate, and mild at PaO 2 /FiO 2 ratios of 100, 200, and 300 mmHg, respectively.", [["PE", "DISEASE", 16, 18], ["PE", "PROBLEM", 16, 18], ["oxygenation failure", "PROBLEM", 30, 49], ["mild at PaO", "PROBLEM", 90, 101], ["FiO 2 ratios", "TEST", 105, 117], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["PE", "OBSERVATION", 16, 18], ["oxygenation failure", "OBSERVATION", 30, 49], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["moderate", "OBSERVATION_MODIFIER", 76, 84], ["mild", "OBSERVATION_MODIFIER", 90, 94]]], ["Nineteen PE infants with PaO 2 /FiO 2 ratios below 200 before ventilation died, and 11 of these infants died within 24 h of hospitalization.", [["PE", "DISEASE", 9, 11], ["infants", "ORGANISM", 12, 19], ["infants", "ORGANISM", 96, 103], ["infants", "SPECIES", 12, 19], ["infants", "SPECIES", 96, 103], ["Nineteen PE", "TEST", 0, 11], ["PaO", "TEST", 25, 28], ["FiO", "TEST", 32, 35], ["ventilation", "TREATMENT", 62, 73], ["PE", "OBSERVATION", 9, 11]]], ["Compared with infants in the non-PE group, surviving infants in the PE group stayed in the intensive care unit for significantly longer periods (3.3\u00b10.5 vs. 7.2\u00b11.2 d; P<0.001).", [["infants", "ORGANISM", 14, 21], ["non-PE", "CANCER", 29, 35], ["infants", "ORGANISM", 53, 60], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 53, 60], ["significantly longer periods", "PROBLEM", 115, 143], ["P", "TEST", 168, 169], ["PE", "OBSERVATION", 68, 70]]], ["The average ventilation time of the surviving infants was 4.2\u00b10.3 d.", [["infants", "ORGANISM", 46, 53], ["infants", "SPECIES", 46, 53], ["average", "OBSERVATION_MODIFIER", 4, 11], ["ventilation", "OBSERVATION_MODIFIER", 12, 23]]], ["Concurrently, 30 infants in the preoperative period of elective inguinal hernia surgery were selected after age-matching with PE infants.", [["inguinal hernia", "ANATOMY", 64, 79], ["PE", "DISEASE", 126, 128], ["infants", "ORGANISM", 17, 24], ["hernia", "ORGAN", 73, 79], ["infants", "ORGANISM", 129, 136], ["infants", "SPECIES", 17, 24], ["infants", "SPECIES", 129, 136], ["elective inguinal hernia surgery", "TREATMENT", 55, 87], ["PE infants", "PROBLEM", 126, 136], ["inguinal", "ANATOMY", 64, 72], ["hernia", "OBSERVATION", 73, 79], ["PE", "OBSERVATION", 126, 128]]], ["Table 1 shows the clinical data for the infants in the three groups.ResultsCSF pressure increased markedly in the PE and non-PE groups but was higher in the former.", [["infants", "ORGANISM", 40, 47], ["ResultsCSF", "SIMPLE_CHEMICAL", 68, 78], ["infants", "SPECIES", 40, 47], ["the clinical data", "TEST", 14, 31], ["ResultsCSF pressure", "TEST", 68, 87], ["the PE", "PROBLEM", 110, 116], ["pressure", "OBSERVATION_MODIFIER", 79, 87], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["markedly", "OBSERVATION_MODIFIER", 98, 106], ["PE", "OBSERVATION", 114, 116], ["higher", "OBSERVATION_MODIFIER", 143, 149]]], ["Nucleated cell counts were normal or moderately increased in the non-PE group and even higher in the PE group, but the difference was not statistically significant.", [["cell", "ANATOMY", 10, 14], ["Nucleated cell", "CELL", 0, 14], ["non-PE", "CANCER", 65, 71], ["Nucleated cell counts", "TEST", 0, 21], ["cell counts", "OBSERVATION", 10, 21], ["normal", "OBSERVATION", 27, 33], ["moderately", "OBSERVATION_MODIFIER", 37, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["PE", "OBSERVATION", 101, 103]]], ["The majority of these nucleated cells were monocytes.", [["nucleated cells", "ANATOMY", 22, 37], ["monocytes", "ANATOMY", 43, 52], ["nucleated cells", "CELL", 22, 37], ["monocytes", "CELL", 43, 52], ["nucleated cells", "CELL_TYPE", 22, 37], ["monocytes", "CELL_TYPE", 43, 52], ["monocytes", "TEST", 43, 52], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["nucleated cells", "OBSERVATION", 22, 37]]], ["CSF protein levels were normal in both groups.ResultsCompared with infants in the non-PE group, those in the PE group had a higher blood sugar level (6.3\u00b11.3 vs. 15.5\u00b1 9.7 mmol/L; P=0.002) and WBC count (10.2\u00b12.8 vs. 22.0\u00b1 9.1\u00d710 9 /L; P<0.001).", [["blood", "ANATOMY", 131, 136], ["WBC", "ANATOMY", 193, 196], ["sugar", "CHEMICAL", 137, 142], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["infants", "ORGANISM", 67, 74], ["non-PE", "CANCER", 82, 88], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["sugar", "SIMPLE_CHEMICAL", 137, 142], ["WBC", "CELL", 193, 196], ["CSF protein", "PROTEIN", 0, 11], ["infants", "SPECIES", 67, 74], ["CSF protein levels", "TEST", 0, 18], ["a higher blood sugar level", "PROBLEM", 122, 148], ["mmol", "TEST", 172, 176], ["P", "TEST", 180, 181], ["WBC count", "TEST", 193, 202], ["\u00b1", "TEST", 208, 209], ["\u00b1", "TEST", 221, 222], ["P", "TEST", 236, 237], ["normal", "OBSERVATION", 24, 30], ["PE", "OBSERVATION", 109, 111]]], ["Serum albumin level was lower in the PE group than in the non-PE group (33.3\u00b14.7 vs. 43.2\u00b1 3.0 g/L; P<0.001).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 6, 13], ["non-PE", "CANCER", 58, 64], ["Serum albumin level", "TEST", 0, 19], ["\u00b1", "TEST", 89, 90], ["g", "TEST", 95, 96], ["P", "TEST", 100, 101], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["PE", "OBSERVATION", 37, 39]]], ["No statistically significant differences were found in WBC count or blood sugar and serum albumin levels between the non-PE and control groups.ResultsPE fluid was acquired from only 18 infants with severe PE.", [["WBC", "ANATOMY", 55, 58], ["blood", "ANATOMY", 68, 73], ["serum", "ANATOMY", 84, 89], ["ResultsPE fluid", "ANATOMY", 143, 158], ["PE", "DISEASE", 205, 207], ["sugar", "CHEMICAL", 74, 79], ["WBC", "CELL", 55, 58], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["sugar", "SIMPLE_CHEMICAL", 74, 79], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["albumin", "GENE_OR_GENE_PRODUCT", 90, 97], ["infants", "ORGANISM", 185, 192], ["serum albumin", "PROTEIN", 84, 97], ["infants", "SPECIES", 185, 192], ["WBC count", "TEST", 55, 64], ["blood sugar", "TEST", 68, 79], ["serum albumin levels", "TEST", 84, 104], ["the non-PE", "TEST", 113, 123], ["ResultsPE fluid", "TEST", 143, 158], ["severe PE", "PROBLEM", 198, 207], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["fluid", "OBSERVATION", 153, 158], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["PE", "OBSERVATION", 205, 207]]], ["The total protein, albumin, and lactate dehydrogenase levels of the fluid are given in Table 2 .", [["fluid", "ANATOMY", 68, 73], ["lactate", "CHEMICAL", 32, 39], ["lactate", "CHEMICAL", 32, 39], ["albumin", "GENE_OR_GENE_PRODUCT", 19, 26], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 32, 53], ["fluid", "ORGANISM_SUBSTANCE", 68, 73], ["albumin", "PROTEIN", 19, 26], ["lactate dehydrogenase", "PROTEIN", 32, 53], ["The total protein", "TEST", 0, 17], ["albumin", "TEST", 19, 26], ["lactate dehydrogenase levels", "TEST", 32, 60], ["fluid", "OBSERVATION", 68, 73]]], ["The PE fluid-to-serum (P/S) ratio of total protein was 0.9\u00b10.2, and all P/S ratios of albumin were 1.0\u00b10.3.ResultsThe Ang-2 levels in the non-PE group were higher than those in the control group, although the difference was not statistically significant (333.2 \u00b1 79.7 pg/ml vs. 199.9 \u00b1 26.7 pg/ml; P=0.115; Fig. 1 ).", [["serum", "ANATOMY", 16, 21], ["Ang", "CHEMICAL", 118, 121], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["albumin", "GENE_OR_GENE_PRODUCT", 86, 93], ["Ang-2", "GENE_OR_GENE_PRODUCT", 118, 123], ["non-PE", "CANCER", 138, 144], ["The PE fluid", "TEST", 0, 12], ["serum (P/S", "TEST", 16, 26], ["total protein", "TEST", 37, 50], ["all P/S ratios", "TEST", 68, 82], ["albumin", "TEST", 86, 93], ["The Ang-2 levels", "TEST", 114, 130], ["P", "TEST", 298, 299], ["PE", "OBSERVATION", 4, 6], ["fluid", "OBSERVATION", 7, 12]]], ["Ang-2 levels in the PE group (2819.2\u00b1908.7 pg/ml) were higher than those in the non-PE and control groups (P<0.001).", [["Ang", "CHEMICAL", 0, 3], ["Ang-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ang", "TEST", 0, 3], ["the PE group", "TEST", 16, 28], ["PE", "OBSERVATION", 20, 22]]], ["Compared with Ang-2 levels in the serum, those in the PE fluid were similar or slightly higher ( Table 2) .ResultsAfter reaching confluence, the HPMEC monolayers were incubated for 24 h with low levels of serum Ang-2 (121.6 pg/ ml) from healthy infants, and the links between the HPMECs were observed to be intact (Fig. 2a-c) .", [["serum", "ANATOMY", 34, 39], ["PE fluid", "ANATOMY", 54, 62], ["HPMEC monolayers", "ANATOMY", 145, 161], ["serum", "ANATOMY", 205, 210], ["HPMECs", "ANATOMY", 280, 286], ["Ang", "CHEMICAL", 14, 17], ["Ang", "CHEMICAL", 211, 214], ["Ang-2", "GENE_OR_GENE_PRODUCT", 14, 19], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["HPMEC monolayers", "CELL", 145, 161], ["serum", "ORGANISM_SUBSTANCE", 205, 210], ["Ang-2", "GENE_OR_GENE_PRODUCT", 211, 216], ["infants", "ORGANISM", 245, 252], ["HPMECs", "CELL", 280, 286], ["Ang", "PROTEIN", 14, 17], ["HPMEC monolayers", "CELL_LINE", 145, 161], ["HPMECs", "CELL_TYPE", 280, 286], ["infants", "SPECIES", 245, 252], ["Ang", "TEST", 14, 17], ["the serum", "TEST", 30, 39], ["the PE fluid", "TEST", 50, 62], ["the HPMEC monolayers", "TEST", 141, 161], ["serum Ang", "TEST", 205, 214], ["PE", "OBSERVATION", 54, 56], ["fluid", "OBSERVATION", 57, 62], ["slightly", "OBSERVATION_MODIFIER", 79, 87], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["confluence", "OBSERVATION_MODIFIER", 129, 139], ["intact", "OBSERVATION", 307, 313]]], ["When the HPMEC monolayers were incubated with recombinant human Ang-2 (final concentration, 4414.4 pg/ml) from PE infants, actin stress fibers were stained, whereas VE-cadherin staining was attenuated, and endothelial gaps were noted (Fig. 2d-f ).", [["HPMEC monolayers", "ANATOMY", 9, 25], ["stress fibers", "ANATOMY", 129, 142], ["endothelial", "ANATOMY", 206, 217], ["Ang", "CHEMICAL", 64, 67], ["HPMEC monolayers", "CELL", 9, 25], ["human", "ORGANISM", 58, 63], ["Ang-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["infants", "ORGANISM", 114, 121], ["actin", "GENE_OR_GENE_PRODUCT", 123, 128], ["fibers", "CELLULAR_COMPONENT", 136, 142], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 165, 176], ["endothelial", "CELL", 206, 217], ["HPMEC monolayers", "CELL_LINE", 9, 25], ["actin", "PROTEIN", 123, 128], ["cadherin", "PROTEIN", 168, 176], ["human", "SPECIES", 58, 63], ["infants", "SPECIES", 114, 121], ["human", "SPECIES", 58, 63], ["the HPMEC monolayers", "TEST", 5, 25], ["recombinant human Ang", "TREATMENT", 46, 67], ["PE", "PROBLEM", 111, 113], ["actin stress fibers", "TEST", 123, 142], ["VE-cadherin staining", "TEST", 165, 185], ["attenuated", "PROBLEM", 190, 200], ["endothelial gaps", "TEST", 206, 222], ["PE", "OBSERVATION", 111, 113]]], ["The same effects were observed when recombinant Ang-2 was substituted with serum from PE infants for incubation with the HPMEC monolayers (Ang-2 concentration adjusted to 4414.4 pg/ml; Fig. 2g -i).", [["serum", "ANATOMY", 75, 80], ["HPMEC monolayers", "ANATOMY", 121, 137], ["Ang", "CHEMICAL", 48, 51], ["Ang", "CHEMICAL", 139, 142], ["Ang-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["infants", "ORGANISM", 89, 96], ["HPMEC monolayers", "CELL", 121, 137], ["Ang-2", "GENE_OR_GENE_PRODUCT", 139, 144], ["HPMEC monolayers", "CELL_LINE", 121, 137], ["infants", "SPECIES", 89, 96], ["serum from PE", "TEST", 75, 88], ["incubation", "TREATMENT", 101, 111], ["the HPMEC monolayers", "TREATMENT", 117, 137], ["PE", "OBSERVATION", 86, 88]]], ["When the HPMEC monolayers were simultaneously incubated with recombinant human Ang-1 (10 ng/ml) and serum from PE infants (Ang-2, 4414.4 pg/ ml), a significant attenuation in stress fiber formation and maintenance of VE-cadherin cell junctions were noted (Fig. 2j-l) .", [["HPMEC monolayers", "ANATOMY", 9, 25], ["serum", "ANATOMY", 100, 105], ["stress fiber", "ANATOMY", 175, 187], ["VE-cadherin cell junctions", "ANATOMY", 217, 243], ["Ang", "CHEMICAL", 79, 82], ["Ang", "CHEMICAL", 123, 126], ["HPMEC monolayers", "CELL", 9, 25], ["human", "ORGANISM", 73, 78], ["Ang-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["Ang-2", "GENE_OR_GENE_PRODUCT", 123, 128], ["stress fiber", "CELLULAR_COMPONENT", 175, 187], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 217, 228], ["HPMEC monolayers", "CELL_LINE", 9, 25], ["recombinant human Ang-1", "PROTEIN", 61, 84], ["human", "SPECIES", 73, 78], ["infants", "SPECIES", 114, 121], ["human", "SPECIES", 73, 78], ["the HPMEC monolayers", "TEST", 5, 25], ["recombinant human Ang", "TREATMENT", 61, 82], ["serum from PE", "TEST", 100, 113], ["Ang", "TEST", 123, 126], ["a significant attenuation in stress fiber formation", "PROBLEM", 146, 197], ["VE-cadherin cell junctions", "TREATMENT", 217, 243], ["PE", "OBSERVATION", 111, 113], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["attenuation", "OBSERVATION_MODIFIER", 160, 171], ["stress fiber formation", "OBSERVATION", 175, 197], ["cell junctions", "OBSERVATION", 229, 243]]], ["The links between the endothelial cells were relatively intact without gaps.DiscussionThe pathogenesis of PE can be subcategorized into two mechanisms: elevated pulmonary hydrostatic pressure and increased pulmonary capillary permeability; the treatment for each type differs accordingly.", [["endothelial cells", "ANATOMY", 22, 39], ["pulmonary", "ANATOMY", 161, 170], ["pulmonary capillary", "ANATOMY", 206, 225], ["PE", "DISEASE", 106, 108], ["endothelial cells", "CELL", 22, 39], ["pulmonary", "ORGAN", 161, 170], ["pulmonary capillary", "TISSUE", 206, 225], ["endothelial cells", "CELL_TYPE", 22, 39], ["PE", "PROBLEM", 106, 108], ["elevated pulmonary hydrostatic pressure", "PROBLEM", 152, 191], ["increased pulmonary capillary permeability", "PROBLEM", 196, 238], ["the treatment", "TREATMENT", 240, 253], ["endothelial cells", "ANATOMY", 22, 39], ["PE", "OBSERVATION", 106, 108], ["elevated", "OBSERVATION", 152, 160], ["pulmonary", "ANATOMY", 161, 170], ["hydrostatic pressure", "OBSERVATION", 171, 191], ["increased", "OBSERVATION_MODIFIER", 196, 205], ["pulmonary", "ANATOMY", 206, 215], ["capillary permeability", "OBSERVATION", 216, 238]]], ["The mechanism of EV71-induced PE remains unclear.", [["EV71", "DISEASE", 17, 21], ["PE", "DISEASE", 30, 32], ["EV71", "ORGANISM", 17, 21], ["PE", "MULTI-TISSUE_STRUCTURE", 30, 32], ["EV71", "PROBLEM", 17, 21], ["PE", "PROBLEM", 30, 32], ["EV71", "OBSERVATION", 17, 21], ["PE", "OBSERVATION", 30, 32]]], ["One study reported that in PE caused by elevated pulmonary hydrostatic pressure, the P/S ratio of total protein is less than 0.60, whereas the P/S ratio of albumin is less than 0.7 [12] .", [["pulmonary", "ANATOMY", 49, 58], ["PE", "DISEASE", 27, 29], ["pulmonary", "ORGAN", 49, 58], ["albumin", "GENE_OR_GENE_PRODUCT", 156, 163], ["albumin", "PROTEIN", 156, 163], ["One study", "TEST", 0, 9], ["PE", "PROBLEM", 27, 29], ["elevated pulmonary hydrostatic pressure", "PROBLEM", 40, 79], ["the P/S ratio", "TEST", 81, 94], ["total protein", "TEST", 98, 111], ["the P/S ratio", "TEST", 139, 152], ["albumin", "TEST", 156, 163], ["PE", "OBSERVATION", 27, 29], ["elevated", "OBSERVATION", 40, 48], ["pulmonary", "ANATOMY", 49, 58], ["hydrostatic pressure", "OBSERVATION", 59, 79]]], ["In the present study, the authors found that the P/S ratio of total protein was 0.9\u00b10.2, and the P/S ratios of albumin were greater than 1.0\u00b10.3, which indicated that EV71-induced PE is associated with increased pulmonary capillary permeability.", [["pulmonary capillary", "ANATOMY", 212, 231], ["EV71", "DISEASE", 167, 171], ["PE", "DISEASE", 180, 182], ["albumin", "GENE_OR_GENE_PRODUCT", 111, 118], ["EV71", "ORGANISM", 167, 171], ["pulmonary capillary", "TISSUE", 212, 231], ["albumin", "PROTEIN", 111, 118], ["the P/S ratio", "TEST", 45, 58], ["total protein", "TEST", 62, 75], ["the P/S ratios", "TEST", 93, 107], ["albumin", "TEST", 111, 118], ["EV71", "PROBLEM", 167, 171], ["induced PE", "PROBLEM", 172, 182], ["increased pulmonary capillary permeability", "PROBLEM", 202, 244], ["EV71", "OBSERVATION", 167, 171], ["PE", "OBSERVATION", 180, 182], ["associated with", "UNCERTAINTY", 186, 201], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["pulmonary", "ANATOMY", 212, 221], ["capillary permeability", "OBSERVATION", 222, 244]]], ["Wu et al. used pulmonary artery catheterization to monitor pulmonary circulation hemodynamics in 5 infants with EV71-induced PE and found that pulmonary arterial pressure and pulmonary artery wedge pressure were normal or slightly elevated [3] , which suggested that PE is not caused by elevated hydrostatic pressure of pulmonary capillaries.", [["pulmonary artery", "ANATOMY", 15, 31], ["pulmonary", "ANATOMY", 59, 68], ["pulmonary arterial", "ANATOMY", 143, 161], ["pulmonary artery", "ANATOMY", 175, 191], ["pulmonary capillaries", "ANATOMY", 320, 341], ["EV71", "DISEASE", 112, 116], ["PE", "DISEASE", 125, 127], ["PE", "DISEASE", 267, 269], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 15, 31], ["pulmonary circulation", "MULTI-TISSUE_STRUCTURE", 59, 80], ["infants", "ORGANISM", 99, 106], ["EV71", "ORGANISM", 112, 116], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 143, 161], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 175, 191], ["wedge", "MULTI-TISSUE_STRUCTURE", 192, 197], ["pulmonary capillaries", "MULTI-TISSUE_STRUCTURE", 320, 341], ["infants", "SPECIES", 99, 106], ["pulmonary artery catheterization", "TREATMENT", 15, 47], ["pulmonary circulation hemodynamics", "TEST", 59, 93], ["EV71", "PROBLEM", 112, 116], ["PE", "PROBLEM", 125, 127], ["pulmonary arterial pressure", "TEST", 143, 170], ["pulmonary artery wedge pressure", "TEST", 175, 206], ["slightly elevated", "PROBLEM", 222, 239], ["PE", "PROBLEM", 267, 269], ["elevated hydrostatic pressure of pulmonary capillaries", "PROBLEM", 287, 341], ["pulmonary artery", "ANATOMY", 15, 31], ["catheterization", "OBSERVATION", 32, 47], ["pulmonary", "ANATOMY", 59, 68], ["PE", "OBSERVATION", 125, 127], ["pulmonary arterial", "ANATOMY", 143, 161], ["pressure", "ANATOMY_MODIFIER", 162, 170], ["pulmonary artery", "ANATOMY", 175, 191], ["wedge pressure", "OBSERVATION", 192, 206], ["slightly", "OBSERVATION_MODIFIER", 222, 230], ["elevated", "OBSERVATION_MODIFIER", 231, 239], ["PE", "OBSERVATION", 267, 269], ["not caused", "UNCERTAINTY", 273, 283], ["elevated", "OBSERVATION", 287, 295], ["hydrostatic pressure", "OBSERVATION", 296, 316], ["pulmonary capillaries", "ANATOMY", 320, 341]]], ["The present clinical data showed that infants with PE had noticeable tachycardia, high blood pressure, and other signs of symptomatic nervous system; however, myocardial enzymogram, the images of heart and left ventricle ejection fraction were basically normal.", [["blood", "ANATOMY", 87, 92], ["nervous system", "ANATOMY", 134, 148], ["myocardial", "ANATOMY", 159, 169], ["heart", "ANATOMY", 196, 201], ["left ventricle", "ANATOMY", 206, 220], ["PE", "DISEASE", 51, 53], ["tachycardia", "DISEASE", 69, 80], ["high blood pressure", "DISEASE", 82, 101], ["infants", "ORGANISM", 38, 45], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["nervous system", "ANATOMICAL_SYSTEM", 134, 148], ["myocardial", "MULTI-TISSUE_STRUCTURE", 159, 169], ["heart", "ORGAN", 196, 201], ["ventricle", "MULTI-TISSUE_STRUCTURE", 211, 220], ["infants", "SPECIES", 38, 45], ["The present clinical data", "TEST", 0, 25], ["PE", "PROBLEM", 51, 53], ["noticeable tachycardia", "PROBLEM", 58, 80], ["high blood pressure", "PROBLEM", 82, 101], ["symptomatic nervous system", "PROBLEM", 122, 148], ["myocardial enzymogram", "TEST", 159, 180], ["the images of heart and left ventricle ejection fraction", "TEST", 182, 238], ["PE", "OBSERVATION", 51, 53], ["symptomatic", "OBSERVATION", 122, 133], ["nervous system", "ANATOMY", 134, 148], ["heart", "ANATOMY", 196, 201], ["left ventricle", "ANATOMY", 206, 220], ["normal", "OBSERVATION", 254, 260]]], ["Treatments such as heart strengthening and diuresis had no effect.", [["heart", "ANATOMY", 19, 24], ["heart", "ORGAN", 19, 24], ["Treatments", "TREATMENT", 0, 10], ["heart strengthening", "TREATMENT", 19, 38], ["diuresis", "TREATMENT", 43, 51], ["heart", "ANATOMY", 19, 24]]], ["Therefore, none of these clinical data support the hypothesis that EV71induced PE is associated with elevated hydrostatic pressure.DiscussionOther studies have shown that Ang-2 is related to increased vascular permeability [9, 13] .", [["vascular", "ANATOMY", 201, 209], ["PE", "DISEASE", 79, 81], ["Ang", "CHEMICAL", 171, 174], ["Ang-2", "GENE_OR_GENE_PRODUCT", 171, 176], ["vascular", "MULTI-TISSUE_STRUCTURE", 201, 209], ["these clinical data", "TEST", 19, 38], ["EV71induced PE", "PROBLEM", 67, 81], ["elevated hydrostatic pressure", "PROBLEM", 101, 130], ["DiscussionOther studies", "TEST", 131, 154], ["increased vascular permeability", "PROBLEM", 191, 222], ["PE", "OBSERVATION", 79, 81], ["elevated", "OBSERVATION_MODIFIER", 101, 109], ["hydrostatic pressure", "OBSERVATION", 110, 130], ["increased", "OBSERVATION_MODIFIER", 191, 200], ["vascular", "ANATOMY", 201, 209], ["permeability", "OBSERVATION_MODIFIER", 210, 222]]], ["In ARDS, in which vascular leakage is the major pathophysiological basis, Ang-2 is associated with development and prognosis [14, 15] .", [["vascular", "ANATOMY", 18, 26], ["ARDS", "DISEASE", 3, 7], ["Ang", "CHEMICAL", 74, 77], ["vascular", "MULTI-TISSUE_STRUCTURE", 18, 26], ["Ang-2", "GENE_OR_GENE_PRODUCT", 74, 79], ["ARDS", "PROBLEM", 3, 7], ["ARDS", "OBSERVATION", 3, 7], ["vascular", "ANATOMY", 18, 26], ["leakage", "OBSERVATION", 27, 34]]], ["In the present study, the authors measured the levels of Ang-2 in the serum and PE fluid and found that compared with the Ang-2 serum levels in the non-PE and control groups, that in the PE group was significantly higher, and the Ang-2 level in the PE fluid was similar to or slightly higher than that in the serum, which indicated that Ang-2 may be related to the development of EV71-induced PE.DiscussionTo confirm the association between Ang-2 and EV71induced PE, the authors cultivated human recombinant Ang-2 with HPMECs and found that Ang-2 increased F-actin staining, whereas VE-cadherin staining was reduced and gaps in the intracellular junctions were noted.", [["serum", "ANATOMY", 70, 75], ["PE fluid", "ANATOMY", 80, 88], ["serum", "ANATOMY", 128, 133], ["non-PE", "ANATOMY", 148, 154], ["PE fluid", "ANATOMY", 249, 257], ["serum", "ANATOMY", 309, 314], ["HPMECs", "ANATOMY", 519, 525], ["intracellular junctions", "ANATOMY", 632, 655], ["Ang", "CHEMICAL", 57, 60], ["Ang", "CHEMICAL", 122, 125], ["PE", "CHEMICAL", 187, 189], ["Ang", "CHEMICAL", 230, 233], ["Ang", "CHEMICAL", 337, 340], ["EV71", "DISEASE", 380, 384], ["PE", "DISEASE", 393, 395], ["Ang", "CHEMICAL", 441, 444], ["Ang", "CHEMICAL", 508, 511], ["Ang", "CHEMICAL", 541, 544], ["Ang-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["PE fluid", "ORGANISM_SUBSTANCE", 80, 88], ["Ang-2", "GENE_OR_GENE_PRODUCT", 122, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["Ang-2", "GENE_OR_GENE_PRODUCT", 230, 235], ["serum", "ORGANISM_SUBSTANCE", 309, 314], ["Ang-2", "GENE_OR_GENE_PRODUCT", 337, 342], ["EV71", "ORGANISM", 380, 384], ["Ang-2", "GENE_OR_GENE_PRODUCT", 441, 446], ["human", "ORGANISM", 490, 495], ["Ang-2", "GENE_OR_GENE_PRODUCT", 508, 513], ["HPMECs", "CELL", 519, 525], ["Ang-2", "GENE_OR_GENE_PRODUCT", 541, 546], ["F-actin", "GENE_OR_GENE_PRODUCT", 557, 564], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 583, 594], ["intracellular junctions", "CELLULAR_COMPONENT", 632, 655], ["Ang-2", "PROTEIN", 57, 62], ["human recombinant Ang-2", "PROTEIN", 490, 513], ["HPMECs", "CELL_TYPE", 519, 525], ["F-actin", "PROTEIN", 557, 564], ["cadherin", "PROTEIN", 586, 594], ["human", "SPECIES", 490, 495], ["EV71", "SPECIES", 380, 384], ["human", "SPECIES", 490, 495], ["Ang", "TEST", 57, 60], ["the serum and PE fluid", "TEST", 66, 88], ["the Ang", "TEST", 118, 125], ["serum levels", "TEST", 128, 140], ["the Ang", "TEST", 226, 233], ["the PE fluid", "TEST", 245, 257], ["the serum", "TEST", 305, 314], ["EV71", "PROBLEM", 380, 384], ["induced PE", "PROBLEM", 385, 395], ["Ang", "TEST", 441, 444], ["EV71induced PE", "PROBLEM", 451, 465], ["HPMECs", "TREATMENT", 519, 525], ["Ang", "TEST", 541, 544], ["increased F-actin staining", "PROBLEM", 547, 573], ["VE-cadherin staining", "TEST", 583, 603], ["PE", "OBSERVATION", 80, 82], ["fluid", "OBSERVATION", 83, 88], ["PE", "OBSERVATION", 187, 189], ["significantly", "OBSERVATION_MODIFIER", 200, 213], ["higher", "OBSERVATION_MODIFIER", 214, 220], ["PE", "OBSERVATION", 249, 251], ["fluid", "OBSERVATION", 252, 257], ["slightly", "OBSERVATION_MODIFIER", 276, 284], ["higher", "OBSERVATION_MODIFIER", 285, 291], ["EV71", "OBSERVATION", 380, 384], ["PE", "OBSERVATION", 393, 395], ["PE", "OBSERVATION", 463, 465], ["increased", "OBSERVATION_MODIFIER", 547, 556], ["F-actin staining", "OBSERVATION", 557, 573], ["reduced", "OBSERVATION_MODIFIER", 608, 615], ["intracellular junctions", "ANATOMY", 632, 655]]], ["The endothelial cells incubated with serum from infants with PE showed the same results; however, these changes were not noted in cells incubated with serum from control group infants.", [["endothelial cells", "ANATOMY", 4, 21], ["serum", "ANATOMY", 37, 42], ["cells", "ANATOMY", 130, 135], ["serum", "ANATOMY", 151, 156], ["endothelial cells", "CELL", 4, 21], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["infants", "ORGANISM", 48, 55], ["cells", "CELL", 130, 135], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["infants", "ORGANISM", 176, 183], ["endothelial cells", "CELL_TYPE", 4, 21], ["infants", "SPECIES", 48, 55], ["infants", "SPECIES", 176, 183], ["The endothelial cells", "TEST", 0, 21], ["serum from infants", "TEST", 37, 55], ["PE", "PROBLEM", 61, 63], ["endothelial cells", "OBSERVATION", 4, 21], ["PE", "OBSERVATION", 61, 63]]], ["Endothelial cells normally connect with one another through cell adhesion molecules [16] , and VE-cadherin is one of the adhesive proteins necessary for maintaining vascular integrity.", [["Endothelial cells", "ANATOMY", 0, 17], ["cell", "ANATOMY", 60, 64], ["vascular", "ANATOMY", 165, 173], ["Endothelial cells", "CELL", 0, 17], ["cell", "CELL", 60, 64], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 95, 106], ["vascular", "MULTI-TISSUE_STRUCTURE", 165, 173], ["Endothelial cells", "CELL_TYPE", 0, 17], ["cell adhesion molecules", "PROTEIN", 60, 83], ["VE", "PROTEIN", 95, 97], ["cadherin", "PROTEIN", 98, 106], ["adhesive proteins", "PROTEIN", 121, 138], ["Endothelial cells", "PROBLEM", 0, 17], ["cell adhesion molecules", "TEST", 60, 83], ["VE", "TEST", 95, 97], ["the adhesive proteins", "TREATMENT", 117, 138], ["vascular", "ANATOMY", 165, 173], ["integrity", "OBSERVATION", 174, 183]]], ["The VE-cadherin molecule is related to F-actin.", [["VE-cadherin", "GENE_OR_GENE_PRODUCT", 4, 15], ["F-actin", "GENE_OR_GENE_PRODUCT", 39, 46], ["VE-cadherin molecule", "PROTEIN", 4, 24], ["F-actin", "PROTEIN", 39, 46], ["related to", "UNCERTAINTY", 28, 38], ["F-actin", "OBSERVATION_MODIFIER", 39, 46]]], ["When inflammatory mediators stimulate the endothelium, F-actin rearranges and centripetal tension increases.", [["endothelium", "ANATOMY", 42, 53], ["F-actin", "ANATOMY", 55, 62], ["endothelium", "TISSUE", 42, 53], ["F-actin", "GENE_OR_GENE_PRODUCT", 55, 62], ["inflammatory mediators", "PROTEIN", 5, 27], ["F-actin", "PROTEIN", 55, 62], ["inflammatory mediators", "PROBLEM", 5, 27], ["centripetal tension increases", "PROBLEM", 78, 107], ["endothelium", "ANATOMY", 42, 53], ["F-actin rearranges", "OBSERVATION", 55, 73], ["centripetal", "OBSERVATION_MODIFIER", 78, 89], ["tension", "OBSERVATION_MODIFIER", 90, 97], ["increases", "OBSERVATION_MODIFIER", 98, 107]]], ["Changes in the F-actin skeleton affect the endothelial connections and lead to the formation of gaps in the endothelium, thereby increasing permeability [17] .", [["F-actin skeleton", "ANATOMY", 15, 31], ["endothelial", "ANATOMY", 43, 54], ["endothelium", "ANATOMY", 108, 119], ["F-actin", "GENE_OR_GENE_PRODUCT", 15, 22], ["endothelial", "CELL", 43, 54], ["endothelium", "TISSUE", 108, 119], ["F-actin", "PROTEIN", 15, 22], ["Changes in the F-actin skeleton", "PROBLEM", 0, 31], ["increasing permeability", "PROBLEM", 129, 152], ["F-actin skeleton", "OBSERVATION", 15, 31], ["endothelial", "ANATOMY", 43, 54], ["gaps", "OBSERVATION", 96, 100], ["endothelium", "ANATOMY", 108, 119], ["increasing", "OBSERVATION_MODIFIER", 129, 139], ["permeability", "OBSERVATION_MODIFIER", 140, 152]]], ["Several inflammatory cytokines-including granulocyte colony-stimulating factor, interleukin (IL)-6, IL-10, IL-13, and interferon-\u03b3-that can increase endothelial permeability are elevated in the serum of EV71-infected infants [18] [19] [20] .", [["endothelial", "ANATOMY", 149, 160], ["serum", "ANATOMY", 194, 199], ["EV71-infected", "DISEASE", 203, 216], ["granulocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 41, 78], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 80, 98], ["IL-10", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-13", "GENE_OR_GENE_PRODUCT", 107, 112], ["interferon-\u03b3-", "GENE_OR_GENE_PRODUCT", 118, 131], ["endothelial", "TISSUE", 149, 160], ["serum", "ORGANISM_SUBSTANCE", 194, 199], ["EV71", "ORGANISM", 203, 207], ["infants", "ORGANISM", 217, 224], ["inflammatory cytokines", "PROTEIN", 8, 30], ["granulocyte colony-stimulating factor", "PROTEIN", 41, 78], ["interleukin (IL)-6", "PROTEIN", 80, 98], ["IL-13", "PROTEIN", 107, 112], ["interferon", "PROTEIN", 118, 128], ["infants", "SPECIES", 217, 224], ["EV71", "SPECIES", 203, 207], ["Several inflammatory cytokines", "PROBLEM", 0, 30], ["granulocyte colony", "TEST", 41, 59], ["interleukin (IL)", "TREATMENT", 80, 96], ["IL", "TEST", 100, 102], ["IL", "TREATMENT", 107, 109], ["interferon", "TREATMENT", 118, 128], ["endothelial permeability", "TEST", 149, 173], ["elevated", "PROBLEM", 178, 186], ["the serum", "TEST", 190, 199], ["EV71", "TEST", 203, 207], ["inflammatory", "OBSERVATION_MODIFIER", 8, 20], ["cytokines", "OBSERVATION", 21, 30], ["granulocyte colony", "OBSERVATION", 41, 59]]], ["To exclude the effects of other factors, the authors incubated HPMECs with Ang-1, the natural antagonist of Ang-2, combined with infected infant serum and found that F-actin expression decreased, VEcadherin staining increased, and cell connections remained intact.", [["HPMECs", "ANATOMY", 63, 69], ["serum", "ANATOMY", 145, 150], ["cell", "ANATOMY", 231, 235], ["Ang", "CHEMICAL", 75, 78], ["Ang-2", "CHEMICAL", 108, 113], ["HPMECs", "CELL", 63, 69], ["Ang-1", "GENE_OR_GENE_PRODUCT", 75, 80], ["Ang-2", "GENE_OR_GENE_PRODUCT", 108, 113], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["F-actin", "GENE_OR_GENE_PRODUCT", 166, 173], ["VEcadherin", "GENE_OR_GENE_PRODUCT", 196, 206], ["cell", "CELL", 231, 235], ["HPMECs", "CELL_TYPE", 63, 69], ["F-actin", "PROTEIN", 166, 173], ["VEcadherin", "PROTEIN", 196, 206], ["infant", "SPECIES", 138, 144], ["other factors", "PROBLEM", 26, 39], ["Ang", "TEST", 75, 78], ["infected infant serum", "TEST", 129, 150], ["F-actin expression", "PROBLEM", 166, 184], ["VEcadherin staining", "PROBLEM", 196, 215], ["F-actin expression", "OBSERVATION", 166, 184], ["decreased", "OBSERVATION_MODIFIER", 185, 194], ["increased", "OBSERVATION_MODIFIER", 216, 225], ["cell connections", "OBSERVATION", 231, 247], ["intact", "OBSERVATION", 257, 263]]], ["The present experimental results indicated that Ang-2 from infected infant serum played a central role in damaging the endothelial connection, and this damage may be the key contributory factor in the development of PE.DiscussionMeanwhile, it is also indicated that some inflammatory mediators in the serum of EV71-infected PE infants had high expressions, and several inflammatory cytokines could increase the vascular permeability.", [["serum", "ANATOMY", 75, 80], ["endothelial", "ANATOMY", 119, 130], ["serum", "ANATOMY", 301, 306], ["vascular", "ANATOMY", 411, 419], ["Ang", "CHEMICAL", 48, 51], ["PE", "DISEASE", 216, 218], ["Ang-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["infant", "ORGANISM", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["endothelial", "CELL", 119, 130], ["PE", "PATHOLOGICAL_FORMATION", 216, 218], ["serum", "ORGANISM_SUBSTANCE", 301, 306], ["EV71", "ORGANISM", 310, 314], ["PE infants", "ORGANISM", 324, 334], ["vascular", "MULTI-TISSUE_STRUCTURE", 411, 419], ["inflammatory mediators", "PROTEIN", 271, 293], ["inflammatory cytokines", "PROTEIN", 369, 391], ["infant", "SPECIES", 68, 74], ["infants", "SPECIES", 327, 334], ["EV71", "SPECIES", 310, 314], ["Ang", "TEST", 48, 51], ["this damage", "PROBLEM", 147, 158], ["PE", "PROBLEM", 216, 218], ["some inflammatory mediators", "PROBLEM", 266, 293], ["the serum", "TEST", 297, 306], ["EV71", "TEST", 310, 314], ["infected PE", "PROBLEM", 315, 326], ["high expressions", "PROBLEM", 339, 355], ["several inflammatory cytokines", "PROBLEM", 361, 391], ["the vascular permeability", "PROBLEM", 407, 432], ["endothelial", "ANATOMY", 119, 130], ["PE", "OBSERVATION", 216, 218], ["inflammatory", "OBSERVATION_MODIFIER", 271, 283], ["infected", "OBSERVATION_MODIFIER", 315, 323], ["PE", "OBSERVATION", 324, 326], ["high expressions", "OBSERVATION_MODIFIER", 339, 355], ["inflammatory", "OBSERVATION_MODIFIER", 369, 381], ["cytokines", "OBSERVATION", 382, 391], ["vascular", "ANATOMY", 411, 419], ["permeability", "OBSERVATION_MODIFIER", 420, 432]]], ["Thus, further studies are needed to verify the effects of elevated Ang-2 levels in PE fluid and serum on vascular leakage in EV71-induced PE.ConclusionsThe results of this study showed that the PE fluid of EV71induced PE infants is rich in proteins and that the serum of PE infants break the cell connections of HPMECs, which implicates increased vascular leakage in the pathogenesis of EV71-induced PE.", [["PE fluid", "ANATOMY", 83, 91], ["serum", "ANATOMY", 96, 101], ["vascular", "ANATOMY", 105, 113], ["PE fluid", "ANATOMY", 194, 202], ["serum", "ANATOMY", 262, 267], ["cell", "ANATOMY", 292, 296], ["HPMECs", "ANATOMY", 312, 318], ["vascular", "ANATOMY", 347, 355], ["Ang", "CHEMICAL", 67, 70], ["EV71", "DISEASE", 125, 129], ["PE", "DISEASE", 138, 140], ["PE", "CHEMICAL", 218, 220], ["EV71", "DISEASE", 387, 391], ["PE", "DISEASE", 400, 402], ["Ang-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["PE fluid", "ORGANISM_SUBSTANCE", 83, 91], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["vascular", "MULTI-TISSUE_STRUCTURE", 105, 113], ["EV71", "ORGANISM", 125, 129], ["infants", "ORGANISM", 221, 228], ["serum", "ORGANISM_SUBSTANCE", 262, 267], ["PE infants", "ORGANISM", 271, 281], ["cell", "CELL", 292, 296], ["HPMECs", "CELL", 312, 318], ["vascular", "MULTI-TISSUE_STRUCTURE", 347, 355], ["EV71", "ORGANISM", 387, 391], ["HPMECs", "CELL_TYPE", 312, 318], ["infants", "SPECIES", 221, 228], ["infants", "SPECIES", 274, 281], ["EV71", "SPECIES", 387, 391], ["further studies", "TEST", 6, 21], ["elevated Ang", "PROBLEM", 58, 70], ["PE fluid", "PROBLEM", 83, 91], ["serum on vascular leakage", "PROBLEM", 96, 121], ["EV71", "PROBLEM", 125, 129], ["induced PE", "PROBLEM", 130, 140], ["this study", "TEST", 167, 177], ["the PE fluid", "PROBLEM", 190, 202], ["EV71induced PE", "PROBLEM", 206, 220], ["the serum", "TEST", 258, 267], ["PE", "PROBLEM", 271, 273], ["increased vascular leakage", "PROBLEM", 337, 363], ["EV71", "PROBLEM", 387, 391], ["induced PE", "PROBLEM", 392, 402], ["PE", "OBSERVATION_MODIFIER", 83, 85], ["fluid", "OBSERVATION", 86, 91], ["vascular", "ANATOMY", 105, 113], ["leakage", "OBSERVATION", 114, 121], ["PE", "OBSERVATION", 138, 140], ["PE", "OBSERVATION", 194, 196], ["fluid", "OBSERVATION_MODIFIER", 197, 202], ["PE", "OBSERVATION", 218, 220], ["PE", "OBSERVATION", 271, 273], ["cell connections", "OBSERVATION", 292, 308], ["increased", "OBSERVATION_MODIFIER", 337, 346], ["vascular", "ANATOMY", 347, 355], ["leakage", "OBSERVATION", 356, 363], ["PE", "OBSERVATION", 400, 402]]], ["The breakage of HPMEC connections by Ang-2 from the serum of infants with PE was reversed by human recombinant Ang-1, which suggests that Ang-2 is associated with the development and progression of PE induced by EV71.ConclusionsAcknowledgments The authors thank the Binzhou Center for Disease Control for their help in collecting specimens and providing the virus analysis data.ConclusionsContributions XW: Principal investigator, oversaw the study design, conducted most of the data analysis, and wrote most of the manuscript; ZQ: Study physician, oversaw patient care, and assisted with interpreting the results and editing the paper; ZL: Oversaw the laboratory measurements and assisted with interpreting the results and editing the manuscript; DH: Assisted with statistical analysis and editing the paper; TW: Collected serum and pulmonary edema fluid samples, and assisted with interpreting the results and editing the manuscript; YX: Collected the Fig. 2 Serum from infants with pulmonary edema had disrupted endothelial architecture that was reversed by recombinant human angiopoietin (Ang)-1.", [["serum", "ANATOMY", 52, 57], ["specimens", "ANATOMY", 330, 339], ["serum", "ANATOMY", 824, 829], ["pulmonary edema fluid samples", "ANATOMY", 834, 863], ["Serum", "ANATOMY", 961, 966], ["pulmonary edema", "ANATOMY", 985, 1000], ["endothelial", "ANATOMY", 1015, 1026], ["Ang-2", "CHEMICAL", 37, 42], ["PE", "DISEASE", 74, 76], ["Ang", "CHEMICAL", 111, 114], ["Ang", "CHEMICAL", 138, 141], ["PE", "DISEASE", 198, 200], ["EV71", "DISEASE", 212, 216], ["pulmonary edema", "DISEASE", 834, 849], ["pulmonary edema", "DISEASE", 985, 1000], ["Ang", "CHEMICAL", 1093, 1096], ["HPMEC", "SIMPLE_CHEMICAL", 16, 21], ["Ang-2", "GENE_OR_GENE_PRODUCT", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["infants", "ORGANISM", 61, 68], ["human", "ORGANISM", 93, 98], ["Ang-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["Ang-2", "GENE_OR_GENE_PRODUCT", 138, 143], ["EV71", "ORGANISM", 212, 216], ["specimens", "CANCER", 330, 339], ["patient", "ORGANISM", 557, 564], ["serum", "ORGANISM_SUBSTANCE", 824, 829], ["pulmonary edema", "TISSUE", 834, 849], ["Serum", "ORGANISM_SUBSTANCE", 961, 966], ["infants", "ORGANISM", 972, 979], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 985, 1000], ["endothelial architecture", "TISSUE", 1015, 1039], ["human", "ORGANISM", 1073, 1078], ["angiopoietin (Ang)-1", "GENE_OR_GENE_PRODUCT", 1079, 1099], ["HPMEC", "PROTEIN", 16, 21], ["human recombinant Ang-1", "PROTEIN", 93, 116], ["recombinant human angiopoietin (Ang)-1", "PROTEIN", 1061, 1099], ["infants", "SPECIES", 61, 68], ["human", "SPECIES", 93, 98], ["patient", "SPECIES", 557, 564], ["infants", "SPECIES", 972, 979], ["human", "SPECIES", 1073, 1078], ["human", "SPECIES", 93, 98], ["EV71", "SPECIES", 212, 216], ["human", "SPECIES", 1073, 1078], ["The breakage of HPMEC connections", "PROBLEM", 0, 33], ["PE", "PROBLEM", 74, 76], ["PE", "PROBLEM", 198, 200], ["EV71", "PROBLEM", 212, 216], ["Disease Control", "TREATMENT", 285, 300], ["collecting specimens", "TEST", 319, 339], ["the virus analysis data", "TEST", 354, 377], ["the study", "TEST", 439, 448], ["the data analysis", "TEST", 475, 492], ["statistical analysis", "TEST", 766, 786], ["Collected serum", "TEST", 814, 829], ["pulmonary edema fluid samples", "PROBLEM", 834, 863], ["Serum", "TEST", 961, 966], ["pulmonary edema", "PROBLEM", 985, 1000], ["disrupted endothelial architecture", "PROBLEM", 1005, 1039], ["recombinant human angiopoietin (Ang)", "TREATMENT", 1061, 1097], ["breakage", "OBSERVATION_MODIFIER", 4, 12], ["PE", "OBSERVATION", 74, 76], ["PE", "OBSERVATION", 198, 200], ["pulmonary", "ANATOMY", 834, 843], ["edema", "OBSERVATION", 844, 849], ["pulmonary", "ANATOMY", 985, 994], ["edema", "OBSERVATION", 995, 1000], ["endothelial architecture", "OBSERVATION", 1015, 1039]]], ["Ang-2 (121.6 pg/ml) from the serum of healthy infants was incubated with human pulmonary microvascular endothelial cell monolayers to examine the effects on the endothelial architecture (ac).", [["serum", "ANATOMY", 29, 34], ["pulmonary microvascular endothelial cell monolayers", "ANATOMY", 79, 130], ["endothelial", "ANATOMY", 161, 172], ["Ang", "CHEMICAL", 0, 3], ["Ang-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["infants", "ORGANISM", 46, 53], ["human", "ORGANISM", 73, 78], ["pulmonary microvascular endothelial cell monolayers", "CELL", 79, 130], ["endothelial architecture", "TISSUE", 161, 185], ["human pulmonary microvascular endothelial cell monolayers", "CELL_LINE", 73, 130], ["infants", "SPECIES", 46, 53], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["Ang", "TEST", 0, 3], ["human pulmonary microvascular endothelial cell monolayers", "PROBLEM", 73, 130], ["pulmonary microvascular", "ANATOMY", 79, 102], ["endothelial cell monolayers", "OBSERVATION", 103, 130], ["endothelial", "ANATOMY", 161, 172]]], ["Recombinant human Ang-2 (4414.4 pg/ml) induced thick actin stress fibers and intercellular gap formation (d-f).", [["stress fibers", "ANATOMY", 59, 72], ["intercellular gap", "ANATOMY", 77, 94], ["Ang", "CHEMICAL", 18, 21], ["human", "ORGANISM", 12, 17], ["Ang-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["actin", "GENE_OR_GENE_PRODUCT", 53, 58], ["stress fibers", "CELLULAR_COMPONENT", 59, 72], ["intercellular gap", "CELLULAR_COMPONENT", 77, 94], ["actin", "PROTEIN", 53, 58], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Recombinant human Ang", "TREATMENT", 0, 21], ["thick actin stress fibers", "PROBLEM", 47, 72], ["intercellular gap formation", "PROBLEM", 77, 104], ["intercellular gap", "OBSERVATION", 77, 94]]], ["The same effect was observed when HPMEC monolayers were incubated with high concentrations of Ang-2 serum (4414.4 pg/ml) from infants with PE (g-i).", [["HPMEC monolayers", "ANATOMY", 34, 50], ["serum", "ANATOMY", 100, 105], ["Ang", "CHEMICAL", 94, 97], ["HPMEC monolayers", "CELL", 34, 50], ["Ang-2", "GENE_OR_GENE_PRODUCT", 94, 99], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["infants", "ORGANISM", 126, 133], ["HPMEC monolayers", "CELL_LINE", 34, 50], ["infants", "SPECIES", 126, 133], ["HPMEC monolayers", "TEST", 34, 50], ["Ang", "TEST", 94, 97], ["PE", "PROBLEM", 139, 141], ["PE", "OBSERVATION", 139, 141]]], ["The gap effect was reversed by the addition of 10 ng/ml recombinant human Ang-1 (j-l).", [["Ang", "CHEMICAL", 74, 77], ["human", "ORGANISM", 68, 73], ["Ang-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["j-l", "GENE_OR_GENE_PRODUCT", 81, 84], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["gap effect", "OBSERVATION", 4, 14]]], ["Arrows indicate intercellular gaps clinical data; TS: Completed cell experiments; JW: Completed sample analyses; FZ: Supervised many of the study participants.", [["intercellular", "ANATOMY", 16, 29], ["cell", "ANATOMY", 64, 68], ["cell", "CELL", 64, 68], ["participants", "SPECIES", 146, 158], ["the study", "TEST", 136, 145]]]], "PMC7437535": [["FundingNone.CRediT authorship contribution statementAll authors had access to the data and a role in writing this manuscript.Declaration of competing interestDr.", [["interestDr", "PROTEIN", 150, 160]]], ["Barnes reports consulting for Pfizer/Bristol-Myers Squibb, Janssen, Portola, Acelis Connected Health, and AMAG Pharmaceuticals; grant support from Blue Cross Blue Shield of Michigan.", [["AMAG Pharmaceuticals", "TREATMENT", 106, 126]]], ["The other authors report no conflicts.", [["no", "UNCERTAINTY", 25, 27], ["conflicts", "OBSERVATION", 28, 37]]]]}